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ABSTRACT OF DISSERTATION

EVALUATING THE MICROBIOME TO BOOST RECOVERY FROM STROKE: THE
EMBRS STUDY
Accumulating evidence suggests that gut microbes modulate brain plasticity via the
bidirectional gut-brain axis and may play a role in stroke rehabilitation. A severely
imbalanced microbial community has been shown to occur following stroke, causing a
systemic flood of neuro- and immunomodulatory substances due to increased gut
permeability and decreased gut motility. Here we measure post-stroke increased gut
dysbiosis and how it correlates with gut permeability and subsequent cognitive
impairment.
We recruited 12 participants with acute stroke, 12 healthy control participants, and 18
participants who had risk factors for stroke, but had not had a stroke. We measured the
gut microbiome with whole shotgun sequencing on stool samples. We measured
cognitive and emotional health with MRI imaging and the NIH toolbox. We normalized
all variables and used linear regression methods to identify gut microbial levels
associations with cognitive and emotional assessments.
Beta diversity analysis revealed that the bacteria populations of the stroke group were
statistically dissimilar from the risk factors and healthy control groups. Relative
abundance analysis revealed notable decreases in butyrate-producing microbial taxa. The
stroke group had higher levels of the leaky gut marker alpha-1-antitrypsin than the
control groups, and roseburia species were negatively correlated with alpha-1antitrypsin. Several Actinobacteria species were associated with cerebral blood flow and
white matter integrity in areas of the brain responsible for language, learning, and
memory. Stroke participants scored lower on the picture vocabulary and list sorting tests
than those in the control groups. Stroke participants who had higher levels of roseburia
performed better on the picture vocabulary task.
We found that microbial communities are disrupted in a stroke population. Many of
the disrupted bacteria have previously been reported to have correlates to health and
disease. This preparatory study will lay the foundation for the development of
therapeutics targeting the gut following stroke.
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CHAPTER 1. BACKGROUND
1.1

Stroke

Every year, more than 795,000 people suffer a stroke in the United States.1 Stroke
is characterized as a neurological deficit caused by an acute focal injury of the central
nervous system vasculature, including cerebral infarction, intracerebral hemorrhage, and
subarachnoid hemorrhage.2 The major blood supply to the brain comes from the anterior,
middle, and posterior cerebral arteries.3 Cerebral infarction is most commonly caused by a
blockage to the blood supply of the brain in the form of a thrombus or an embolus.4 A
thrombus is a blood clot consisting of fibrin, platelets, and red blood cells that forms within
the artery that it is occluding.5 An embolus is a blood clot that travels from another region
such as the heart or the carotid artery that lodges in the vasculature of the brain.6 When the
blood supply to the brain is blocked, the downstream tissue is injured by lack of oxygen
and necrosis ensues.7 Cell apoptosis, excitotoxicity, and the inflammatory response cause
further damage and result in a loss of function.8
Thrombus and embolus formation are a natural product of atherosclerosis.9 The
major risk factors for atherosclerosis include hyperlipidemia, hypertension, cigarette
smoking, and diabetes.10 Most of these risk factors are more likely in an aging population,
and stroke is much more prevalent in individuals over 55. According to the Centers for
Disease Control and Prevention, the chance of having a stroke about doubles every 10 years
after age 55. There are also several genetic factors that make stroke more likely, including
the ε4 variant of the apolipoprotein E, a cholesterol carrying protein in the body also
associated with a higher incidence of Alzheimer’s disease.11
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1.1.1

Available Stroke Treatments

The discovery and implementation of tissue plasminogen activator (tPA) therapy
and endovascular procedures have greatly reduced stroke mortality.12 The first line
treatment for acute ischemic stroke is tPA; however, it must be given within 4.5 hours of
the onset of stroke.13 If the stroke is treated within 24 hours of the onset of stroke,
mechanical thrombectomy can be used to partially or fully remove the offending clot.14
These treatments are helpful for minimizing the injury caused by the stroke; however,
many patients do not have access to these treatments and are left with disabilities. It is
estimated that 26% of survivors of stroke are impaired in activities of daily living and 50%
have reduced mobility.15 Efforts have been made to investigate therapies that will halt the
downstream ischemic cascade at the level of various biochemical, metabolic and molecular
processes in the infarct border zone using neuroprotective agents, but have all failed in
clinical trials.16
1.1.2

Rehabilitation following stroke

Survivors of stroke are often left with severe impairments. There is a period of
about 3 months following stroke that many survivors will see some spontaneous recovery.17
The molecular changes underlying this spontaneous recovery include structural changes in
axons, dendrites, and synapses; increase activation and migration of endogenous neural
stems; and changes in extracellular matrix, glia, and angiogenesis.18 Therapies following
stroke are commonly used to supplement this spontaneous recovery.19 Rehabilitation
therapies such as physical therapy, occupational therapy, and speech therapy are designed
to induce neuroplasticity in these survivors to promote functional recovery20. Stroke
survivors spend three weeks on average in an acute rehabilitation facility followed by
2

months of outpatient rehab and follow up. Unfortunately, approximately 40% of stroke
survivors still remain with moderate to severe impairments that markedly reduce quality of
life and require special care21.
1.1.3

Neuroplasticity

Rehabilitation strategies following stroke attempt to take advantage of the
principles of neuroplasticity to bring about recovery.22 Neuroplasticity encompasses the
functional and structural alterations in the brain enabling adaptation to the environment,
learning, memory, as well as rehabilitation after brain injury.23 Basic principles of
neuroplasticity include synaptogenesis, neurogenesis, clearance of toxic amyloid beta and
tau protein aggregates, and neuroprotection.24 There have been many compounds produced
that have been reported to induce long-lasting neuroplasticity including natural products
(bilobalides25 and curcumin26) and novel vaccine AADvac127. Activity-dependent
neuroplasticity is also inducible by regimens of exercises and therapies. Mechanical
stimulation of brain regions can induce neuroplasticity through therapeutic hypothermia28
or deep brain stimulation.29
1.1.4

Markers of Stroke Severity

Several markers have been developed to monitor stroke severity. Several recovery
assessments have been created to monitor functional recovery over the course of
rehabilitation. Among these is the Self-Care Assessment created by the American
Occupational Therapy Association.30 The Self-Care Assessment determines how
independently an individual can perform the follow tasks related to daily living (eating,
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oral hygiene, toilet hygiene, shower/bathe self, upper body dressing, lower body dressing,
and putting on/taking off footwear).
In addition to functional assessments, other tools such as magnetic resonance
imaging can detect neurological recovery following stroke. T1 and T2 structural imaging
is commonly used to calculate lesion size and location following stroke,31 but advanced
imaging modalities such as diffusion tensor imaging,32 magnetic resonance spectroscopy,33
and arterial spin labelling34 can be used to detect white matter integrity, brain metabolites,
and cerebral blood flow, respectively.
Finally, the NIH toolbox has been developed to assess cognitive, emotional, and
sensation function in individuals using validated questionnaires.35 It has been validated for
use in stroke participants,36 and is an effective way of monitoring additional modalities of
recovery.
1.2

Gut Microbiome

The gut microbiome consists of more than a trillion microbes that dwell in the human
gut.37 While these microbes include bacteria, archaea, viruses, fungi, and protozoa, the
bacterial component of the gut microbiome has been the best studied.38 The major bacterial
phyla that dwell in this community are Firmicutes and Bacteroidetes, with Actinobacteria,
Proteobacteria, and Verrucomicrobia also making sizable contributions.39 Within these
phyla, there are approximately 300-500 bacterial species that live in a delicate balance.40
These bacteria perform many metabolic tasks that are symbiotic to the host organism,
including breaking down nutrients and producing important vitamins.39 Dysbiosis occurs
whenever the delicate balance of microbial communities is disrupted and is seen in the
context of antibiotic therapy, inflammatory bowel diseases, diabetes, and obesity.41
4

The gut microbiome plays many roles in disease. For example, antibiotic therapy can
lead to a dysbiotic state that allows Clostridium difficile infection to thrive.42 Genome wide
association studies have linked inflammatory bowel disease with loci that implicate an
aberrant immune response to the intestinal microbiota.43 Acute gastroenteritis following
exposure to pathogens can precipitate the development of irritable bowel syndrome, and
studies have demonstrated changes in the gut microbiome in irritable bowel syndrome
patients.44 Bacteria causing weight gain are thought to induce the expression of genes
related to lipid and carbohydrate metabolism thereby leading to greater energy harvest from
the diet.45 Experiments using gut microbiota transplants to germ-free animal models have
shown that fatty liver disease development is determined by gut bacteria.46
Attempts to modulate the gut microbiome typically come in the following
mechanisms:

fecal

microbiota

transplant,

antibiotic

administration,

probiotic

administration, dietary modifications, and exercise. Fecal microbiota transplantation is the
transfer of stool from a healthy donor into the colon of a patient whose disease is a result
of an altered microbiome, with the goal of restoring the normal microbiota and
ameliorating the disease.47 Fecal microbiota transplant is already an effective and approved
therapy for Clostridium difficile infection.48 Antibiotics have the ability to vastly alter the
composition of the microbiome, with different antibiotics affecting the microbiome in
different ways.49 Probiotics are live organisms that have demonstrated beneficial effect on
human health.50 Diet modification has an effect on the microbiome since different bacterial
species rely on various preferred fuel sources for survival.51 Prebiotic interventions are
comprised of specific fuel sources that beneficial microbiota prefer; in general, these
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prebiotic interventions contain some type of dietary fiber.52 Finally, aerobic exercise has a
positive impact on the microbiome, shifting it towards a more beneficial balance.53
The composition of the microbiome varies across the lifespan. The infant
microbiome is thought to initially be colonized by the mother’s vaginal bacteria or her skin
bacteria, depending on whether the infant was delivered vaginally or by cesarean section.54
Whether an infant in breastfed or formula-fed continues to modulate the early
microbiome.55 During adulthood, the microbiome remains relatively stable, like a dynamic
fingerprint whose ridges sharpen or smooth in response to their environment. The
microbiome has been shown to remain relatively stable between age 55 and 85, but it tends
to look different in younger or older groups55.
The microbiome is typically studied and measured by sequencing the bacteria
recovered from fresh stool samples. The gut microbiome varies across the length of the
gastrointestinal tract, looking a little different in the stomach, duodenum and jejunum,
ileum, and large intestine.56 Additionally, discrete bacterial communities form in the
different layers of the gastrointestinal tract such as the gut lumen, colonic mucus layers,
and colonic crypts.57 The fecal microbiome is the best studied partly because of its ease of
access and partly because a large diversity of microorganisms are known to inhabit the
colon and to be transferred to the fecal material. The microbiome has frequently been
sequenced using the highly conserved 16S ribosomal RNA gene.58 This technique allows
genus-level resolution of the microbiota to be detected. Whole genome shotgun sequencing
is a newer technique that allows for species-level resolution measurements of the
microbiome.

6

Once the bacteria have been sequenced, there are various metrics used for comparing
the microbiome from one sample to another. The most popular metric is called alpha
diversity, which measures the richness and evenness of a given microbial community.
Richness measures how many different taxa are present while evenness measures how
evenly the quantities of one species compare to the quantities of another.59 Another metric
considers beta diversity, which measures the degree of dissimilarity between one
community and another.60 Finally, relative abundance is used to measure the taxa as a
proportion of the community from one sample to another.61
1.2.1

Gut-Brain Axis

The microbiome has been shown to affect and be affected by the brain via the
bidirectional gut-brain axis62. The gut houses the largest collection of neurons outside of
the central nervous system, the enteric nervous system. These neurons communicate with
the brain via the vagus nerve superhighway. The brain can send autonomic inputs to the
gut, modulating gut permeability and gut motility63 and thereby disrupting the microbial
ecosystem.
Members of the gut microbiota have been established as potent modulators of
intestinal, systemic, and central nervous system immune cell function.64 The microbes
interact with the gut associated lymphoid tissue and the Peyer’s Patches which activate
cytokines and immune cells which travel systemically through the circulation and impact
central nervous system function.65 Immune cells in the blood circulation and gut lymphatic
tissues that have been shaped by immune components including gut microbiota and
metabolites can infiltrate the brain and, once there, influence neuronal function either
directly or by modulating the properties of brain-resident immune cells.66
7

Accumulating evidence suggests that gut microbes are modulators of brain plasticity
via the gut-brain axis.67 The microbiome is an important modulator of tryptophan
metabolism, which is the precursor of the neurotransmitter serotonin.68 About 95% of the
serotonin in the body is found in the gut, with the other 5% in the brain.69 In addition to
tryptophan, other microbial metabolites are important in gut-brain signaling. The most
important of these appears to be the short chain fatty acids, which are produced during the
fermentation of partially and nondigestible polysaccharides. In the brain, the short chain
fatty acids act as histone deacetylase inhibitors regulating gene expression and G-protein
coupled receptors regulating metabolism and inflammation.70 SCFA supplementation can
induce cortex connectivity, spine and synapse density, and induce microglial cells to
contribute to structural and functional remodeling of the brain via recruitment of T cells.71
Many changes in the brain associated with the gut microbiome and gut disorders
have been documented with imaging. Ulcerative colitis has been associated with a
significantly reduced blood oxygen level-dependent signal in the amygdala, thalamic
regions, and cerebellar regions.72 Irritable bowel syndrome has been associated with longterm white matter integrity changes in the brain, especially in regions associated with
integration of sensory information and corticothalamic modulation,73 and lower volumes
in the bilateral superior frontal gyrus, insula, amygdala, hippocampus, and middle orbital
frontal gyrus.74 Probiotic administration for 4 weeks has been associated with changes in
brain activation patterns in response to emotional decision-making tasks.75,76 Short chain
fatty acids (SCFAs) are known to influence blood brain barrier permeability77 and alter
cerebral blood flow78. Finally, the gut microbiome is known to influence the transcriptional
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activity of genes involved in neuronal myelination, thereby altering white matter
integrity.79
Other changes in the brain associated with the gut microbiome and gut disorders have
been documented with functional, cognitive, emotional, and sensation testing. Increased
proteobacteria and bacteroidetes and decreased firmicutes have been associated with
poorer early functional outcomes following stroke80 as measured by the modified Rankin
Scale (mRS). Increased Ruminococcaceae and Lachnospiraceae families have been
associated with good cognition.81,82 Microbiota-modulated metabolites such as
cholecystokinin have the ability to impact emotion in the brain.83 The abundance of
streptococcus species have been associated with feeling more pain.84
1.2.2

Stroke and the Gut Microbiome

Animal studies have shown that stroke causes severe gut dysbiosis85. Stress signals
project from the brain following stroke via the autonomic nervous system (ANS) and the
hypothalamic pituitary adrenal (HPA) axis which lead to immunomodulation and increased
gut permeability and decreased gut motility86-88. The microbial communities are
subsequently disrupted and can cause issues in the context of stroke rehabilitation. The gut
microbiome can produce neuro- and immunomodulatory substances such as short chain
fatty acids, tryptophan and indole metabolites, neurotoxins, neurotransmitters,
lipopolysaccharide (LPS), and peptidoglycan that can act locally on enteric neurons and
immune populations to modulate distant functions in the CNS89. In the context of stroke,
gut dysbiosis leads to increased TH1 cells, TH17 cells, γδ-T cells, and monocytes in gutassociated immune tissues that migrate to the peri-infarct region of the brain and increase
infarct size90,91. Fecal microbiota transplant can reverse stroke-induced dysbiosis in mice
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and its negative effects on stroke recovery92,93. Fecal transplant with sodium butyrate can
also attenuate ischemic stroke injury.71,94-96 Age,97 diet,98-100 and exercise101 modify the
severity of dysbiosis following stroke.
Very few human studies have been performed to date to examine the gut-brain axis
following stroke in a human population. Human studies thus far have suggested that gut
dysbiosis occurs shortly following stroke at a single time point and that this dysbiosis is
associated with increased alpha diversity,102 blood Apolipoprotein E,103 IL-6,104
phenylacetylglutamine,105,106

blood

Trimethylamine-N-Oxide,107-111,

and

risk

of

pneumonia112 and depression113 and decreased HDL114 and butyrate115, plus poor
functional outcome80,116,117, and 180-day mortality118. The severity of the dysbiosis can be
modified by features such as enteral nutrition119 and Vitamin B12 deficiency.120 However,
no human studies have yet been performed to analyze changes in the microbiome over the
first three-month course of stroke rehabilitation when recovery is known to be the greatest,
and no human studies have analyzed whether these longitudinal changes correlate with
increased gut permeability and subsequent recovery as measured by neuroimaging and
functional testing.
1.3

Scope of Dissertation

Novel multimodal rehabilitation approaches are needed to promote plasticity and
sensorimotor function to help these survivors by combining current rehabilitation therapies
with other treatments designed to foster neuroplasticity. A baseline understanding of how
the microbiome is associated with markers of brain health in acute stroke and in community
dwelling older adults is foundational to this end. We plan to follow two Specific Aims:
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Specific Aim 1. Analyze dysbiosis in the gut microbiome during first three weeks of
stroke rehabilitation and associations with functional ability.
From stool samples, we will measure 1) changes in the gut microbiome using
metagenomic sequencing and functional analysis of bacterial DNA and 2) intestinal
inflammation and permeability markers in human subjects during the first three months of
rehabilitation following ischemic stroke compared to control subjects who demonstrate risk
factors for, but have not had, a stroke, and healthy controls. We will consider past medical
history, medication history, diet, racial/ethnic background, and APOE genotype in our
analysis. We will determine the associations between microbiota composition and markers
of stroke recovery detectable by functional assessments in the Self Care Assessment and the
NIH toolbox (cognitive, emotional, and sensation assessments).
Specific Aim 2. Identify the associations between dysbiosis and downstream
neuroimaging markers in community dwelling older adults
We will identify the associations between microbiota composition and markers of brain
health detectable by MRI imaging including structural imaging, hyperintensities, cerebral
blood flow, and white matter integrity.
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CHAPTER 2. MATERIALS AND METHODS

2.1

Participants

We recruited 42 Individuals aged 55-85 for this study. Participants were recruited
according to the incidence of stroke statistics taking into consideration the population
distribution of Kentucky. According to the Heart Disease and Stroke Statistics-2017
Update: A Report from the American Heart Association,121 stroke has a higher incidence
in females than it does in males (54:46 ratio). Additionally, Blacks and Hispanics may be
more likely to have a stroke than non-Hispanic whites. The Kentucky population
distribution (Source: US Census 2017 5-Year American Community Survey) is 85.08%
White Non-Hispanic and 7.88% Black or African American Non-Hispanic.
We recruited 12 patients in acute stroke rehabilitation care after first time ischemic
stroke at Cardinal Hill Rehabilitation Hospital. A complete list of inclusion/exclusion
criteria are in Table 2.1. Participants were required to not have an acute disease of chronic,
clinically significant (unresolved, requiring on-going medical management or medication)
pulmonary, gastrointestinal, dermatologic, hepatic or renal functional abnormality.
Participants were required to not have had cancer or a positive test for HIV, HBV, or HCV.
Participants were required to not be immunosuppressed or have had major surgery of the
GI tract in the past five years. We obtained past data, including radiographic studies and
medical history. These data were used solely for research purposes. Other variables
including age, gender, marital status, education level, Body Mass Index, Apolipoprotein E
status, history of conventional vascular risk factors (hypertension, diabetes mellitus, atrial
fibrillation, hyperlipoproteinemia, and smoking habit), pre-stroke therapy, and acute

treatment (i.e., oral anticoagulants, antiplatelet agents, tPA, IV thrombolysis and/or
mechanical thrombectomy, and/or antibiotics) were recorded for our analyses.
We recruited 30 patients from the University of Kentucky (UK) Internal Medicine
clinic to serve as controls. 18 of these participants had not had a stroke but did have 1 or
more common cardiovascular risk factors for stroke. 12 of these participants had not had a
stroke or common cardiovascular risk factors for stroke. Participants followed the same
inclusion/exclusion criteria listed above but must not have had a stroke.
2.1.1

Recruitment workflow for participants with acute stroke

Participants from the University of Kentucky (UK) stroke unit were informed of
the study by the case management team at Cardinal Hill Rehabilitation Hospital upon
admission. If patient or family gave permission, the case management team alerted study
personnel to evaluate eligibility. If the patient was eligible, the study personnel approached
the patient and/or family to explain the study and ask for consent. If the patient and/or
family consented, the applicant collected demographic information, dietary assessment,
NIH toolbox assessments, Self-Care Assessment, and oral swab. To retain the participants,
study personnel placed a purple laminated banner in the patient room alerting hospital staff
about the research study and alerted the attending physician, case manager, lab manager,
Cardinal Hill Clinical Research Director, and department chair for Physical Medicine and
Rehabilitation (PM&R) at Cardinal Hill. Study personnel again collected functional
recovery assessments at hospital discharge and scheduled a follow-up visit at the UK
Magnetic Resonance Imaging and Spectroscopy Center (MRISC) at the participants’
preferred date and time. An appointment reminder with map and parking instructions was
given to participants to decrease the chance of a forgotten appointment. Participants were
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reminded by their preferred method of communication about the follow-up visit.
Participants returned for a three-month follow-up visit for functional testing assessment,
imaging, and mail-in kit for final stool sample. When the kit was received in the mail,
participants received $50 reimbursement to cover time and travel expenses. Due to the
COVID-19 pandemic, many follow up appointments had to take place via Zoom.
2.1.2

Recruitment workflow for control participants with no stroke

Study personnel worked with the Center for Clinical and Translational Research at
the University of Kentucky to advertise the study to the community. Brochures were placed
in high traffic areas around campus. Study personnel also set up a profile with
ResearchMatch that connects interested participants with research studies. When
participants submitted interest in the research study, study personnel evaluated them for
eligibility. If potential participants were eligible for the study (see Table 2.2), they were
scheduled for a visit at UK MRISC for consent at the participants’ preferred date and time.
An appointment card with map and parking instructions was given to participants to
decrease the chance of a forgotten appointment. If the participant consented, study
personnel administered the functional recovery testing and imaging protocol, collected an
oral swab sample, and provided the participant with a mail-in stool collection kit. The
participant scheduled a follow-up visit at UK MRISC. Participants were reminded by their
preferred method of communication about the follow-up visit. When the kit was received
in the mail, participants received $25 reimbursement to cover time and travel expenses.
Due to the COVID-19 pandemic, many study visits were held via Zoom.
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2.2

Study Design

Participants were followed over the course of three months as we collected the
following information:
•

Past medical history, medication history, diet, and racial/ethnic background at
admission using questionnaire and Electronic Health Record

•

APOE genotype at admission using oral swab

•

Cognitive and motor function at baseline, discharge, and 3-month follow-up using
NIH toolbox and Self-Care Assessment

•

Gut microbiome and permeability markers at admission, discharge, and 3-month
follow-up using stool samples

•

MRI imaging at 3-month follow-up

The timeline of study visits and procedures is detailed in Table 2.3. This is a minimal
risk, category 1 protocol that only includes donating stool and oral swab samples and
assessing structural and functional outcomes using imaging and standardized cognitive,
motor, sensory, and emotional measures that are validated against gold standard
instruments. Any measures with a fall risk were eliminated. The only additional risk
involved in this research is breach of confidentiality, although all precautions were be made
to only collect and database de-identified data from the participants. The following was
collected from participants:
•

Medical History: We obtained past medical history from the electronic health
record and questionnaire. These data were used solely for research purposes. Each
individual received a verbal and written explanation of the purposes, procedures,
and potential hazards of the study, and written consent was obtained. Variables
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including age, gender, racial/ethnic background, marital status, education level,
Body Mass Index, history of conventional vascular risk factors (hypertension,
diabetes mellitus, atrial fibrillation, hyperlipoproteinemia, and smoking habit), prestroke therapy, and acute treatment (i.e., oral anticoagulants, antiplatelet agents,
tPA, IV thrombolysis and/or mechanical thrombectomy, and/or antibiotics) were
recorded and used as covariates for our analyses.
•

Food Frequency: The Dietary Screener Questionnaires (DSQ) in the NHANES
2009-10: DSQ was used to measure dietary intake over the last month.

•

Oral Swab Sample: Oral Swab was used to determine APOE genotype.

•

NIH Toolbox: Cognitive, Motor, Emotional, and Sensation measures from the NIH
toolbox were performed upon admission and at 3 months follow-up following
discharge. These tests are standard in the field and take approximately 30 minutes
to perform.

•

Self-Care CARE Items: Section GG Self-Care Items are routinely used in the
clinical care of inpatient stroke rehab patients to measure functional recovery. We
recorded all CARE scores from hospital stay for analysis.

•

Stool Samples: Stool samples were collected at admission, discharge, and 3-month
follow-up. Samples will be collected, genotyped, and analyzed using methods
obtained from the International Human Microbiome Standards consortium to
determine gut microbial biodiversity.

•

Imaging: A follow-up brain scan using MRI was obtained at outpatient follow-up
visit 3 months following discharge for research purposes.
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Each individual received a verbal and written explanation of the purposes, procedures,
and potential hazards of the study, and written consent was obtained. Study personnel
consented subjects using the University of California, San Diego Brief Assessment of
Capacity to Consent (UBACC) to ensure capacity. Subjects lacking capacity were allowed
to enroll and participate in the study if a legal representative authorized it. Signed consent
was be obtained before definite enrollment of the subject in this study. Subjects were free
to withdraw from the study at any time. This research had minimal risk.
Given the broad heterogeneity of the gut microbiome composition among individuals,
the prospect of performing a true case-control study is not likely. However, the study
design presented here provides average conglomerates of the gut microbiome in two
control groups: 1) older adults who have risk factors for stroke but have never had a stroke
and 2) healthy older adults. These conglomerates were important comparators to gain a
general idea of which microbial communities are disturbed following stroke and how they
change over time. All analyses were performed in a quasi-experimental difference-indifferences fashion122 in which the difference of the outcome measures in the stroke rehab
group was compared to the difference of the outcome measures in the control groups. The
repeated-measures design allows each participant to be compared to his or her own
baseline, which was especially useful to reduce variability in the data since randomization
was not possible in our setting123.

2.2.1

Stool Sample Collection

Stool samples were collected in Zymo DNA stabilization solution with sarstedt feces tubes
from feces catcher placed on toilet seat.
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2.2.2

Metagenomic Sequencing

Genomic DNA was extracted from 0.25 grams of stool using ZymoBIOMICS™ DNA
Mini Kit and shipped to the Genomics and Microbiome core facility at Rush University for
DNA quantification using fluorometer Qubit 3.0. Libraries were constructed and the PCR
products purified using 1.0X speed beads and eluted in 15 uL of nuclease-free water and
quantified by PicoGreen fluorometric assay (100X final dilution). The libraries were
pooled and loaded onto a high sensitivity chip run on the Caliper LabChipGX (Perkin
Elmer, Waltham, MA) for size estimation and sequenced using Illumina NextSeq/HiSeq
platform.
2.2.3

Metagenomic Bioinformatic Analysis

Unassembled sequencing reads were analyzed by the Core for Research Informatics at the
University of Illinois Chicago for microbiome analysis. Alpha diversity, beta diversity, and
relative abundance counts were calculated. For alpha diversity, raw counts were rarefied
to 2000k and the Shannon diversity index was calculated using the vegan R package. For
beta diversity, the Bray-Curtis dissimilarity index was used and a Principal Component
Analysis (PCA) plot was generated to visualize the diversity. We used MetaPhlAn
(Metagenomic Phylogenetic Analysis) to profile the composition of microbial
communities using unique clade-specific marker genes identified from ~17,000 reference
genomes (~13,500 bacterial and archaeal, ~3,500 viral, and ~110 eukaryotic).124 We used
MaAsLin2 R package to normalize all microbiome variable and correlate them with
metadata variable using linear regression models.125
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2.2.4

Intestinal Inflammation and Permeability Analysis

We tested stool samples for markers of intestinal inflammation and permeability using
ELISA. The Biovendor Alpha-1-antitrypsin in stool human ELISA was used to detect fecal
Alpha-1-Antitrypsin (A1AT), a biomarker of intestinal permeability126-128. It is one of the
principal serum proteins, and, in the context of intestinal permeability, A1AT can
extravasate from the serum into the gut and be detected in the feces since it is highly
resistant to proteolysis in the intestine129. The Biovendor Fecal calprotectin ELISA was
used to detect fecal calprotectin, a sensitive marker of intestinal inflammation130,131. It
constitutes up to 60% of the cytosolic proteins in human neutrophil granulocytes, and, in
the context of intestinal inflammation, activated granulocytes migrating into the intestinal
wall will overexpress and release calprotectin into feces129.
2.2.5

Diet Analysis

We assessed diet history using the Dietary Screener Questionnaire in the National Health
and Nutrition Examination Survey. We analyzed the results of the survey using SAS
statistical software to determine estimated intake of fiber, calcium, whole grains, sugar,
dairy, fruits and vegetables, and sugar sweetened beverages.
2.2.6

APOE Genotyping

We collected oral swabs from all participants and placed them in Zymo DNA stabilization
solution. We sent the oral swabs to the Core for Research Informatics at the University of
Illinois Chicago for DNA extraction and amplification. The core performed PCR to amplify
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and measure SNPs rs429358 and rs7412 that define the common allelic variants of
Apolipoprotein E.
2.2.7 Imaging Analysis

MRI images were collected from all participants on a 3T Prisma MR scanner
(Siemens, Germany) at UK’s Magnetic Resonance Imaging & Spectroscopy Center. We
collected the following sequences from participants: Turbo Gradient Spin Echo for Arterial
Spin Labelling, resting state functional magnetic resonance imaging, magnetizationprepared 180 degrees radio-frequency pulses and rapid gradient-echo, diffusion tensor
imaging, spectroscopy using chemical shift imaging sLASER sequence with a TE of 40ms,
and Fluid-attenuated inversion recovery (FLAIR) imaging.
2.2.7.1 Arterial Spin Labeling
Quantitative CBF (with units of mL/g per minute) was measured using a pulsed arterial
spin labeling (PASL) PICORE Q2T sequence with a TR=4400ms and a TE=20.8ms. We
used FreeSurfer software to process relative cerebral blood flow (relCBF) data produced
by the Siemens scanner. The automated software provides relCBF averages over the
FreeSurferColorLUT.txt set of ROIs.
2.2.7.2 Structural Imaging
High-resolution, 3D anatomic images were acquired using an MP-RAGE sequence
[repetition time (TR) = 2530 ms, echo time (TE) = 2.26 ms, flip angle (FA) = 7°, 1 mm
isotropic voxels, 6:19 min]. We used the FreeSurfer Software Suite to segment and quantify
brain volumes.
2.2.7.3 Diffusion Tensor Imaging
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White matter integrity was measured using an axial double refocused spin echo, echo
planar imaging
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Diffusion Tensor Imaging (DTI) sequence with the following

parameters: TR=3400 ms, TE=71 ms, field of view = 232 mm, 81 slices, 2 mm isotropic
resolution. The DTI images were acquired with 128 noncollinear encoding directions
(b=2000 s/mm2) and 6 images without diffusion weighting (b = 0 s/mm2, b0). DTI data
were analyzed with FSL (Functional MRI of the Brain software library, FMRIB) to
calculate fractional anisotropy (FA) values.
2.2.7.4 Fluid-attenuated inversion recovery (FLAIR) imaging
Hyperintensities were measured with fluid-attenuated inversion recovery (FLAIR) imaging
[TR=5000ms, TE=388ms, FA=120°, 1mm isotropic voxels, 176 slices.] Vascular
hyperintensity volumes will be calculated using the WMH cross-sectional kit, a
combination of several programming tools and software, including Matlab, FSL, SPM,
FreeSurfer, and Singularity container133,134.
2.2.7.5 Magnetic Resonance Spectroscopy
Brain metabolites were measured with a chemical shift imaging (CSI) sequence that
incorporates localization by adiabatic selective refocusing (LASER) for FOV-reduction135.
semi-laser sequence [TR=1700ms and TE=40ms]. All MRS slices were placed parallel to
the anterior commissure-posterior commissure line. The volume of interest was centered
to the medial to posterior part of the corpus callosum, with with VOI = 80 (l-r) × 80 (ap) and field of view (FOV) = 160 × 160 mm3. The acquired matrix size was 10 × 10 × 15
mm. Two voxels that contained pure white matter were selected from each participant and
averaged for analysis. Spectra were calculated using LCModel Software136.
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2.3

Functional Analysis

Functional analysis was measured using the Self-Care CARE Assessment from Section
GG of the standardized patient assessment data elements in the following domains: Eating,
Oral Hygiene, Toileting Hygiene, Shower/Bathe Self, Upper Body Dressing, Lower Body
Dressing, Putting on/Taking off Footwear.30 Stroke patients were graded on these domains
for how independently they were able to perform them on a scale from 1 to 6, with 1 being
dependent and 6 being independent.
2.4

NIH Toolbox

Cognitive, Emotional, and Sensation function was measured using assessments from the
NIH toolbox. The picture vocabulary test was used to measure long-term or crystallized
memory.137 The list sorting test was used to measure short-term memory, attention, and
executive function.138 The sadness,139 meaning and purpose,140 self-efficacy,141 and
support142 questionnaires were used to measure self-reported values of these emotional
domains. The pain intensity scale143 was used to measure sensation.
2.5

Statistical Analysis

All statistical analyses were completed using JMP Statistical Software (SAS, Cary,
NC, USA) and R Statistical Software125,144 . For all chapters, two-sample t-test and 2-way
ANOVA were used to determine differences between groups. The MaAsLin 2 R Package
was used to normalize all variables and employ linear regression analysis to correlate
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various variables with microbiome measures. 144 A false discovery rate of q<0.25 was used
in selecting significant variables to correct for multiple comparisons.
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Table 2.1 Inclusion and Exclusion Criteria used to evaluate eligibility for acute stroke
patients

Inclusion Criteria
•

•

Ischemic

Exclusion Criteria
stroke

(small

•

vessel lacunar stroke or

significant (unresolved, requiring ongoing

cortical stroke <70 cc3)

medical management or medication) lung,

Discharged

bowel, skin, liver, kidney, or brain

from

acute

abnormality

stroke service with NIHSS
of 5-14 (moderate stroke)
•
•

Any acute disease or chronic, clinically

•

Dementia,

Cancer,

HIV,

hepatitis,

Has diagnostic stroke MRI

immunosuppressed, major GI surgery in the

imaging available

past 5 years

Age 55-85

•

Not MRI compatible

•

Participating in another research study
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Table 2.2 Inclusion and Exclusion Criteria used to evaluate eligibility for no stroke
patients with A) risk factors for stroke and B) no risk factors for stroke
A)
Inclusion Criteria
Exclusion Criteria
• Age 55-85
• Any previous stroke
• Has at least one major risk
• Any acute disease or chronic, clinically
factor for stroke (High blood
significant
(unresolved,
requiring
pressure, Diabetes, Heart and
ongoing medical management or
blood
vessel
diseases,
medication) lung, bowel, skin, liver,
High LDL cholesterol levels,
kidney, or brain abnormality
Smoking,
• Dementia, Cancer, HIV, hepatitis,
Brain aneurysms or
immunosuppressed, major GI surgery in
arteriovenous malformations
the past 5 years
(AVMs),
Infections
or
• Not MRI compatible
conditions
that
cause
• Participating in another research study
inflammation, such as lupus
or rheumatoid arthritis, birth
control pills, or hormone
replacement therapy)
B)
Inclusion Criteria
Exclusion Criteria
• Age 55-85
• Any previous stroke
• Any acute disease or chronic, clinically
significant
(unresolved,
requiring
ongoing medical management or
medication) lung, bowel, skin, liver,
kidney, or brain abnormality
• Dementia, Cancer, HIV, hepatitis,
immunosuppressed, major GI surgery in
the past 5 years
• Major risk factors for stroke (High blood
pressure, Diabetes, Heart and blood
vessel
diseases,
High LDL
cholesterol levels,
Smoking,
Brain aneurysms or
arteriovenous
malformations (AVMs), Infections or
conditions that cause inflammation, such
as lupus or rheumatoid arthritis, birth
control pills, or hormone replacement
therapy)
• Not MRI compatible
• Participating in another research study
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Table 2.3 Timeline of study visits and procedures
Table 1. Timeline of study visits and procedures
Participants with Acute Stroke
Procedure

Admission

Discharge

Signing the consent form
Stool Sample
Mouth Swab Sample
MRI Scan
Functional Recovery Testing

X
X
X

Outpatient follow
up visit 3 months
after admission

X
X

X

X

X
X
X
X
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Control Participants (no
stroke and chronic stroke)
Baseline Visit
3-month
follow
up visit
X
X
X
X
X
X
X

CHAPTER 3. THE GUT MICROBIOME IS ALTERED IN THE CONTEXT OF
STROKE AND IS CORRELATED WITH IMPAIRED FUNCTION
3.1

Introduction

Over 795,000 people suffer a stroke every year in the United States alone1. Recent
advances in acute stroke therapies have lowered stroke mortality, but survivors are often
left severely impaired12. Rehabilitation therapies such as physical therapy, occupational
therapy, and speech therapy are beneficial for inducing neuroplasticity to overcome these
impairments20, but over 40% of stroke survivors are left with moderate to severe disabilities
that markedly reduce quality of life21. Novel multimodal approaches are needed to promote
plasticity and sensorimotor function through a combination of current rehabilitation
therapies with other treatments designed to foster neuroplasticity.
Accumulating evidence from animal studies suggests that gut microbes modulate
brain plasticity via the bidirectional gut-brain axis and may play a role in stroke
rehabilitation67. A severely imbalanced microbial community, or dysbiosis, has been
shown to occur following stroke, causing a systemic flood of neuro- and
immunomodulatory substances due to increased gut permeability and decreased gut
motility85. These substances can impact neuroinflammation as commensal bacteria invade
the bloodstream and as intestinal lymphocytes migrate from gut-associated lymphoid tissue
to the brain

92

. Fecal microbiota transplant has been shown to normalize brain lesion-

induced dysbiosis and to improve stroke outcome in mice92. The microbiome is modifiable
as it is influenced by environmental factors such as diet and exercise and could potentially
be a therapeutic target in stroke rehabilitation through nutritional and pharmacological
interventions and physical therapy89,145. Though it is unknown whether the findings from

the bidirectional gut-brain axis in animals translate the same way into humans. Human
studies thus far have suggested that gut dysbiosis occurs shortly following stroke at a single
time point and that this dysbiosis is associated with increased blood Apolipoprotein E103
and IL-6104, and decreased blood Trimethylamine-N-Oxide107 and HDL114, plus poor early
functional outcomes80, and 180-day mortality118. However, no human studies have been
performed to analyze changes in the microbiome over the first three-week course of stroke
rehabilitation and whether these changes correlate with gut permeability and subsequent
recovery as measured by functional testing, making it difficult to confirm whether the
microbiome could be a therapeutic target in stroke rehabilitation.
Several markers have been developed to monitor stroke severity. Several recovery
assessments have been created to monitor functional recovery over the course of
rehabilitation. Among these is the Self-Care Assessment created by the American
Occupational Therapy Association30. The Self-Care Assessment determines how
independently an individual can perform the following tasks related to daily living: eating,
oral hygiene, toileting hygiene, shower/bathe self, upper body dressing, lower body
dressing, and putting on/taking off footwear. The NIH Toolbox has been developed to
assess cognitive, emotional, and sensation function in individuals using validated
questionnaires35. Changes in the brain associated with the gut microbiome and gut
disorders have been documented with functional, cognitive, emotional, and sensation
testing. Increased Proteobacteria and Bacteroidetes and decreased Firmicutes have been
associated with poorer early functional outcomes following stroke80 as measured by the
modified Rankin Scale (mRS). Increased Ruminococcaceae and Lachnospiraceae families
have been associated with good cognition81,82. Microbiota-modulated metabolites such as
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cholecystokinin have the ability to impact emotion in the brain83. The abundance of
Streptococcus species have been associated with heightened sensitivity to pain84.
Here we document the gut-brain axis changes that occur following stroke in the first three
weeks of rehabilitation and their associations with functional recovery measures in 12
stroke participants and 30 community dwelling adults. We measure the gut microbiome
using whole genome shotgun sequencing on stool samples. We measure Self-Care CARE
Assessment for function, the picture vocabulary and list sorting tasks for cognition, selfefficacy, sadness, support, meaning and purpose questionnaires for emotion, and pain
intensity for sensation. We compare associations of tasks with the microbiome in the stroke
population and control populations separately to provide a foundational knowledge of how
the microbiome is associated with functional tasks in healthy and stroke populations.
3.2
3.2.1

Results

Participant Characteristics

We recruited 12 participants from the acute rehabilitation hospital setting upon
admission and 30 control participants from a community dwelling sample divided into two
categories: 1) controls at risk for stroke who have not had a stroke and 2) healthy controls.
Participants were required to not have an acute disease of chronic, clinically significant
(unresolved, requiring on-going medical management or medication) pulmonary,
gastrointestinal, dermatologic, hepatic, or renal functional abnormality. Participants were
required to not have had cancer or a positive test for HIV, HBV, or HCV. Participants were
required to not be immunosuppressed or have had major surgery of the GI tract in the past
five years. Participants also had to be MRI compatible. Table 1 describes the basic
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demographic characteristics of the participants. There were 12 participants in the acute
stroke group, 18 in the at risk group, and 12 in the healthy control group. Those in the acute
stroke group were slightly older than those in either control group. The healthy control
group had a higher percentage of female participants. All of the groups were mostly white,
with the at risk group containing two black participants and the healthy control group
containing one Asian participant. The acute stroke group and healthy control group had
over 20% APOE ε2 carriers while the at risk group contained none. The participants in the
acute stroke group were less educated than those in the control groups. The healthy group
had a lower BMI than the stroke group and the at risk control group. The healthy control
group by definition had no participants with diabetes, hypertension, or hyperlipidemia.
3.2.2

Stroke microbiome with pro-inflammatory and fewer butyrate producing taxa

Figure 3.1 shows the alpha diversity of the various groups using the Shannon diversity
index. The acute stroke group had a diversity of 3.85 ± 0.385, the at risk group had a
diversity of 3.88 ± 0.273, and the healthy control group had a diversity of 3.81 ± 0.392.
There were no significant differences between the groups on a pairwise Mann-Whitney test
with an alpha=0.05. Figure 3.2 shows the beta diversity of the various groups using the
Bray-Curtis dissimilarity index. An ANOSIM R test reveals a significant dissimilarity
between the acute stroke and at risk groups (R=0.405, p=0.001) and a significant
dissimilarity between the acute stroke and healthy control groups (R=0.126, p=0.039). The
dissimilarity between the at risk and healthy control groups was not significant (R=0.0381,
p=0.228). Figure 3.3 shows the distribution of the most prevalent bacterial phyla amongst
the participant groups. The acute stroke group was 39.4% Bacteroidetes, 2.44%
Verrucomicrobia, 24.3% Proteobacteria, 7.1% Actinobacteria, and 25.2% Firmicutes. The
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at risk group was 33.1% Bacteroidetes, 1.68% Verrucomicrobia, 21.9% Proteobacteria,
6.4% Actinobacteria, and 35.5% Firmicutes. The healthy control group was 35.4%
Bacteroidetes, 3.0% Verrucomicrobia, 25.6% Proteobacteria, 4.7% Actinobacteria, and
29.7% Firmicutes (Figure 3.3). A detailed analysis of the microbial taxa shows significant
decreases in butyrate producers (Agathobaculum butyriciproducens, Lawsonibacter
asaccharolyticus, Anaerostipes hadrus, the genus Roseburia, and Eubacterium rectale
(Figure 3.4a-e)), secondary bile acid producers (Blautia obeum and the genus
Ruminococcus (Figure 3.4f,g)), equol producers (Adlercreutzia equolifaciens (Figure
3.4h)) and sulfate reducers (the family Desulfovibrionaceae (Figure 3.4i)). There was a
significant increase in several pro-inflammatory taxa, including Clostridium aldenense,
Clostridium bolteae, the genus Anaeromassilibacillus, Ruthenibacterium lactatiformans,
and Acidaminoccus intestini (Figure 3.4j-n).
3.2.3

Stroke dysbiosis is associated with leaky gut markers

Figure 3.5 shows the average of the leaky gut markers amongst the groups. The
calprotectin assay is a marker for intestinal inflammation and did not show differences
among the groups (Figure 3.5a). Alpha-1-antitrypsin is a marker for intestinal permeability
and was significantly increased in the acute stroke group (Figure 3.5b). Table 3.2 shows
the associations of alpha-1-antitrypsin with various microbial taxa. The presence of alpha1-antitrypsin was inversely associated with several microbial taxa, including Adlercreutzia
equolifaciens, Lawsonibacter asaccharolyticus, the genus Anaerostipes, Blautia obeum,
Coprococcus eutactus, Dorea longicatena, Lachnospira pectinoschiza, the genus
Roseburia, Agathobaculum butyriciproducens, and the genus Ruminococcus. (Figure
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3.6a-j). Alpha-1-antitrypsin was positively associated with Eggerthella lenta, Clostridium
bolteae, Anaerotruncus colihominis, and Clostridium leptum. (Figure 3.6k-n).
3.2.4

Some bacteria are associated with diet

Figure 3.7 shows the diet composition amongst the different participant groups. The
stroke group ate significantly less fiber (Figure 3.7a) and fruits and vegetables (Figure
3.7f) and more sugar sweetened beverages (Figure 3.7g). We correlated diet composition
with microbial taxa in the stroke group using linear correlation (Table 3.3). We found that
an increase of fruits and vegetables was associated with a lower abundance of the genus
Bacteroides, Eisenbergiella massiliensis, and Holdemania filiformis (Figure 3.8a-c) and a
higher abundance of Ruminococcus torques and Faecalibacterium prausnitzii (Figure
3.8d,e). A higher intake of vegetables only was associated with an increase in the relative
abundance of Clostridium bolteae (Figure 3.8f).
3.2.5

Microbiota are associated with markers of stroke recovery
3.2.5.1 Functional Testing

On the GG Self Care Assessment, the stroke group reported an average score of
25.4 out of 42 on admission to the hospital and an average score of 36.6 on discharge from
the hospital (Figure 3.9a). Collinsella aerofaciens was positively correlated with self care
scores (Table 3.4, Figure 3.10a).
3.2.5.1 Cognitive Testing
On average, the stroke group scored in the 35th percentile on the picture vocabulary
test, the at risk group scored in the 52nd percentile, and the healthy control group scored in
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the 53rd percentile. On the list sorting test, the stroke group scored in the 38th percentile,
the at risk group scored in the 52nd percentile, and the healthy control group scored in the
57th percentile (Figure 9b,c). The genus Roseburia was positively correlated with scores
on the picture vocabulary test for the stroke group (Table 3.4, Figure 3.10b).
3.2.5.1 Emotional Testing
On the self-efficacy test, the stroke group scored in the 45th percentile on average,
the at risk group scored in the 54th percentile on average, and the healthy control group
scored in the 57th percentile on average (Figure 3.9d). Bacteroides uniformis and Alistipes
putredinis were positively correlated with self-efficacy score and Escherichia coli was
negatively correlated with self-efficacy (Table 3.4, Figure 3.10c). On the sadness test, the
stroke group scored in the 55th percentile on average, the at risk group scored in the 48th
percentile on average, and the healthy control group scored in the 50th percentile on average
(Figure 3.9e). On the meaning and purpose test, the stroke group scored in the 44th
percentile on average, the at risk group scored in the 53rd percentile on average, and the
healthy group scored in the 52nd percentile on average (Figure 3.9f). The family
Eubacteriaceae was positively correlated with the score on the meaning and purpose
questionnaire (Table 3.4, Figure 3.10e). On the support test, the stroke group reported
support levels in the 47th percentile on average, the at risk group report support levels in
the 51st percentile on average, and the healthy control group reported support levels in the
46th percentile on average (Figure 3.9g). From the Actinobacteria phylum, the class
Coriobacteriia is positively correlated with support. From the Bacteroidetes phylum, the
family Odoribacteraceae is positively correlated with support. From the Firmicutes
phylum, the genus Eubacterium, the family Acidaminococcaceae, Roseburia intestinalis,
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and Phascolarctobacterium faecium are positively correlated with support. From the
Bacteroidetes phylum, Bacteroides ovatus is negatively correlated with support. From the
Firmicutes phylum, Erysipelatoclostridium ramosum and Flavonifractor plautii were
negatively correlated with support. From the Proteobacteria phylum, the family
Veillonellaceae was negatively correlated with support (Table 3.4, Figure 3.10d).
3.2.5.1 Sensation Testing
On the pain questionnaire, the stroke group reported a 4.9 out of 10, the at risk
group reported a 2 out of 10, and the healthy control group reported a 3.25 out of 10 (Figure
3.9h). In the stroke group, Alistipes shahii was positively correlated with pain scores
(Table 3.4, Figure 3.10f).
3.3

Discussion

Here we measured the gut microbiome in the first three weeks of rehabilitation following
stroke and its associations with functional recovery measures in 12 stroke participants and
30 community dwelling adults. We found significantly lower abundances of butyrate
producers, secondary bile acid producers, equol producers, and sulfate reducers in the
stroke group and significantly higher abundances of pro-inflammatory taxa.
Our work found no significant differences in alpha diversity between groups. This
is consistent with a previous human study that found no differences in alpha diversity
between cerebral infarction patients and healthy controls114. However, we did find
significant dissimilarity between the groups on beta diversity which is consistent with
previous human studies that found high dissimilarity between ischemic stroke patients and
healthy controls102,115. A detailed analysis of the relative abundance of the microbial taxa
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revealed several taxa which were lower in the stroke group compared to either of the
control groups. Agathobaculum butyriciproducens is a strictly anaerobic and butyric acidproducing bacteria that has had impressive success in restoring cognition in Alzheimer’s
disease mouse models146. Anaerostipes hadrus can produce butyrate from carbohydrates
or lactate147,148 and is often decreased in diabetes149. Eubacterium rectale is also a butyrate
producer150 responsible for metabolizing dietary plant polysaccharides151; it is increased in
obesity152 and reduces inflammatory dendritic cells150. Lawsonibacter asaccharolyticus is
also a butyrate producer153. Blautia obeum is a natural producer of bile salt hydrolases154
as well as lantibiotics that inhibit the growth of pathogenic bacteria155; it has previously
been shown to be decreased in acute cerebral infarction156. Roseburia is a butyrate
producer157 that utilizes acetate 148 and increases serotonin and melatonin and is reduced in
ulcerative colitis158 and hypertension159; treatment with Roseburia hominis in ulcerative
colitis has been shown to strengthen gut barrier function and enhance T regulatory cells160.
Ruminococcus bacteria produce secondary bile acids161. Adlercreutzia equolifaciens is an
equol producer162 and low abundances have been associated with primary sclerosing
cholangitis163. Desulfovibrionaceae reduces sulfate164.
Several bacterial taxa were higher in the stroke group as compared to the control
groups. Ruthenibacterium lactatiformans is an obligate anaerobe that is a major lactate
producer and is also found to be increased in patients with multiple sclerosis165.
Clostridium bolteae is an obligate anaerobe commonly found to be increased in patients
with autism166, neuromyelitis optica spectrum disorders167, multiple sclerosis168,169, and
spondyloarthritis170. Acidaminococcus intestini has been associated with a proinflammatory diet171. Increased abundance of the genus Lachnoclostridium is associated
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with ulcerative colitis172 and obesity173. The genus Anaeromassilibacillus is associated
with malnutrition174.
Importantly, the healthy control group contained a significant percentage of APOE
ε2 carriers, which potentially shapes the gut microbiome characteristics for this group with
a higher relative abundance of Ruminococcaceae and Gemmiger species and a lower
abundance of Prevotellaceae species175.
Alpha-1-antitrypsin can be a marker of increased intestinal permeability when it is
found in the stool. Calprotectin can be a marker of intestinal inflammation. There was a
large increase of fecal alpha-1-antitrypsin in our participants with stroke. Gut inflammatory
and immune responses following stroke are central to this increased gut permeability. The
bacteria that we found are disrupted following stroke which also correlate with alpha-1antitrypsin include increased Clostridium bolteae and decreased Adlercreutzia
equolifaciens, Anaerostipes, Roseburia, Ruminococcus, Blautia obeum, Agathobaculum
butyriciproducens, and Lawsonibacter asaccharolyticus. Roseburia has consistently been
associated with intestinal permeability both as a microbe that bolsters intestinal
permeability176 and as a microbe that changes in response to changes in the intestinal
permeability177-179. We did not see a significant increase in calprotectin, likely because it
is less stable at room temperature180.
We found that certain dietary features are associated with the abundance of specific
bacteria. This is congruent with other groups who have found that dietary modification is
associated with gut microbiome composition181. In our study particularly, we found that
most of the bacteria which were affected by stroke were not affected by diet, with the
exception of a positive relationship Clostridium bolteae with vegetable intake. This is
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interesting since Clostridium bolteae was increased in stroke. There are many studies that
describe the effects of a vegetarian diet on the microbiome182,183.
Our results indicate that the participants performed functionally better at discharge
than at admission to the hospital. This is expected in the rehab setting. The species
Collinsella aerofaciens was positively correlated with the Self Care Assessment.
Collinsella aerofaciens is a natural bile salt hydrolase producer154,184 that is naturally
increased in response to a cow milk supplemented diet185,186. While Collinsella aerofaciens
is generally considered to be a proinflammatory species that increases gut permeability187,
it has been associated with healthy clinical outcomes188. While bile acids do not normally
cross the blood brain barrier, in the context of a leaky blood brain barrier, they can
accumulate in the hypothalamus and inhibit the hypothalamic-pituitary-adrenal axis,
thereby suppressing the inflammatory response189,190.
Participants in the stroke group perform more poorly on cognitive tests compared
to those in the control groups. Cognitive impairment is common following stroke and is
often the precursor to dementia and cognitive decline191. Amongst stroke participants, the
genus Roseburia was positively correlated with performance on the picture vocabulary test.
Previous groups have seen a correlation of memory performance with Roseburia192,193. It
is possible that Roseburia enhances memory performance through butyrate production
since butyrate has been shown to be a cognitive enhancer of a weak memory194.
We found that the stroke group reported lower self-efficacy than the control groups.
Bacteroides uniformis and Alistipes putredinis were positively correlated with self-efficacy
and Escherichia coli was negatively correlated with self-efficacy. The concept of selfefficacy encapsulates a person’s perception of their capability for performance195. Self37

efficacy has been shown to be a strong variable in impacting recovery following stroke196.
While it is not known why these taxa correlate with self-efficacy, it is possible that
individuals with a higher self-efficacy are more likely to make healthy choices following
stroke which would correlate with butyrate producing bacteria like Bacteroides uniformis
as opposed to inflammatory species like Escherichia coli197. The Enterobacteriaceae
family, which E. coli is from, has previously been reported as being associated with bad
outcomes in the context of stroke118,198,199.
We found that the stroke group reported lower meaning and purpose than the
control groups. The family Eubacteriaceae was positively correlated with scores on the
meaning and purpose questionnaire. Depression is a common phenomenon following
stroke200 and is characterized by low purpose in life. Increasing purpose in life has been
proposed as a possible treatment for stroke201,202. The gut microbiome has previously been
implicated in the development of post-stroke depression and correlated with dysregulation
of lipid metabolism113.
The stroke group reported similar levels of support to those of the control groups.
The class Coriobacteriia was positively correlated with support. Social isolation stress has
been shown to alter the gut-brain axis203. The class Coriobacteriia contains many species
which are equol producers. Since equol producers and butyrate producers are associated
with social support, it is possible that one mechanism by which people who have strokes
who have more support do better is mediated by the microbiome.
The stroke group reported experiencing more pain than the control groups. Pain is
a very common phenomenon following stroke and can include complex regional pain
syndrome, musculoskeletal pain, spasticity-related pain, and post-stroke headache204. In
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the stroke group, Alistipes shahii was positively associated with reported pain. The
abundance of Alistipes shahii is highly positively correlated with trimethylamine-N-oxide
(TMAO), a marker of poor cardiometabolic health205. While it is unknown how Alistipes
shahii is associated with pain, many other studies have linked the microbiome with pain206,
including other species of Alistipes with pain207.
While this study provides valuable insights into the associations of the composition
of bacterial communities in the gut and various markers of stroke recovery, it has many
limitations. As a prospective case control study, it cannot definitively say that the
associations are causing stroke recovery to be altered. Future experiments should test the
associations found here to determine causation. Additionally, our sample consists largely
of older white adults from Kentucky. Larger studies comprising more diverse populations
are needed to see whether these associations are generalizable. Furthermore, we used a
false discovery rate of q<0.25. This means that up to 25% of our found associations may
be false positives. More targeted experiments are needed in the future to better characterize
these associations.
Altogether, we found that stroke was associated with an increase of proinflammatory bacterial taxa and a decrease in taxa that produce butyrate and secondary bile
acids necessary for healthy metabolic function. This shift towards inflammation is likely
due to the activation of the sympathetic nervous system and hypothalamic-pituitary-adrenal
axis in response to the stroke that increase gut permeability and decrease gut motility.
While this inflammatory shift can help to mitigate the acute effects of stroke in the brain,
the residual inflammation in the weeks and months following the stroke is likely
undermining recovery. Previous studies have also found that butyrate-producing bacteria
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were significantly reduced in cerebral ischemia patients and that this reduction is associated
with poor outcomes115,208,209. Future studies should explore treatments targeting the
composition of microbial communities following stroke as a way to boost recovery from
stroke in combination with other rehabilitation therapies. It is possible that optimizing
butyrate producers, secondary bile acid producers, equol producers, and sulfate reducers in
the gut could contribute to creating a rehabilitation environment where recovery is boosted.
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Table 3.1 Participant Characteristics
Acute Stroke

At Risk
Controls

Healthy
Controls

12
68.5 ± 12.68
83.33%
100.00%
0.00%
0.00%
41.67%

18
66.33 ± 6.53
77.78%
88.89%
11.11%
0.00%
61.11%

12
64.75 ± 4.75
91.67%
91.67%
0.00%
8.33%
41.47%

(% APOE ε3/ε4)

33.33%

33.33%

25.00%

(% APOE ε4/ε4)

0.00%

5.56%

0.00%

(% APOE ε2/ε4)

8.33%

0.00%

0.00%

16.67%

0.00%

33.33%

13.27 ± 2.97
29.65 ± 7.78
33.33%
75%
81.82%

16.78 ± 1.52
28.43 ± 5.81
16.67%
72.22%
50.00%

17.92 ± 2.07
24.72 ± 3.95
0%
0%
0%

N
Age
Sex (% Female)
Race (% White)
(% Black)
(% Asian)
Genotype (% APOE ε3/ε3)

(% APOE ε2/ε3)
Education
BMI
Diabetes
Hypertension
Hyperlipidemia
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Table 3.2 Microbial Taxa Associated with fecal Alpha-1-Antitrypsin
Bacteria
Coefficient
Taxa Positively correlated with Alpha-1-Antitrypsin
Eggerthella lenta
0.468
Clostridium bolteae
0.274
Clostridium leptum
0.344
Anaerotruncus colihominis
0.456
Taxa negatively correlated with Alpha-1-Antitrypsin
Adlercreutzia equolifaciens
-0.307
Genus Anaerostipes
-0.298
Family Lachnospiraceae
-0.113
Lachnospira pectinoschiza
-0.215
Genus Roseburia
-0.42
Roseburia inulinivorans
-0.299
Genus Ruminococcus
-0.457
Blautia obeum
-0.359
Dorea longicatena
-0.473
Lawsonibacter asaccharolyticus
-0.256
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Q-Value
0.1731
0.1814
0.2363
0.1814
0.1731
0.1731
0.2074
0.1731
0.07802
0.1731
0.1814
0.1440
0.1626
0.1854

Table 3.3 Diet Correlates with Microbial Taxa in Stroke Participants
Stroke Diet Feature
Fiber
Calcium
Whole Grains
Sugar
Dairy
Fruits and Vegetables

Vegetables Only
Sugar Sweetened Beverages

Microbial Taxa
None
None
None
None
None
Ruminococcus torques
Eisenbergiella massiliensis
Faecalibacterium prausnitzii
Holdemania filiformis
Genus Bacteroides
Clostridium bolteae
None
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Coef

Q Value

1.00
-0.301
0.0974
-0.385
-0.153
0.578

0.04917
0.05379
0.04917
0.04917
0.2464
0.1554

Table 3.4 Microbial Taxa correlated with Markers of Stroke Recovery
Marker of Stroke
Recovery
Self Care Assessment
Picture Vocabulary Test
List Sorting Test
Self-Efficacy
Questionnaire
Sadness Questionnaire
Meaning and Purpose
Questionnaire

Support Questionnaire

Pain Self-Rating

Bacteria
Collinsella aerofaciens
Genus Roseburia
None
Bacteroides uniformis
Family Enterobacteriaceae
Escherichia coli
None
Family Eubacteriaceae
Class Coriobacteriia
Family Odoribacteraceae
Genus Eubacterium
Family Acidaminococcaceae
Roseburia intestinalis
Phascolarctobacterium faecium
Bacteroides ovatus
Erysipelatoclostridium ramosum
Flavonifractor plautii
Family Veillonellaceae
Alistipes shahii

44

Coefficient

Q-Value

0.772
0.593

0.01921
0.1546

0.337
-0.766
-0.483

0.2202
0.1747
0.2202

1.29

0.1205

0.299
0.215
0.870
0.133
0.0584
0.0505
-0.238
-0.375
-0.437
-0.683
0.311

0.1691
0.1888
0.2258
0.2258
0.2258
0.1691
0.1888
0.2258
0.1580
0.2258
0.04039

Figure 3.1 Alpha Diversity amongst the participants groups did not differ on Wilcoxon
rank sum test
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Figure 3.2 Beta Diversity amongst the groups
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Relative Abundance
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Figure 3.3 Relative Abundance of most prevalent phyla
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Figure 3.4 Significant Associations of Microbial Taxa with Stroke and At Risk Groups as
compared to the healthy control group
The following taxa are lower in the stroke group: A) Agathobaculum butyriciproducens,
B) Lawsonibacter asaccharolyticus, C) Anaerostipes hadrus, D) Genus Roseburia, E)
Eubacterium rectale, F) Blautia obeum, G) Genus Ruminococcus, H) Adlercreutzia
equolifaciens, I) Family Desulfovibrionaceae. The following taxa are higher in the stroke
group: J) Clostridium aldenense, K) Clostridium bolteae, L) Genus Anaeromassibacillus,
M) Ruthenibacterium lactatiformans, N) Acidaminococcus intestini
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Figure 3.5 Leaky Gut Markers were compared amongst the participant groups using
Kruskal-Wallis Test.
* p-value < 0.05
** p-value < 0.01
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Figure 3.6 Microbial Taxa Associated with fecal Alpha-1-Antitrypsin.
Stars indicate bacteria which were also associated with stroke. Negative associations
include A) Adlercreutzia equolifaciens, B) Lawsonibacter asaccharolyticus, C) the genus
Anaerostipes, D) Blautia obeum, E) Coprococcus eutactus, F) Dorea longicatena, G)
Lachnospira pectinoschiza, H) the genus Roseburia, I) Agathobaculum
butyriciproducens, and J) the genus Ruminococcus. Positive associations include K)
Eggerthella lenta, L) Clostridium bolteae, M) Anaerotruncus colihominis, and N)
Clostridium leptum.
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Figure 3.7 Diet composition amongst the groups.
Diet was compared between each of the groups using a Wilcoxon rank sum test in
several components: A) fiber, B) calcium, C) whole grains, D) sugar, E) dairy, F) fruits
and vegetables, and G) sugar-sweetened beverages
* p-value < 0.05
** p-value < 0.01
*** p-value < 0.001
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Figure 3.8 Microbial Taxa Associated with diet in stroke participants.
Negative associations with fruits and vegetables are with A) the genus Bacteroides, B)
Eisenbergiella massiliensis, and C) Holdemania filiformis. Positive associations with
fruits and vegetables are with D) Ruminococcus torques, E) Faecalibacterium prausnitzii,
and F) Clostridium bolteae.
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Figure 3.9 Markers of stroke function at baseline and follow up for acute stroke, at risk,
and healthy participants.
Assessments include A) Self Care Assessment, B) Picture Vocabulary, C) List
Sorting, D) Self-Efficacy, E) Sadness, F) Meaning and Purpose, G) Support, and H) Pain
Intensity.
* p-value < 0.05
** p-value < 0.01
*** p-value < 0.001
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Figure 3.10 Microbial Taxa associations with Markers of Stroke recovery.
Association plots depict the correlation between microbial taxa and A) Self Care
Assessment, B) Picture Vocabulary Test, C) Self-Efficacy, D) Support, E) Meaning and
Purpose, and F) Pain
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CHAPTER 4. GUT MICROBIOME IS ASSOCIATED WITH BRAIN IMAGING IN
COMMUNITY DWELLING OLDER ADULTS
4.1

Introduction

Healthy brain aging is a focus of many older adults trying to avoid age-related
neuronal diseases. Popular dietary aids, cognitive puzzles, and exercise regimes have all
been touted as lifestyle interventions to promote healthy aging. The popularity of these
interventions suggests that there is much interest from the general population to achieve
healthy aging and there is a need for a better understanding of the connection of these
interventions with brain health. Accumulating evidence has implicated the gut microbiome
in brain health. Microbial communities that inhabit the gut communicate with the brain
through the vagus nerve in the nervous system, the peyers patches in the immune system,
and metabolites in the circulatory system
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. It is possible that manipulation of the gut

microbiome could lead to healthier brain aging.
Many imaging tools have been developed to measure brain health. T1 and T2
structural imaging is commonly used to calculate brain volume 31, but advanced imaging
modalities such as diffusion tensor imaging

32

, magnetic resonance spectroscopy 33, and

arterial spin labelling 34 can be used to detect white matter integrity, brain metabolites, and
cerebral blood flow, respectively. Many changes in the brain associated with the gut
microbiome and gut disorders have been documented with imaging. Ulcerative colitis has
been associated with a significantly reduced blood oxygen level-dependent signal in the
amygdala, thalamic regions, and cerebellar regions 72. Irritable bowel syndrome has been
associated with long-term white matter integrity changes in the brain, especially in regions
associated with integration of sensory information and corticothalamic modulation 73, and
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lower volumes in the bilateral superior frontal gyrus, insula, amygdala, hippocampus, and
middle orbital frontal gyrus 74. Probiotic administration for 4 weeks has been associated
with changes in brain activation patterns in response to emotional decision-making tasks
75,76

. Short chain fatty acids (SCFAs) are known to decrease blood brain barrier

permeability and cerebral blood flow 77. Finally, the gut microbiome is known to influence
the transcriptional activity of genes involved in neuronal myelination, thereby altering
white matter integrity 79.
Here we document the association of brain imaging markers with the gut
microbiome in 30 community dwelling older adults. We measure global and segmented
brain volume, brain metabolites, cerebral blood flow, and white matter integrity using T1
MP-RAGE imaging, magnetic resonance spectroscopy, arterial spin labeling, and diffusion
tensor imaging, respectively. We measure the gut microbiome using whole genome
shotgun sequencing on stool samples. This analysis of aging subjects is foundational to
understanding how gut microbes are associated with brain health as detected by imaging.
4.2

Results

4.2.1 Participant Characteristics
We recruited 30 participants aged 55-85 from a community dwelling sample.
Participants were recruited from Research Match and advertisements posted online and in
the community by the Center for Clinical and Translational Research at the University of
Kentucky. Participants were required to not have an acute disease of chronic, clinically
significant (unresolved, requiring on-going medical management or medication)
pulmonary, gastrointestinal, dermatologic, hepatic or renal functional abnormality.
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Participants were required to not have had cancer or a positive test for HIV, HBV, or HCV.
Participants were required to not be immunosuppressed or have had major surgery of the
GI tract in the past five years. Participants also had to be MRI compatible. Table 4.1
describes the major demographic characteristics of our participants known to influence
brain aging, with a mean age of 65.7, 17.23 years of education, and body mass index (BMI)
of 26.95. Our population was 83.33% female, 90% white, and 10% had diabetes, 43.33%
had hypertension, and 30% had hyperlipidemia. 53% were genotype APOE ε3/ε3, 33%
were ε4 carriers, and 13% were ε2 carriers.
4.2.2

Microbiome Measurements

4.2.2.1 Gut microbiome is associated with sex, ApoE Genotype,
Obesity, Diabetes, Hypertension
We measured the gut microbiome by performing whole genome shotgun
sequencing on stool samples from the participants at baseline and at a three month follow
up. We detected microbial taxa which were significantly associated (q<0.25) with our
demographic variables using the MaAsLin2 R package 125. While there were no significant
associations with age, race, education, or hyperlipidemia, significant associations existed
with sex, ApoE genotype, BMI, diabetes, and hypertension (Table 4.2). Microbial taxa
were not significantly different between the baseline and three month follow up visit.
Bacteroides plebeius and Haemophilus parainfluenzae were both significantly higher in
males than females and the Genus Clostridium was significantly lower (Figure 4.1a-c).
The firmicutes species Eubacterium eligens, Oscillibacter, and Faecalibacterium
prausnitzii were all lower in the ApoE ε2/ε3 genotype and the firmicutes species Blautia
producta, Clostridium citroniae, Clostridium lavalense, and Clostridium symbiosum were
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all higher (Figure 4.1d-g). In the ApoE ε3/ε4 genotype, the firmicutes species roseburia
and Holdemania filiformis were lower (Figure 4.1h,i). The Verrucomicrobia species
Akkermansia muciniphila was lower in obesity and inversely associated with BMI and the
bacteroidetes species Bacteroides dorei was higher (Figure 4.1j,k). The Proteobacteria
species Escherichia coli and the Bacteroidetes species Parabacteroides goldsteinii were
higher in participtants with diabetes (Figure 4.1l,m). The Firmicutes genus
Phascolarctobacterium was lower in participants with hypertension (Figure 4.1n).
4.2.2.1 Gut microbiome is associated with calcium intake and
vegetables intake
We measured dietary intake over the previous month using the Dietary Screener
Questionnaires (DSQ) in the National Health and Nutrition Examination Survey
(NHANES) 2009-10. While there were no significant associations with fiber, whole grain,
added sugar, dairy, or fruit and vegetables intake, significant associations existed with
calcium intake (Table 4.3). An increased intake of calcium was associated a higher
abundance of Bifidobacterium adolescentis, the family Acidaminococcaceae, Eubacterium
eligens, and Haemophilus parainfluenzae (Figure 4.2a-d) and a lower abundance of
Clostridium asparagiforme, Eubacterium ventriosum, and Sellimonas intestinalis (Figure
4.2e-g).
4.2.3

Imaging Measurements

We collected brain imaging on our participants to find associations between
imaging features and markers of brain health as detected by imaging. We measured brain
volume using structural T1 imaging, brain metabolites using magnetic resonance
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spectroscopy, cerebral blood flow using arterial spin labeling, and white matter integrity
using diffusion tensor imaging.
4.2.3.1 Gut microbiome is associated with Structural Imaging
Table 4.4 shows the microbial taxa that were associated with structural imaging
features. Using a False Discovery Rate of 0.25, we found that Bacteroides ovatus was
associated with the Thalamus Volume (Figure 4.3a) and Bacteroides uniformis was
associated

with

White

Matter

Hypointensities

(Figure

4.3b).

The

Family

Acidaminococcaceae was positively associated the volume of the Mid Posterior portion of
the Corpus Callosum (Figure 4.3c).
4.2.3.2 Gut microbiome is associated with Brain Metabolites
Table 4.5 shows the microbial taxa that were associated with brain metabolites
recorded in the white matter of the posterior corpus callosum. Collinsella aerofaciens was
negatively associated with GABA (Figure 4.4a) and Parasutterella excrementhihomis
were positively associated with GABA (Figure 4.4b). Alistipes putredinis and the Family
Acidaminococcaceae were positively associated with Glycerophosphocholine (GPC)
(Figure 4.4c,d). Ruminococcus lactaris was positively associated with N-acetylaspartate
and N-acetylaspartylglutamate (NAA+NAAG) (Figure 4.4e) as well as several
macromoclecules. Streptococcus thermophilus, the Genus Eubacterium, and Eubacterium
eligens were also associated with several macromolecules.
4.2.3.3 Equol producers are associated with Cerebral Blood Flow
Table 4.6 shows the microbial taxa that were associated with cerebral blood flow
in various brain regions. Several taxa from the Actinobacteria phylum were implicated in
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cerebral blood flow. These included the family Eggerthellaceae, which is negatively
correlated with brain regions responsible for language. Specifically, Adlercreutzia
equolifaciens, Asaccharobacter celatus, Gordonibacter pamelaeae are all negatively
correlated with language function and the limbic system (Figure 4.5) and Collinsella
stercoris is positively correlated with language function and the limbic system. The Genera
Alistipes and Parabacteroides, part of the Bacteroidetes phylum, are negatively correlated
with cerebral blood flow in basal ganglia regions and hippocampal regions, both implicated
in learning and memory (Figure 4.6a-c). The phylum Firmicutes is negatively correlated
with blood flow in the primary auditory cortex. Eubacterium siraeum, a member of the
phylum, is negatively correlated with the frontal eye fields and the primary somatosensory
cortex. The genus Haemophilus, and specifically, Haemophilus parainfluenzae, are
positively correlated with cerebral blood flow in memory and learning areas (Figure 4.6df), while the family desulfovibrionaceae is negatively correlated with blood flow in
memory and learning areas (Figure 4.6g).
4.2.3.4 Equol producers are associated with White Matter Integrity
Table 4.7 shows the microbial taxa that were associated with white matter integrity.
Several taxa from the Actinobacteria phylum were implicated in white matter integrity.
These included the family Eggerthellaceae, which is positively correlated with white
matter tracts in the middle cerebellar peduncle and the left external capsule, which contains
corticocortical

association

fibers.

Specifically,

Adlercreutzia

equolifaciens,

Asaccharobacter celatus, Gordonibacter pamelaeae are also positively correlated with
several tracts that connects brain regions responsible for language function and the limbic
system (Figure 4.7). Two members of the phylum Bacteroidetes, Coprobacter fastidiosus
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and Bacteroides uniformis, are negatively correlated with the superior longitudinal
fasciculus and the tapetum. The firmicutes phylum has several taxa that are positively
correlated with white matter tracts, including Eubacterium siraeum, Clostridium innocuum
(Figure 4.8b), the genus Lactobacillus (Figure 4.8c), Lachnospira pectinoschiza (Figure
4.8d), Roseburia hominis (Figure 4.8e,f), Monoglobus pectinilyticus, Clostridium
citroniae, and the Genus Flavonifractor. The firmicutes taxa Streptococcus thermophilus
and Gemmiger formicilis are negatively correlated with the superior longitudinal fasciculus
connecting the parietal, occipital, and temporal lobes.
4.3

Discussion

Here we measured the gut microbiome of 30 community dwelling older adults and
made associations with it and the imaging features of structural volume, brain metabolites,
cerebral blood flow, and white matter integrity. We found that important butyrate
producers are associated with the volume of the thalamus and corpus callosum which are
superhighway regions of the brain, responsible for relaying and processing lots of
information. We also found proinflammatory species to be associated with GABA
production. Importantly, we found the family eggerthellacaeae to be highly associated
with cerebral blood flow in areas of the brain related to language, memory, and learning
and with the white matter integrity of the tracts connecting these areas.
There were bacterial taxa related to several of the demographic variables including
sex, ApoE Genotype, BMI, Diabetes, and Hypertension. Males had more Bacteroides
plebeius and Haemophilus parainfluenzae, and fewer of the genus Clostridium.
Bacteroides plebeius contains a key enzyme for the digestions of agarose, a polymer
derived from seaweed used in gelatin, ice cream, and other desserts 210,211. Sex hormones
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are thought to play a role in microbiome differences between males and females, with
ovariectomized rats showing higher levels of the genus bacteroides

212

. Haemophilus

parainfluenzae is an infectious species that had lower abundance in conjunction with a
plant-based diet

213

. The ApoE ε2/ε3 genotype had higher lachnoclostridium species and

lower Eubacterium eligens, Oscillibacter, and Faecalibacterium prausnitzii; the ApoE
ε3/ε4 genotype had lower roseburia. The ApoE ε4/ε4 genotype had higher Sellimonas
Eubacterium eligens and Faecalibacterium prausnitzii both exert anti-

intestinalis.

inflammatory effects on the host, suggesting that individuals with ApoE ε2/ε3 genotype
have less capability or need for these anti-inflammatory effects.214 Roseburia is a famous
butyrate producer that is decreased in a genotype known for being a risk factor for cognitive
decline.215. Sellimonas intestinalis is often found increased in inflammatory diseases and
following recovery from dysbiosis

216

. BMI was inversely associated with Akkermansia

muciniphila and positively associated with Bacteroides cellulosilyticus and Bacteroides
dorei. A. muciniphila has previously been found decreased in obesity and is thought to be
protective against metabolic disorders via its excretion of endocannabinoids that control
inflammation, the gut barrier, and gut peptide secretion 217. B. cellulosilyticus can degrade
cellulose and produce short chain fatty acids

218

. B. dorei can attenuate formation of

atherosclerotic plaques by inhibiting lipopolysaccharide formation and a pro-inflammatory
response

219

. Diabetes is associated with increased Escherichia coli and Parabacteroides

goldsteinii. Escherichia coli is a normal gut commensal that has many pathologic variants
that can cause disease 220. Increases in infectious E. coli have previously been reported in
diabetes

221

. P. goldsteinii has been inversely associated with a high fat diet

thought to have anti-inflammatory properties
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223

222

and is

. The genus phascolarctobacterium was

decreased in hypertension and is a producer of short chain fatty acids 224 that has previously
been shown to be decreased in high blood pressure 225.
We found that certain dietary features are associated with the abundance of specific
bacteria. This is congruent with other groups who have found that dietary modification is
associated with gut microbiome composition 181. We found an inverse relationship between
calcium and Clostridium asparagiforme. C. asparagiforme has also been found to be
reduced in smokers with hypertension

226

. Calcium was positively associated with the

family Acidaminococcaceae, Eubacterium eligens, and the genera Haemophilus and
Phascolarctobacterium. Acidaminococcaceae species can produce short chain fatty acids
224

. Eubacterium eligens has anti-inflammatory effects on the host 214. Haemophilus species

are infectious 227. Phascolarctobacterium species are producers of short chain fatty acids
224

. While it is unknown how calcium would affect these microbial taxa, it has previously

been shown that a high calcium diet increases firmicutes species and lactic, acetic, and
butyric acid levels 228. We found a positive relationship of vegetables with Agathobaculum
butyriciproducens, a butyrate producer, and a negative effect with Eggerthella lenta, an
infectious species. There are many studies that describe the positive effects of a vegetarian
diet on the microbiome by limiting inflammatory species and promoting SCFA-producing
species 182,183.
Our results show that Bacteroides ovatus is inversely related to the Thalamus
Volume and that Bacteroides uniformis is inversely related to White Matter
Hypointensities. The Thalamus is an important relay station in the brain that communicates
information from the spinal cord and cerebellum to the cerebral cortex

229

. Bacteroides

ovatus is a commensal microbe that uses various carbohydrates and proteins as its fuel
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source 230 and is a prominent inducer of IgA 231 and promotes the reparative cytokine IL22 232 thereby stimulating epithelial recovery 233. While it is not known why the presence
of this particular bacteria would inversely correlate with thalamus size, a large thalamus
size has previously been associated with irritable bowel syndrome 234. A reduced thalamus
size has been associated with advanced chess players who have a more “streamlined” relay
station allowing them to process information very quickly

235

. White Matter

Hypointensities are a value automatically detected by FreeSurfer from a T1 image that
corresponds to the White Matter Hyperintensities typically found from a T2 image

236

.

White matter hyperintensities are a marker of vascular disease in the brain 237 and are often
associated with cognitive impairment 238. Bacteroides uniformis prefers wheat bran extract
as a fuel source and is a butyrate producer; it strengthens the first line of immune defense
against unhealthy diets 239 and improves glucose tolerance 240. While it is not known why
the presence of Bacteroides uniformis correlates inversely with White Matter
Hypointensities, this microbe has been associated with increased dopamine transporters 241
and normalizing the brain reward response to reduce anxiety in rats 242. Interestingly, the
microbiota-derived phenylacetylglutamine has previously been associated with the amount
of white matter hyperintensities in the brain 106. The Mid Posterior portion of the Corpus
Callosum is responsible for connecting portions of the parietal and temporal cortices on
each side of the brain. Many species of the family Acidaminococcaceae can produce short
chain fatty acids 224, and it has been found to be increased in Major Depression 243. While
it is unknown how Acidaminococcaceae can affect the corpus callosum volume, this taxa
has previously been associated with memory performance 244.
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We also found several taxa to be associated with metabolites in the corpus callosum.
GABA is the main inhibitory neurotransmitter in the human brain

245

. Collinsella

aerofaciens is negatively associated with GABA production, and Parasutterella
excrementhihominis is positively associated with GABA. Collinsella aerofaciens is an
obligate anaerobe
248,249

246,247

and a proinflammatory species associated with Crohn’s Disease

. Parasutterella excrementhihominis is strictly anaerobic 250 and has been associated

with impaired GI health

251

. While Collinsella aerofaciens and Parasutterella

excrementhihominis have not previously been identified as GABA producers or
consumers, bacteroides has been identified as a dominant GABA producer and
Pseudomonas as a prominent GABA consumer 252.
We also found Alistipes putredinis and the Family Acidaminococcaceae to be
positively

correlated

with

Glycerophosphocholine

in

the

corpus

callosum.

Glycerophosphocholine is a precursor to the phospholipids used in lipid bilayers and is a
natural source of choline 253. Glycerophosphocholine has been associated with white matter
microstructure and processing speed254. Alistipes putredinis has been shown to be
protective against ulcerative colitis
microbiome

256

255

and is generally associated with a healthy

. While it is unknown why Alistipes putredinis has a positive association

with glycerophosphocholine, taxa such as parabacteroides, ruminococcus, and bacteroides
have been shown to have a positive association with glycerophosphocholine 257.
We also found Ruminococcus lactaris to be associated with N-acetyl aspartate and
N-acetyl aspartylglutamate. N-acetyl aspartate correlates with neuronal mitochondrial
function and survival258, and N-acetyl arpartyl glutamate has procognitive properties259.
Ruminococcus lactaris is a butyrate producer
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260

and is negatively correlated with the

inflammatory IL-8

261

. A previous group found a link between Ruminococcus and N-

acetylaspartate thought to be mediated by ruminococcus decreasing cortisol, which impacts
brain N-acetyl aspartate 262.
Ruminococcus lactaris, Streptococcus thermophilus, and Eubacterium eligens were
also positively associated with various macromolecules. While the specific identification
of these macromolecules isn’t defined, S. thermophilus is a popular species found in yogurt
that is known to decrease uremic toxins 263, and E. eligens has anti-inflammatory properties
214

.
Several bacteria were also associated with cerebral blood flow in various brain areas.

The family Eggerthellaceae negatively correlated with cerebral blood flow in the banks of
the superior temporal sulcus and the left pars triangularis. The superior temporal sulcus is
commonly referred to as Wernicke’s area as is a central area for speech recognition and
processing.264 The left pars triangularis is commonly referred to as Broca’s area and is a
central part for speech production.265 Members of the family Eggerthellaceae are able to
convert the isoflavone daidzein (a soy product) into equol, an estrogen.266 Specific
members of this family, including Adlercreutzia equolifaciens, Asaccharobacter celatus,
and Gordonibacter pamelaeae all have negative associations with these same areas
responsible for language circuits, in addition to areas of the brain responsible to memory,
learning, and reward processing. Equol supplementation has been shown to improve long
and short term memory in rats by increasing brain antioxidant activity and improving blood
pressure.267,268 Interestingly, equol has previously been reported to increase cerebral blood
flow in rats.269 Previous studies have implicated a role of soy consumption in regulating
hypertension via its consumption by the gut microbiome. 270 Collinsella stercoris is also a
69

member of the coriobacteriia class, and positively correlates with cerebral blood flow in
the same areas of the brain that correlate with language, memory, and learning.
Interestingly, Collinsella stercoris is also highly positively correlated with Chronic Kidney
Disease.271 Interestingly, disruptions to the gut microbiome has previously been linked to
impaired cerebral blood flow via its reduction of endothelial nitric oxide synthase (eNOS)
activity 272. The genera Alistipes and Parabacteroides, part of the order bacteroidales are
inversely correlated with cerebral blood flow in the putamen, accumbens, and
hippocampus, all part of the limbic/rewards circuit. Alistipes species are highly correlated
with cholesterol levels and are short chain fatty acid producers

273,274

. Parabacteroides

species alter dopaminergic signaling 275
The phylum firmicutes and, more specifically, the order clostridiales, are inversely
correlated with blood flow in the left transverse temporal cortex. The transverse temporal
cortex is the site of the primary auditory cortex. 276 Members of the clostridiales order are
obligate anaerobes277. Eubacterium siraeum is a member of this order and is positively
correlated with HDL cholesterol levels 278.
The genus Haemophilus and the family desulfovibrionaceae are both part of the
phylum proteobacteria. Haemophilus is infectious and is positively associated with blood
flow in the cingulate and entorhinal cortices, both part of the limbic system 279. The family
desulfovribionaceae are sulfate reducing bacteria and are inversely associated with blood
flow in the limbic system 280.
The Family eggerthellaceae was also positively correlated with the white matter
integrity of the middle cerebellar peduncle and the left external capsule, which connects
the frontal and parietal cortices with the temporal cortex.281 Members of the family
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eggerthellaceae, including Adlrecreutzia equolifaciens, Asaccharobacter celatus, and
Gordonibacter pamelaeae have an inverse correlation with these same tracts in addition to
the pontine crossing trats, the corticospinal tracts, the tapetum, the fornix, and the inferior
fronto occipital fasciculus. These tracts are important for connecting the structures whose
blood flow was altered as explained in the previous paragraph. Interestingly, the relative
abundance of the Actinobacteria phylum has previously been linked to diffusion tensor
imaging measurements in the thalamus, hypothalamus, and amygdala.282
The genus Bifidobacterium is comprised of several commensal short chain fatty acid
producers 283. It is inversely correlated with the white matter integrity of the corticospinal
tract, while Clostridium innoccuum, an infectious pathogen

284

, and the equol producers

Gordonibacter pamelaeae, Assacharobacter celatus, and Adlercreutzia equolifaciens were
also positively correlated with the white matter integrity of the corticospinal tract.
The genus Lactobacillus strengthens the gut barrier

285

. It is positively associated with

white matter integrity in the medial lemniscus along with Lachnospira pectinoschiza, a
pectin degrading microbe. Monoglobus pectinilyticus also degrades pectin and is positively
associated with white matter integrity in the superior longitudinal fasciculus 286,287.
While this study provides foundational understanding of the gut-brain axis, it has
many limitations. Chief among these is that the observational nature of this study helps us
to make many associations between gut bacteria and markers of brain health on imaging,
but we are unable to determine causation. Additionally, the relatively small sample size for
a human study with a heterogeneous population potentially leaves the study underpowered
to detect smaller associations and changes in the microbiome. Future work should
investigate the long-term nature of the gut microbiome following stroke.
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This foundational study improves scientific knowledge of the bidirectional
microbiome-brain axis by highlighting the gut microbiome changes associated with
markers of brain health as detected by imaging. Future studies should examine potential
mechanisms of association; these mechanisms could be exploited to bolster brain health.
The gut is much easier to target therapeutically than the brain because the brain is protected
by the skull and the blood brain barrier. Potential gut microbiome modifiers include dietary
changes, prebiotics, probiotics, fecal transplants, or other pharmacologic therapies and
could be developed to bolster brain health. Specific methods to employ would be butyrate
and equol supplementation and a probiotic intervention of butyrate and equol producers,
including roseburia. These types of interventions would be easily implemented, would be
inexpensive, and would provide patients with additional tools to optimize healthy brain
aging.

72

Table 4.1 Participant Characteristics
N
30
Age
65.7 ± 5.79
Sex (% Female)
83.33%
Race (% White)
90.00%
(% Black)
6.67%
(% Asian)
3.33%
Genotype (% APOE ε3/ε3) 53.33%
(% APOE ε3/ε4) 30.00%
(% APOE ε4/ε4) 3.33%
(% APOE ε2/ε3) 13.33%
Education
17.23 ± 1.80
BMI
26.95 ± 5.36
Diabetes
10.00%
Hypertension
43.33%
Hyperlipidemia
30.00%
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Table 4.2 Microbial Taxa associated with Demographic Features
Demographic
Feature
Age

Sex (Male)

Taxa Key Characteristics

Bacterial Taxa
None
Bacteroides plebeius
Genus Clostridium
Genus Haemophilus

Race
ApoE ε2
carriers
ApoE ε4
carriers
Education
Obese

Diabetes

None
Eubacterium eligens
Blautia producta
Genus Lachnoclostridium
Genus Oscillibacter
Faecalibacterium prausnitzii
Genus Roseburia
Holdemania filiformis
None
Akkermansia muciniphila
Bacteroides dorei
Escherichia coli

Parabacteroides goldsteinii
Genus
Hypertension
Phascolarctobacterium
Hyperlipidemia None
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β

Q-Value

Metabolizes agarose
Also inhabits female
reproductive tract
Infectious, inversely
associated with plant
based diet

0.969

0.01641

-1.12

0.04952

0.611

0.06091

Anti-inflammatory

-1.44
0.587
1.59
-2.75
-1.26
-0.638
-0.658

0.1697
0.0827
0.1171
0.1808
0.1808
0.2134
0.2049

-0.663
1.62

0.1205
0.0703

1.76

0.1169

1.34

0.2214

-1.26

0.06803

Anti-inflammatory
Butyrate producer

Decreased in obesity
Anti-inflammatory
Normal gut commensal
with capacity to cause
extraintestinal infections
Anti-inflammatory
Produce SCFAs

Table 4.3 Diet correlates with microbial taxa
Diet Feature

Microbial Taxa

Fiber

None

Taxa Key
Characteristics

Clostridium asparagiforme
Family Acidaminococcaceae
Calcium

Eubacterium eligens
Genus Haemophilus

Whole
Grains
Added
Sugars
Dairy
Fruits
Vegetables

Genus Phascolarctobacterium

Produce SCFAs
Antiinflammatory
Infectious,
inversely
associated with
plant based diet
Produce SCFAs

Coef
0.247
0.201

Q
Value
0.1906
0.1906

0.312

0.2166

0.176

0.2166

0.203

0.2421

0.347

0.1405

0.311

0.1405

None
None
None
None

Infectious

Eggerthella lenta

Butyrate
producer

Agathobaculum
butyriciproducens
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Table 4.4 Microbial taxa associated with imaging features
Microbial Taxa
Bacteroides ovatus
Bacteroides
uniformis
Family
Acidaminococcaceae

Taxa Key
Characteristics
Induces IgA
Promotes IL-22
Butyrate
Producer
SCFA Producer

Imaging Feature Volume

Coef

Q
Value

Thalamus

-0.672

0.169

White Matter Hypointensities

-0.376

0.1578

Corpus Callosum Mid
Posterior

0.364

0.2157
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Table 4.5 Microbial taxa associated with brain metabolites
Taxa Key
Characteristics

Metabolite

Coef

Q
Value

GABA

0.357

0.0615
2

Parasutterella
excrementhihominis

GABA

0.703

0.0739
1

Alistipes putredinis

GPC

0.956

0.2127

GPC

0.338

0.2127

NAA+NAAG

0.653

0.0965
8

MM09

0.688

0.0351
9

MM12

0.612

0.0916
0

MM09

0.526

0.1315

MM12

0.547

0.0714
3

MM14+Lip13
a+Lip13b+M
M12

0.484

0.2314

Microbial Taxa
Collinsella aerofaciens

Family
Acidaminococcaceae

Ruminococcus lactaris

Proinflammatory
Bile-Acid Conjugator

SCFA Producer

Butyrate Producer
Inhibits IL-8

Streptococcus
thermophilus

Decreases uremic
toxins

Eubacterium eligens

Anti-inflammatory
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Table 4.6 Microbial Taxa associated with Cerebral Blood Flow
Microbial Taxa
Family
Eggerthellaceae
Adlercreutzia
equolifaciens

Asaccharobacter
celatus

Gordonibacter
pamelaeae

Collinsella stercoris

Genus Alistipes
Genus
Parabacteroides
Order Clostridiales
Eubacterium
siraeum
Genus Haemophilus

Taxa Key
Perfusion Imaging Feature
Characteristics
Banks of Superior Temporal
Equol
Sulcus
Producers
Left Pars Triangularis
Banks of Superior Temporal
Sulcus
Equol Producer
Total Middle Temporal Cortex
Left Pars Triangularis
Total Banks of Superior
Temporal Sulcus
Left Middle Temporal Cortex
Equol Producer Total Middle Temporal Cortex
Total Insula
Left Pars Triangularis Cortex
Right Pars Opercularis Cortex
Total Putamen
Left Pars Triangularis Cortex
Equol Producer
Left Posterior Cingulate Cortex
Total Posterior Cingulate Cortex
Right Banks of Superior
Temporal Sulcus
Bile-Acid
Total Middle Temporal Cortex
Conjugator
Left Pars Triangularis
Left Transverse Temporal
Left Putamen
SCFA Producer
Left Accumbens area
Alter dopamine
Right Hippocampus
signaling
Left Transverse Temporal Cortex
Total Middle Temporal Cortex
Positively
correlated with Right Caudal Middle Frontal
HDL
Cortex
cholesterol
Right Post Central Cortex
Total Rostral Anterior Cingulate
Infectious
Total Posterior Cingulate Cortex

Haemophilus
parainfluenzae
Family
Sulfate reducers
Desulfovibrionaceae

Coef

Q
Value

-0.364

0.1261

-0.219

0.09265

-0.551

0.1261

-0.356
-0.355

0.2146
0.09821

-0.573

0.07049

-0.595
-0.652
-0.527
-0.518
-0.630
-0.577
-0.525
-0.594
-0.635

0.0489
0.01391
0.2112
0.09265
0.02800
0.08859
0.09265
0.1455
0.0503

0.460

0.00409

0.340
0.327
0.339
-0.485
-0.406

0.1678
0.09401
0.2098
0.00174
0.1063

-0.753

0.00210

-0.900
-0.715

0.2098
0.1352

-0.770

0.1239

-0.674
0.267
0.240

0.1691
0.09848
0.1928

Right Entorhinal

0.281

0.02571

Right Entorhinal Cortex

-0.449

0.1875
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Table 4.7 Microbial taxa associated with white matter integrity
Microbial Taxa

Taxa Key
Characteristics

Family
Eggerthellaceae

Equol Producers

Gordonibacter
pamelaeae
Assacharobacter
celatus

Equol Producer

Equol Producer

Adlercreutzia
equolifaciens

Equol Producer

Genus
Bifidobacterium

SCFA Producer

Coprobacter
fastidiosus
Bacteroides
uniformis
Eubacterium
siraeum
Clostridium
innocuum
Genus
Lactobacillus
Lachnospira
pectinoschiza
Roseburia
hominis

Butyrate Producer

White Matter
Integrity Imaging
Feature
Middle Cerebellar
Peduncle
Left External Capsule
Middle Cerebellar
Peduncle
Pontine Crossing Tract
Left Corticospinal
Tract
Left Tapetum
Left Corticospinal
Tract
Left Corticospinal
Tract
Left Fornix
Left Inferior Fronto
Occipital Fasciculus
Left Corticospinal
Tract
Right Superior
Longitudinal
Fasciculus
Right Tapetum

Positively correlated Middle Cerebellar
with HDL cholesterol Peduncle
Left Corticospinal
Infectious
Tract
Left Medial
Strengthen gut barrier
Lemniscus
Left Medial
Degrades pectin
Lemniscus
Left Cingulum
Butyrate Producer
Left Inferior Fronto
Occipital Fasciculus
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Coef

Q Value

0.245

0.05163

0.252

0.09284

0.720

0.004926

0.646

0.05013

0.613

0.1115

0.662

0.02824

0.468

0.1821

0.324

0.2284

0.396

0.1751

0.437

0.06521

0.547

0.1115

0.473

0.2484

0.469

0.03213

0.645

0.1392

0.423

0.2468

0.380

0.2285

0.296

0.2285

0.544

0.09441

0.503

0.06636

Genus
Streptococcus

Decreases uremic
toxins

Monoglobus
pectinilyticus

Degrades pectin

Clostridium
citroniae
Genus
Flavonifractor
Gemmiger
formicilis

Right Superior
Longitudinal
Fasciculus
Right Superior
Longitudinal
Fasciculus
Tapetum
Right Superior
Longitudinal
Fasciculus
Right Superior
Longitudinal
Fasciculus
Superior Longitudinal
Fasciculus
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0.416

0.2484

0.609

0.2484

0.626

0.1934

0.384

0.2484

0.369

0.2484

0.447

0.2047
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Figure 4.1 Microbial taxa associated with demographic features.
Male sex was associated with higher A) Bacteroides plebeius and B) the genus
Haemophilus and lower C) genus Clostridium. The Apolipoprotein E (ApoE) ε2 genotype
was associated with lower D) Eubacterium eligens, E) the genus Oscillibacter, and F)
Faecalibacterium prausnitzii and higher G) genus Lachnoclostridium. The ApoE ε4
genotype was associated with lower H) genus Roseburia and I) Holdemania filiformis.
Obesity was associated with higher J) Bacteroides dorei and lower K) Akkermansia
muciniphila. Diabetes was associated with higher L) Parabacteroides goldsteinii and M)
Escherichia coli. Hypertension was associated with lower N) genus
Phascolarctobacterium.
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Figure 4.2 Microbial Taxa Associations with Dietary Calcium intake.
The following taxa were positively associated with calcium intake: A) Bifidobacterium
adolescentis, B) Eubacterium eligens, C) family Acidaminococcaceae, and D)
Haemophilus parainfluenzae. The following taxa were negatively associated with
calcium intake: E) Clostridium asparagiforme, F) Eubacterium ventriosum, and G)
Sellimonas intestinalis.
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Figure 4.3 Microbial Taxa Associations with Structural Imaging Features.
A) The thalamus volume is positively associated with Bacteroides ovatus abundance. B)
White Matter (WM) hypointensities are positively associated with Bacteroides uniformis
abundance. C) The volume of the mid-posterior portion of the corpus callosum
(CC_Mid_Posterior) is positively associated with the family acidaminococcaceae
abundance.
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Figure 4.4 Notable Microbial Taxa Associations with Brain Metabolites in the white
matter of the corpus callosum.
A) GABA is negatively associated with the genus Collinsella and B) positively
associated with Parasutterella excrementhihominis. C) Glycerophosphorylcholine (GPC)
is positively associated with Alistipes putredinis and D) the family Acidaminococcaceae.
E) N-acetyl aspartate (NAA) or N-acetyl aspartyl glutamate (NAAG) is positively
associated with Ruminococcus lactaris.
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Figure 4.5 Species from the eggerthellaceae family are negatively associated with
cerebral blood flow (CBF) in language, memory, and limbic brain areas.
Eggerthellaceae spp. are negatively associated with CBF in A-C) the banks of the
superior of the superior temporal sulcus, D-F) the pars triangularis, G,H) the middle
temporal gyrus, I) the putamen, J) the pars opercularis, K) the insula, and L) the posterior
cingulate.
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Figure 4.6 Notable Microbial Taxa Associations with cerebral blood flow (CBF) in
limbic and memory regions.
The genus Alistipes is negatively associated with CBF in the A) Putamen and B)
Accumbens area. The genus Parabacteroides is negatively associated with CBF in the C)
Hippocampus. The genus Haemophilus is positively associated with CBF in the D)
posterior cingulate cortex, E) entorhinal cortex, and F) rostral anterior cingulate cortex.
The family Desulfovibrionaceae is negatively associated with G) the entorhinal cortex.
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Figure 4.7 Species from the eggerthellaceae family are positively correlated with
white matter integrity (WMI) in language, memory, and limbic brain circuits.
Eggerthellaceae spp. Are positively associated with WMI in A) the external capsule, B)
the middle cerebellar peduncle, C,F,G) the corticospinal tract, D) the tapetum, E) the
pontine crossing tract, H) the fornix, and I) the Inferior fronto-occipital fasciculus.
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Figure 4.8 Notable Microbial Taxa Associations with cerebral blood flow (CBF) in
limbic and memory regions.
A) The Genus Bifidobacterium is negatively associated with WMI in the corticospinal
tract. B) Clostridium innocuum is positively associated with WMI in the corticospinal
tract. C) The Genus Lactobacillus is positively associated with WMI in the medial
lemniscus. D) Lachnospira pectinoschiza is positively associated with WMI in the medial
lemniscus. Roseburia hominis is positively associated with WMI in E) the cingulum and
F) the Inferior fronto-occipital fasciculus.

89

CHAPTER 5. GENERAL DISCUSSION
In summary, we found that stroke was associated with an increase of pro-inflammatory
bacterial taxa and a decrease in taxa that produce butyrate and secondary bile acids
necessary for healthy metabolic function. Roseburia, an important butyrate producer, had
a lower relative abundance in association with a leaky gut. In individuals with the APOE
ε2/ε3 genotype, bacteria with anti-inflammatory properties were reduced and in individuals
with APOE ε3/ε4 genotype, roseburia was reduced.
On imaging analysis, we found that butyrate producers are associated with the volume
of the thalamus and corpus callosum which are superhighway regions of the brain,
responsible for relaying and processing mass information. Proinflammatory species were
associated with GABA production. Importantly, the family eggerthellacaeae was highly
associated with cerebral blood flow in areas of the brain related to language, memory, and
learning and with the white matter integrity of the tracts connecting these areas.
Finally, many functional tasks were associated with gut microbiome levels. Recovery
from stroke was associated with Collinsella aerofaciens, a bile-salt conjugator that may
inhibit the hypothalamic-pituitary-adrenal axis in the context of a leaky blood brain barrier.
Long-term memory performance in stroke is associated with roseburia abundance.
Bacteroides uniformis, a butyrate producer, is positively correlated with self-efficacy,
while Enterobacteriaceae, a classically inflammatory family, is negatively correlated with
self-efficacy. Eubacteriaceae is positively associated with meaning and purpose.
Coriobacteriia, an equol producer, is positively correlated with social support. Alistipes
shahii, a TMAO producer is correlated with perceived pain.
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Butyrate-producing bacteria continuously emerged as being decreased in the context
of stroke and inversely related to stroke severity markers. Previous studies have also found
a reduction of butyrate-producing bacteria in the context of stroke.208 Butyrate is a histone
deacetylase inhibitor and a ligand for a subset of G protein-coupled receptors that has the
power to affect gene expression and have many downstream applications.288 Butyrate
treatment in stroke has been associated with an increase in the number of cells expressing
markers of developing and migrating neurons and synaptogenesis.289 In rats, administration
of butyrate following stroke reduces infarct volume and improves neurological function at
24 and 72 hours after middle cerebral artery occlusion by ameliorating the apoptosis caused
by the stroke by binding to G-protein coupled receptors that regulate apoptosis and
inflammation.95
While many butyrate producing bacteria appeared important in the context of stroke,
the genus roseburia was continuously hallmarked as one of the most important butyrate
producers. We found that roseburia was decreased in our stroke participants in association
with the leaky gut marker fecal alpha-1-antitrypsin. Additionally, roseburia was decreased
in individuals with the ApoE ε3/ε4 genotype, a risk factor for severe stroke and post-stroke
cognitive impairment. Finally, long term memory performance was associated with
roseburia abundance. A previous study found that individuals with a higher abundance of
roseburia generally experienced strokes that were more mild compared with their
counterparts with a lower abundance who experienced more severe strokes, suggesting a
neuroprotective effect of roseburia.290 Roseburia uses its flagella to penetrate the colonic
mucus layer to interact with the epithelium and is therefore one of the most abundant
butyrate-producing bacteria that adhere to intestinal mucin, positioning it well for use as a
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probiotic.291 Beyond its function as a butyrate producer, roseburia is also a powerful
stimulator of the gut immune system to produce IL-22, a cytokine involved in wound
healing and protection against microbes,292,293 and reduce IL-6 and IL-17, both
proinflammatory factors.294
A surprising role of members of the class coriobacteriia in the phylum actinobacteria
was found in our markers of stroke severity. Collinsella aerofaciens was found to be
positively associated with functional recovery in the rehabilitation setting. It was also found
to be negatively associated with GABA abundance in the corpus callosum. While C.
aerofaciens is commonly considered to be a pro-inflammatory species in the context of
inflammatory bowel disease,248,249 in the context of a leaky blood brain barrier like that
found in stroke, it has been reported as a bile-salt conjugator that may inhibit the
hypothalamic-pituitary-adrenal axis via bile acid deposition in the hypothalamus and
reduce CNS and systemic inflammation.189,190 The family eggerthellaceae containing the
species Asaccharobacter celatus, Adlercreutzia equolifaciens, and Gordonibacter
pamelaeae were all inversely associated with cerebral blood flow in brain regions related
to language, memory, and learning, and positively associated with the white matter
integrity connecting these regions. Additionally A. equolifaciens was inversely associated
with leaky gut and coriobacteriia as a whole was positively associated with social support.
One of the hallmark features of these bacteria is their role as equol producers. Equol is an
estrogen metabolized from soy that possesses antiatherogenic properties and improves
arterial stiffness.295 One group found that plasma levels of equol were reduced in response
to stroke in proportion to the severity of the stroke.296 A separate study found that equol
administration in rats is able to inhibit the activation of Src and the upregulation of
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gp91(phox) thought to play a prominent role in mediating ischemic alteration in neurons
following stroke.297
While this study provides foundational understanding of the gut-brain axis in the
context of stroke rehabilitation, it has many limitations. Chief among these is that the
observational nature of this study helps us to make many associations between gut bacteria
and markers of stroke severity, but we are unable to determine causation. Additionally, the
relatively small sample size for a human study with a heterogeneous population potentially
leaves the study underpowered to detect smaller associations and changes in the
microbiome. Finally, due to the challenges of the COVID-19 pandemic, many of our stroke
subjects were lost to follow-up making a longitudinal study challenging. Future work
should investigate the long-term nature of the gut microbiome following stroke.
This foundational study improves scientific knowledge of the bidirectional
microbiome-brain axis by highlighting the gut microbiome changes associated with stroke
in humans and how these changes are associated with markers of stroke severity. Future
studies should examine potential therapies targeting the microbiome after stroke in order
to optimize functional recovery. The gut is much easier to target therapeutically than the
brain because the brain is protected by the skull and the blood brain barrier. Potential gut
microbiome modifiers include dietary changes, prebiotics, probiotics, fecal transplants, or
other pharmacologic therapies and could be developed to target the specific microbial
community imbalances seen following stroke. Specific methods to employ would be
butyrate and equol supplementation and a probiotic intervention of butyrate and equol
producers, including roseburia. These types of interventions would be easily implemented,
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would be inexpensive, and would provide patients with additional tools to optimize
neuroplasticity in their difficult rehabilitation journey.
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CHAPTER 6. [SUPPLEMENT] β-AMYLOID AND TAU DRIVE EARLY
ALZHEIMER’S DISEASE DECLINE WHILE HYPOMETABOLISM DRIVES
LATE DECLINE
6.1

Summary

Clinical trials focusing on therapeutic candidates that modify β-amyloid (Aβ) have
repeatedly failed to treat Alzheimer’s disease (AD), suggesting that Aβ may not be the
optimal target for treating AD. The evaluation of Aβ, tau, and neurodegenerative (A/T/N)
biomarkers has been proposed for classifying AD. However, it remains unclear whether
disturbances in each arm of the A/T/N framework contribute equally throughout the
progression of AD. Here, using the random forest machine learning method to analyze
participants in the Alzheimer’s Disease Neuroimaging Initiative dataset, we show that
A/T/N biomarkers show varying importance in predicting AD development, with elevated
biomarkers of Aβ and tau better predicting early dementia status, and biomarkers of
neurodegeneration, especially glucose hypometabolism, better predicting later dementia
status. Our results suggest that AD treatments may also need to be disease stage-oriented
with Aβ and tau as targets in early AD and glucose metabolism as a target in later AD.
6.2

Introduction

Alzheimer’s disease (AD) is the most common form of dementia worldwide and is
defined biologically as the pathologic deposition of folded β-amyloid (Aβ) plaques and
hyperphosphorylated

neurofibrillary

tau

tangles

in

the

brain

leading

to

neurodegeneration298-300. Clinically, AD presents as a syndrome of progressive episodic
memory and executive functioning problems across a cognitive continuum ranging through
cognitively unimpaired (CU), mild cognitive impairment (MCI), and AD. While there are
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currently five drugs approved by the FDA to treat the symptoms of AD, there are no
disease-modifying therapies that alter the course of the disease. Over the past few decades,
the development of treatments for AD has been largely focused on compounds which aim
to reduce Aβ plaques, either by directly targeting Aβ itself through antibodies or by
targeting the enzymes that cleave amyloid precursor protein (APP) to produce it301,302.
However, clinical trials of drugs targeting Aβ had a 99.6% failure rate between 2002 and
2012303, and two more Aβ-focused drug trials failed in phase three in 2019304. This failure
rate is among the highest of any disease area. The high failure rate for AD drug candidates
focused on Aβ indicates that Aβ may not be the optimal therapeutic target to combat AD.
Careful analysis of AD biomarkers may give important insights into underlying AD
pathogenesis and clues about appropriate AD treatments since these biomarkers exist as
proxies for AD neuropathologic changes. Furthermore, an understanding of how the
biomarkers correlate with clinical symptoms of AD could inform clinicians making AD
management decisions to improve patient quality of life. The A/T/N biomarker framework
promulgated by the National Institute on Aging-Alzheimer’s Association was created to be
an unbiased classification scheme for the three arms of biomarkers known to underlie AD
pathology, namely neuropathological loads of Aβ (A) and tau (T), and neurodegeneration
(N, including hypometabolism and brain atrophy)

305,306

. Indeed, some research groups

have demonstrated that the distribution of tau tangles307 and hypometabolism (due to low
glucose uptake) are more strongly correlated with cognitive performance than Aβ308.
Moreover, brain atrophy is also suggested to be highly correlated with AD progression309.
However, it remains unclear whether disturbances in each arm of the A/T/N framework
contribute equally to the progression of AD symptoms or if these factors instead have
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varying impacts at different stages of AD progression. Understanding this stage-dependent
nature of the biomarkers could lead to important clues in preventing and treating AD.
In order to determine the nature of the association of AD biomarkers with the
progression of AD symptoms, in this study we assessed the statistical importance of each
arm of the A/T/N framework in predicting three progressive clinical statuses of cognitive
performance: cognitively unimpaired (CU), late mild cognitive impairment (LMCI), and
AD305. To do so, we used data from the Alzheimer’s Disease Neuroimaging Initiatives
(ADNI) database, relating to four biomarkers: Aβ (assessed from
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Florbetapir-positron

emission tomography (PET)), phosphorylated tau (pTau181, assessed from cerebrospinal
fluid), glucose uptake (assessed from 18fluorodeoxyglucose (FDG)-PET), and volumetric
measures (assessed from MRI). We used a random forest machine learning algorithm to
rank the importance of each biomarker in predicting clinical dementia status. We chose the
random forest machine learning method because it not only has the ability to fit models
with high prediction accuracy due to its use of multiple decision trees that combine to yield
a consensus prediction, but also is very interpretable due to its ranking capability of the
relative importance of predictors used in the classification (AD biomarkers in our case).
We also analyzed the relationship between A/T/N biomarkers and memory composite and
executive functioning composite scores in order to assess more directly their association
with cognitive performance. We show that A/T/N biomarkers have differing contributions
in predicting clinical dementia status based on the stage of cognitive impairment, with Aβ
and pTau having higher contribution in predicting early cognitive impairment (LMCI vs
CU) and glucose uptake having higher contribution in predicting later cognitive
impairment (AD vs LMCI and AD vs. CU). Our findings could help real-world patient
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populations by informing clinicians to make AD management decisions according to
disease stage based on the expression of the relevant A/T/N biomarkers and by informing
drug development teams to design treatments to target the pathophysiology underlying the
expression of the biomarkers at the appropriate stage of disease progression.
6.3
6.3.1

Results

Participant characterizations and data selection

Participant data was extracted from the ADNI database for inclusion in the analysis.
Participants were required to have baseline Aβ imaging biomarkers (from
PET), glucose uptake imaging biomarkers (from
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FDG PET), brain volume imaging

biomarkers (from T1-weighted structural MRI), and cognitive testing to be included in the
analysis. Participants with three or more missing values were excluded from the analysis.
As tau imaging was not available for most participants in the ADNI database, we used a
phosphorylated tau biomarker (pTau) from cerebrospinal fluid (CSF) as a measure of tau
levels. These criteria yielded a final sample of 405 participants clinically diagnosed as
being either cognitively unimpaired (CU; n = 148) or with late mild cognitive impairment
(LMCI; n = 147) or Alzheimer’s disease (AD; n = 110) (Table 6.1).
The three study groups were balanced in terms of gender, race, and ethnicity, but
not age or education, across clinical status, with the AD group being significantly older
than LMCI subjects and less educated than CU and LMCI subjects; accordingly, we
adjusted the features for age before applying them to the random forest model since age is
known to affect brain volumetric measures. Notably, the groups differed in terms of the
expression of the ε4 allele of apolipoprotein E (APOE ε4), the largest genetic risk factor
for Alzheimer’s disease310, and cognitive testing scores, with the AD group being
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significantly more likely to carry APOE ε4 and to have lower cognitive testing scores than
CU and LMCI subjects. The cognitive tests completed included the Mini-Mental State
Examination (MMSE), Clinical Dementia Rating Sum of Boxes (CDRSB), Alzheimer’s
Disease Assessment Scale-Cognitive Subscale (ADAS-cog 13), composite memory score
(ADNI_MEM), and composite executive functioning score (ADNI_EF). The biomarkers
were further stratified into 16 features classified according to the A/T/N framework,
comprising Aβ measures from 6 brain regions (frontal lobe, cingulate gyrus, parietal lobe,
temporal lobe, precuneus, and hippocampus), glucose uptake (FDG) data from 3 brain
regions (angular gyrus, temporal lobe, and posterior cingulum), volumetric measures from
6 regions (ventricles, whole brain, entorhinal cortex, hippocampus, gray matter, white
matter), and pTau levels from the CSF (Table 6.2). We show the correlation of the 16
features with each other using a heatmap. It shows that the Aβ measures were highly
correlated with each other, as were the FDG measures, and the volumetric measures, while
Aβ and pTau were negatively correlated with FDG and volumetric measures.
6.3.2

Relative importance of AD biomarkers in early and late AD

We first sought to determine the relative importance of each biomarker feature in
predicting clinical dementia status in three participant group pairings: CU vs LMCI, LMCI
vs AD, and CU vs AD. Table 6.3 shows the descending order ranking of the relative
importance of the 16 features in predicting clinical dementia status based on the random
forest method, a machine-learning algorithm that utilizes multiple decision trees to classify
and rank variables according to their accuracy in predicting outcomes. Notably, the top half
(top 8) of the features made up the majority of the relative importance (69.1%, 75.45%,
and 86.74%) for each cognitive state classification. In CU vs LMCI, hippocampal volume
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ranked highest in relative prediction accuracy with a relative importance of 12.69%,
followed by four Aβ features, pTau, FDG in the angular gyrus (FDG-Angular), and
entorhinal cortex volume; thus, features from all three arms of the A/T/N framework were
represented in the top 8 features in the CU vs LMCI comparison. In contrast, in LMCI vs
AD, neurodegeneration, i.e., the N component of the framework, dominated the top 8
features, with all three FDG glucose uptake measurements (temporal lobe = 18.88%
relative importance) and entorhinal cortex, hippocampal and ventricle volumes
represented. In particular, the three FDG features were ranked as the top three contributors
in the LMCI vs AD comparison. Moreover, the contribution of FDG was weighted even
higher in CU vs AD, with FDG-Angular making up 23.78%, and FDG in the posterior
cingulum (FDG-CingulumPost) making up 16.99% of the relative importance. Another N
component, hippocampal volume, also had an increased relative importance in the CU vs
AD comparison relative to the other comparisons. The findings suggest that, overall, Aβ
and pTau are important contributors to the progression from normal cognitive functioning
to LMCI, but that neurodegeneration, especially glucose hypometabolism, emerges as a
more important contributor when progressing from LMCI to AD. Glucose hypometabolism
also serves as a prominent distinguishing feature between normal cognitive functioning
and AD. We replicated our analysis using the SHapley Additive exPlanations (SHAP)
technique and obtained a feature ranking analysis consistent with those from the random
forest analysis.

6.3.3 Accuracy of the top 8 features vs all 16 features
We next determined the prediction accuracy of all 16 features in classifying the
three participant group pairs. For all 16 features, accuracies of 73.17%, 71.01%%, and
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90.34% were obtained for the CU vs LMCI, LMCI vs AD, and CU vs AD comparisons,
respectively (Table 6.4). To ensure that our cognitive status classification model was
robust, the F1 score was also used to evaluate the precision and recall of the model. The
results show that the 16 features were able to classify the three group pairs with high
accuracy. Knowing that the top 8 biomarker features have high relative importance in
predicting cognitive status, we also explored whether the classification accuracy of the top
8 features was comparable to that of all 16 features. Using the top 8 features only,
accuracies of 72.74%, 70.15%, and 91.63% were obtained for the CU vs LMCI, LMCI vs
AD, and CU vs AD comparisons, respectively, thus confirming that the accuracy of the top
8 features was similar to that of all 16 features. Figure 6.1 depicts the comparison of the
receiver operating characteristic curves with five-fold cross validation311 between all 16
features and between the top 8 features. We found similar results in accuracy when using
three- and ten-fold cross validations for comparison. The ROCs show that the top 8 features
performed slightly better than all 16 features in distinguishing CU vs LMCI and LMCI vs
AD. Precision recall (PR) curves verified similar levels of accuracy. These results suggest
that there may be feature redundancy present when all 16 features are used to predict
cognitive state: indeed, we found some of the features to be insignificant for cognitive state
classification, especially those with the lowest ranking. Our findings suggest that the
accuracy of the cognitive state prediction model does not depend strictly on the number of
features used in the model, and that the top 8 features may be sufficient to accurately
classify the three clinical cognitive statuses.
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6.3.4

Correlation of AD biomarkers with cognitive performance

To understand if the Top 8 features in classifying the three participant group pairs are
associated with performance on memory and executive functioning tests, we performed a
correlation analysis of each feature on a memory composite score312 and on an executive
functioning composite score313. These composite scores are validated, psychometrically
sophisticated composite scores based on the ADNI battery of neuropsychological tests
described above. Ranking the biomarker features based on their r correlation value, we
found that the pattern of biomarker correlation with performance on memory and executive
functioning tests across participant groups was similar to the pattern found in the feature
ranking analysis. When comparing the CU and LMCI groups (Figure 6.2A), memory
performance was inversely correlated with Aβ biomarkers, especially Aβ in the temporal
(Aβ-Temporal), Aβ in the precuneus (Aβ-Precuneus) and Aβ in the frontal lobe (AβFrontal). Hippocampal volume was also highly positively correlated and pTau was highly
negatively correlated with memory when comparing CU and LMCI. However, when
comparing LMCI and AD data (Figure 6.2B), in all three brain areas assessed, glucose
uptake (FDG) was the feature most highly positively correlated with memory, showing
larger correlation coefficients (r values) than those in the CU vs LMCI analysis. A similar
correlation pattern was observed when comparing CU and AD data (Figure 6.2C), with
the correlation constants being even larger for the FDG measurements than in the LMCI
and AD comparison. These results suggest that FDG biomarkers become increasingly
predictive of memory performance as cognitive decline progresses from LMCI to AD. In
particular, FDG-Angular appears to be an especially important predictor of memory
function, as it has the highest correlation coefficient of the three FDG biomarkers in these
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memory correlation analyses. A similar pattern to that observed in the memory
performance analyses emerged when correlating executive functioning with the top 8
biomarkers with FDG biomarkers becoming increasingly predictive of executive
functioning as cognitive decline progresses (Figure 6.3). Notably, however, pTau and AβPrecuneus were more highly correlated with memory than executive functioning in the CU
vs LMCI group (Figure 6.2A and Figure 6.3A). Interestingly, out of all the features, pTau
showed the smallest correlation with executive functioning in each group (Figure 6.3, AC).
6.3.5

Biomarker quantification for predicting LMCI and AD

Having shown through ranking and correlation that the top 8 features from each
participant group may be used as effective biomarkers to predict disease progression from
CU to LMCI and AD, we next sought to assess the average values for each biomarker
feature in each diagnosis group that can be used for the clinical diagnosis of these three
cognitive statuses. Table 6.5 summarizes the values of each of the top 8 features that can
be used to distinguish CU, LMCI and AD.
6.4

Discussion

We demonstrated three novel aspects in this study. First, we employed AD
biomarkers from all arms of the newly developed A/T/N framework in a random forest
machine learning analysis powerful enough to accurately predict an AD diagnosis of CU,
LMCI, or AD and to rank biomarkers in order of their importance in the prediction. Second,
we showed that biomarkers from the A/T/N framework have differing importance in
predicting clinical dementia status across the disease progression, with Aβ and pTau having
higher importance in predicting early cognitive impairment (CU vs LMCI) and glucose
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uptake having higher importance in predicting later cognitive impairment (LMCI vs AD
and CU vs AD) (Figure 6.4). Our findings suggest that Aβ and pTau accumulation
contribute to the cognitive decline that leads to LMCI, but may not be sufficient to lead to
clinical AD. Instead, neurodegeneration, especially in the form of glucose
hypometabolism, appears to be crucial for exacerbating cognitive decline and furthering
its progression to clinical AD. Additionally, we found that Aβ and pTau are more strongly
correlated with cognitive performance in LMCI, while glucose hypometabolism is more
strongly correlated with cognitive performance in AD, with FDG biomarkers becoming
increasingly predictive of memory and executive functioning as cognitive decline
progresses. While others have previously documented the temporal ordering of biomarkers
preceding clinical symptomatology of Alzheimer’s disease314, the real strength of our
analysis is in creating algorithms for computational analyses that are consistent with
available clinical and imaging data from data that has been collected over many years. The
challenge moving forward will be to translate these algorithms into usable tools to that can
assess the capacity of patients in a clinically-friendly manner. Finally, we demonstrated
that the top 8 features used in classifying the three participant group pairs were just as
accurate in predicting clinical dementia status as all 16 features combined. The top 8
biomarker features that can be used to distinguish between stages of cognitive impairment,
which may prove useful for the future prediction and diagnosis of LMCI and AD.
Machine learning techniques have previously been used to predict cognitive status
in AD using several separate biomarkers, including those measured by FDG-PET
structural MRI

315,317-319

, amyloid-PET

317,320,321

315,316

,

, and CSF-phosphorylated tau318,319.

However, this is the first study to our knowledge to combine biomarkers from all arms of
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the A/T/N framework into one integrated analysis using a machine learning method
capable of classifying clinical dementia status and ranking the biomarker features
according to their relative importance in the prediction model. Consistent with our findings,
a previous study showed that Aβ was more highly associated with cognitive decline in
cognitively normal participants, while glucose hypometabolism was more closely linked
with cognitive decline in moderate and later stages of the disease (LMCI/AD)

322

.

Additionally, another study showed that FDG-PET, which assesses glucose uptake, is more
highly correlated to cognitive ability than Aβ levels in patients with MCI and AD308. These
studies, in conjunction with our findings strongly support the argument that cognitive
decline in AD is initially propagated by Aβ and tau aggregation but is further exacerbated
by glucose hypometabolism as cognitive decline progresses. Our findings could better
inform clinical AD management decisions and may shift the targets of therapies to treat
and prevent AD in future drug development.
We found that Aβ and pTau accumulation are more highly correlated with cognitive
test scores in the CU vs LMCI comparison than other biomarker features. In particular, Aβ
deposition in the temporal cortex, precuneus, and frontal cortex, as well as increased
hippocampal volume, appear to be the most important features in predicting memory and
executive functioning performance in early stage disease. Indeed, these areas play a central
role in a wide spectrum of highly integrated tasks that are noticeably disturbed in patients
with MCI. For example, the temporal cortex is involved in memory, auditory cognition and
semantics323; the precuneus is involved in visuo-spatial image processing and episodic
memory retrieval324; the frontal lobe is involved in executive function, attention, memory,
and language325; and the hippocampus is important for declarative memory326.
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Additionally, we found that increased levels of pTau were associated with memory
performance but not executive functioning in LMCI, which is consistent with previous
findings327. We note that some groups have found a high correlation between tau levels and
cognitive decline across the entire AD spectrum328,329; even so, our results align with those
of Mielke et al., who found a significant association between tau and cognitive
performance in MCI, but a nonsignificant association between these factors in AD330. We
also noticed that the atrophy of the hippocampus and entorhinal cortex (measures of
neurodegeneration) were highly correlated in the CU vs LMCI comparison of cognitive
test scores; in addition to Aβ and pTau burden, brain atrophy in these two regions may thus
substantially contribute to progression from CU to LMCI status, as other groups have
reported331.
We observed that impaired glucose uptake is most highly correlated with cognitive
test scores in LMCI vs AD and CU vs AD groups. In particular, we found glucose uptake
in the angular gyrus (FDG-Angular) to be the most important feature for predicting
memory and executive functioning performance in later stages of AD, which is consistent
with other groups who have found reduced glucose uptake in the angular gyrus in later
cognitive decline332. This area is involved in semantic processing, word comprehension,
number processing, memory retrieval, attention, spatial and social cognition, and
reasoning333, all of which are known to decline later in disease progression. Sustained
deficits in glucose uptake in key brain areas dramatically impair cognitive functions by
reducing proper support of neuronal activity and functional processes334-336, and it is
therefore unsurprising that we found that impaired glucose uptake is highly correlated with
advancing cognitive decline.
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Notably, the individuals with AD that were included in the current study were older
and less educated than individuals in other groups, and a higher percentage of AD patients
carried the APOE ε4 allele, the largest genetic risk factor for AD, than LMCI and CU
patients. Interestingly, all three of these factors are linked to metabolic function337-341. A
widely accepted cause of the functional losses that accompany aging is decreased brain
metabolic function.342,343 Indeed, mitochondrial function declines with age in the brain and,
thus, neural ATP production decreases, which has been proposed to be a major factor in
the aging-associated loss of brain function337,340,343. Moreover, a recent study demonstrated
that regional brain metabolism and functional connectivity as measured by fMRI differed
with years of education338: relative to less educated participants, highly educated
participants had higher glucose metabolism in the ventral areas of the cerebrum, which are
mainly involved in memory, language, and neurogenesis, and functional connectivity
experiments illustrated that the brains of the highly educated individuals were overall more
efficient and resilient to aging338. The APOE gene plays a role in cholesterol and Aβ
homeostasis336, and the APOE ε4 allele is the strongest genetic risk factor for AD. Two
recent studies showed that disturbances in cholesterol metabolism, such as alterations in
bile acid metabolism, are highly associated with AD344,345. Notably, the bile acid
composition signatures were much more highly associated with brain hypometabolism and
atrophy (i.e., the “N” component of the A/T/N framework) than with Aβ and tau. Moreover,
cross-sectional FDG-PET studies found that cognitively unimpaired carriers of the APOE
ε4 allele have abnormally low glucose uptake in the same brain regions that show
hypometabolism in AD patients. Indeed, these metabolic abnormalities were observed in
late-middle-aged (40-60 years of age) and young (20-39 years of age) APOE ε4 carriers,
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who had intact memory and were free of Aβ or tau pathology346-350. These neuroimaging
results suggest that APOE ε4 carriers develop functional brain abnormalities several
decades before the possible onset of dementia, and the results are in line with our finding
that a high percentage of those with clinical AD were APOE ε4 carriers.
There are many plausible reasons to explain why we found glucose
hypometabolism to be an important biomarker in predicting progressive cognitive decline
in clinical AD. For example, impairments in brain glucose metabolism are associated with
insulin resistance, which, in turn, exacerbates Aβ deposition336,351. Indeed, AD is
characterized by impaired brain insulin signaling352. In line with this finding, type 2
diabetes mellitus, hyperlipidemia, obesity, and other metabolic diseases increase the risk
of developing AD309,336. Indeed the metabolic abnormalities present in AD are often
likened to a form of diabetes of the brain353. The preservation of normal brain glucose
metabolism is, thus, highly associated with cognitive resilience. A recent study showed
that FDG-PET uptake in the bilateral anterior cingulate cortex and anterior temporal pole
was positively associated with global cognition in cognitively unimpaired individuals over
80 years of age, despite the fact that they were Aβ-positive and APOE ε4-positive341. The
results also suggest that normal cognitive performance can be preserved even in the
presence of Aβ and APOE ε4 in 80+ year-old individuals. Another study using deep
learning methods showed that FDG-PET imaging can be used to predict AD an average of
75.8 months prior to its final diagnosis with 82% specificity and 100% sensitivity316.
Taken together, our current findings and those of previous reports suggest that
maintaining normal brain glucose metabolism is critical for cognitive resilience; therefore,
therapeutic strategies for preventing or treating AD may need to shift focus from Aβ toward
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the preservation and restoration of normal brain metabolism. Interventions with this
therapeutic strategy have been reported that use intranasal insulin administration and a
ketogenic diet. Specifically, intranasal insulin therapy provides rapid delivery of insulin to
the central nervous system via bulk flow along olfactory and trigeminal perivascular
channels without adversely affecting blood insulin or glucose levels and has been shown
to improve AD symptomology, although individual patient responses may depend on
gender, APOE genotype and insulin formulation354-356. With regards to the potential
benefits of a ketogenic diet, ketone bodies can function as an alternative fuel substrate in
the brain when glucose is unavailable or when glucose metabolism is impaired due to
insulin resistance340,357-359. One study showed that a ketogenic diet can modulate deposition
of Aβ and Tau in the CSF of MCI patients in conjunction with its modulation of the gut
microbiome and the production of short-chain fatty acids360. This finding is consistent with
an animal study showing that a ketogenic diet enhanced Aβ clearance across the bloodbrain barrier and improved the composition of the gut microbiome361. The gut microbiome
produces secondary bile acids, and, as mentioned above, alterations of bile acid production
have been observed in AD patients due to gut microbiome imbalances, suggesting another
mechanism by which AD patients may benefit from therapeutic strategies aiming to restore
normal brain metabolism like the ketogenic diet344,345. Another animal study showed that
by modulating the gut microbiome with a prebiotic diet, mice with the human APOE ε4
gene had enhanced systemic metabolism and reduced neuroinflammatory gene expression,
another hallmark of AD pathology362. Collectively, modulating metabolic function and the
gut microbiome may have a profound impact on reducing the risk of AD.
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Future efforts should include the continued collection of the A/T/N framework
biomarkers to fill critical gaps in our understanding of how their expression is associated
with AD and aging. In our model construction and analysis, we used CSF-pTau to fulfill
the “T” component of the A/T/N framework306; however, imaging-derived biomarkers
provide information about the location of the pathology in the brain that CSF-derived
markers do not305. Therefore, future work is needed to incorporate Tau-PET imaging into
the model363. In addition, glucose metabolism is tightly coupled with cerebral blood flow
(CBF)364,365, and neurovascular dysfunction also plays a critical role in cognitive
impairment; thus, it will also be important to include CBF-MRI measures in the future for
a more thorough representation of AD pathology. Indeed, Tau and CBF imaging data are
currently available for only a small subset of the ADNI cohort, and thus could not be
incorporated into our model. Additionally, while the available dataset from ADNI has more
male participants, it should be noted that AD disproportionately affects women366. Future
efforts may be needed to re-evaluate the outcome when data from the female participants
become more available.
In summary, we show that A/T/N biomarkers have cognitive impairment stagedependent roles in AD, with Aβ and pTau better predicting LMCI and neurodegeneration
(especially low glucose uptake) better predicting clinical AD. Our findings may partly
explain the repeated failures of clinical trials attempting to treat AD by modifying the Aβ
load: it may be too late to gain therapeutic benefit from the treatment of Aβ when patients
have already progressed to the clinical AD stage. Therefore, our results imply that
treatments for AD may also need to be disease stage-oriented: Aβ and tau may be
appropriate targets early in the disease course, but the restoration of brain glucose
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metabolism should be explored as a treatment strategy for clinical AD. Our findings may
influence the thinking in the field regarding AD progression and therapeutics.
6.5

Methods

6.5.1 Data pre-processing
Study data were obtained from the ADNI database, a longitudinal multicenter study
designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early
detection and tracking of Alzheimer’s disease. Specifically, data were downloaded from
the ADNI2 dataset within the ADNI database since these data contained all the biomarkers
of interest for the present study. Specific details about the acquisition of the imaging
measures have been reported elsewhere367,368. Briefly, all subjects were consented under
the approval of the IRB at each testing site and scanned at 3T for 3D T1-weighted volume,
FLAIR, a long TE gradient echo volumetric acquisition for micro hemorrhage detection,
arterial spin-labeling perfusion, resting state functional connectivity, and diffusion tensor
imaging; all enrolled subjects were also scanned for [18F]fluorodeoxyglucose PET (FDGPET) glucose uptake and [18F]florbetapir PET for amyloid imaging. The data were merged
from five subset datasets within the ADNI2 dataset to achieve a final dataset for analysis
consisting of demographic information, structural MRI volumes, FDG-PET SUVs,
amyloid-PET SUVs, White Matter Hyperintensities, and CSF-ptau measurements. Age,
gender, education, APOE ε4 carrier status, cognitive scores, and diagnosis and the
structural MRI variables of ventricle volume, whole brain volume, entorhinal cortex
volume, and hippocampal volume were extracted from the ADNIMERGE subset dataset.
FDG-Angular, FDG-Temporal, and FDG-CingulumPost were extracted from the UC
Berkeley FDG subset dataset. Aβ-Frontal, Aβ-Cingulate, Aβ-Parietal, Aβ-Temporal, Aβ111

Precuneus, and Aβ-Hippocampus were extracted from the UC Berkeley AV45 subset
dataset. Gray matter volume, White matter volume, and White matter hyperintensity were
extracted from the UC Davis White Matter Hyperintensity Volumes subset dataset. pTau
concentration was extracted from the UPENN CSF Biomarkers Elecsys subset dataset.
Missing values were imputed by selecting the twenty closest patients based on Euclidean
distance with non-missing values in the same group and averaging these values. Most of
the missing values appeared in the structural MRI data. Data imputation was performed on
patients who had less than three missing values. Patients with three or more missing values
were deleted to avoid bias caused by excessive imputation.
6.5.2

Machine learning analysis

The random forest (RF) classification algorithm was used to assess the importance
of all seventeen biomarker features in predicting the AD clinical diagnosis, as determined
by the progression of cognitive impairment as a result of the disease process (CU, LMCI,
or AD) (Table 7.2). The algorithm was chosen, as opposed to other traditional statistical
(e.g., ANOVA) and machine learning methods, because (i) it is a robust classification
method and (ii) it enables feature ranking. An RF is trained by fitting multiple decision
trees, each to a different random subset of the examples and features of the full dataset.
The predictions of these decision trees are then combined to yield a single consensus
classification prediction. Given the trained RF, each feature is considered more important
if decision trees constructed from subsets that include the feature give predictions that are
more accurate. This is calculated by averaging the out-of-bag accuracy (i.e., the accuracy
on examples there were not used when training the tree) of the individual decision trees
that were trained using the corresponding feature.
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We acknowledge that some of the features (e.g., brain volumetric measures) are
impacted with age; therefore, we adjusted the feature values for age accordingly.
Specifically, we used CU group dataset and performed a linear regression with the seven
brain volumetric measures used in our model as the feature variables and age as the target
regression variable. We applied the derived beta coefficients from the regression model to
the brain volumetric measures of the whole dataset and trained these balanced brain
volumetric measure values in our RF model. In the implementation, we used the function
sklearn.linear_model.LinearRegression of the ‘scikit-learn’ package to calculate the linear
regression coefficients between brain volumetric measures and age.
Figure 6.5A illustrates the workflow of the feature ranking and accuracy
performance using the random forest machine learning method. K-fold cross validation (k
= 5) was used to evaluate the performance of the RF classification algorithm in predicting
the AD clinical diagnosis. Using this strategy, the dataset was randomly partitioned into 5
equal parts, and 5 RF models were trained, each on a dataset consisting of 4 parts. Each of
the trained RF models was evaluated based on the prediction performance on the
corresponding omitted validation set. For evaluation, each complete data copy was
forwarded into a random forest classifier model utilizing the Python scikit-learn library
v0.21.3369.

All

default

parameters

were

used

for

the

sklearn.ensemble.RandomForestClassifier function, with the exception of the criterion
parameter, where we used the entropy option. Specifically, decision trees are classified in
a binary fashion where the split in the trees are from either true or false responses to feature
thresholds. The RandomForestClassifier decides the thresholds based on Gini Impurity.
“Purity” is a measure as to how homogenous the samples are, with “0” as maximal purity,
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and “1” as maximal impurity. As the decision tree progresses down, the Gini values
eventually decrease to 0 (Figure 6.5B). Final predictions were calculated and features were
ranked based on the prediction of the majority of trees within that training dataset. The
resulting predictions were evaluated on their ability to correctly predict the AD clinical
diagnosis in the validation dataset.
The cross-validated model prediction accuracy, receiver operating characteristic
curve (ROC) and F1 score were used to assess model performance.
The accuracy is calculated with the following equation [1]:
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑟𝑟𝑎𝑎𝑎𝑎𝑎𝑎 =

𝑇𝑇𝑇𝑇+𝑇𝑇𝑇𝑇

[1]

𝑇𝑇𝑇𝑇+𝑇𝑇𝑇𝑇+𝐹𝐹𝐹𝐹+𝐹𝐹𝐹𝐹

where TP = true positives, TN = true negatives, FP = false positives, and FN = false
negatives.
The F1 score is calculated by the following equation [2]:
𝐹𝐹1 = 2 ∙

𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 ∙𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟

[2]

𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝+𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟

where precision = TP/ (TP+FP) and recall = TP/ (TP+ FN). ROC curves compare the true
positive rate (TPR) and false positive rate (FPR) at different decision thresholds and are
often used to judge the performance of binary classifiers. F1 scores combine precision and
recall and are often used to evaluate models on imbalanced dataset, since it is possible to
obtain high accuracy on imbalanced datasets simply by predicting the most common class.
A high F1 score indicates low false positives and low false negatives.
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6.5.3

Statistics and Reproducibility

In the Table 6.1, the overall dataset was initially evaluated for group differences in age, gender,
education, APOE genotype, ethnicity, race, and cognitive test differences using non-parametric
Kruskal-Wallis tests comparing the groups CU, LMCI, and AD using JMP 1.4 software. approximate values and p-values were documented to identify statistical significance. 2 values
for effect sizes were calculated using the ‘rcompanion’ package in R statistical software.
To verify the reproducibility of five-fold validation used in the RF analysis, we compared
the results of accuracy and F1 score from those using three- and ten-fold cross validations.
To verify the accuracy measurements validated using ROC, we also performed precision
recall (PR) curves calculation. Precision-Recall Curve is another method to evaluate classification
models, especially binary classification models where the dataset is imbalanced. The Average of
Precision (AP) is calculated to determine the average precision score under different possible
thresholds. We used the scikit learn package sklearn.model_selection.RandomizedSearchCV for
hyperparameters optimization. The hyperparameters of the RF model is as follows:
'n_estimators'=3600,

'min_samples_split'=5,

'min_samples_leaf'=8,

'max_features'='auto',

'max_depth'=50, and 'bootstrap'=False.
We also used the SHapley Additive exPlanations (SHAP) technique to implement an
additional feature ranking analysis. In our experiments, we applied the SHAP on Random Forest
Classifier. Using the SHAP method as a reference for feature ranking analysis, the results showed
similar feature importance ranking as RF.
Gradient tree boosting (GTB), another classification method from the scikit-learn package,
was used as a comparison for the RF classification method. The same tree estimators from the RF
method were used for GTB with all other default function parameters. The accuracies for the GTB
method were similar to the RF method. The accuracy of the GTB classifiers were 72.30%, 71.26%,
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and 91.87% respectively for CU vs LMCI, LMCI vs AD, and CU vs AD clinical diagnosis. The
model was also trained with 3- and 10-fold cross validation for comparison. There were minor
difference in the feature rankings estimated using the GTB model as compared to the RF model but
the same general patterns hold true: Aβ and pTau are important contributors to the prediction of
early AD decline, but neurodegeneration, especially glucose hypometabolism, is a more important
predictor of later AD decline.

6.5.4

Pearson correlation analysis of cognitive performance

Pearson correlation was used to evaluate linear relationships between individual
biomarker features and cognitive function using the JMP 1.4 software (Figures 6.2 and
6.3). Pearson correlation coefficient is calculated by the covariance of two variables over
the product of their standard deviation. The value range of Pearson correlation coefficient
is from -1 to 1 with a higher absolute value indicating a stronger association and the sign
indicating a positive or negative association between the two variables.
6.5.5

Calculation of biomarker values

In the Table 6.5, biomarker Values were calculated for the different diagnosis
groups and compared using two-sided Wilcoxon rank-sum tests. Z-score test statistics were
calculated using JMP 1.4 software and effect sizes r were calculated with r ( = Z/(√Nobs)).
Amyloid standard uptake values (SUVs) were intensity normalized to the whole
cerebellum and volume was normalized by dividing by the region of interest (ROI) in cubic
centimeters (cm3). FDG SUVs were normalized according to metaROIs described
elsewhere370. Briefly, a set of pre-defined regions of interest (FDG-ROIs) were developed
by identifying regions cited frequently in FDG-PET studies of AD and MCI patients. All
coordinates of significant voxels were transformed into MNI space. Intensity values were
generated for coordinates that reflected a combination of the Z-scores associated with the
coordinate. The volumes were intensity normalized using the maximum value, and volume
was normalized by dividing by the ROI in cubic centimeters (cm3).
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6.5.6

Data Availability

The datasets analyzed during the current study are available in the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) respository.
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Table 6.1 Demographic and cognitive data for the cross-sectional study population
χ2 ε2
P-value
CU
LMCI
AD
approx
Subject characteristics
n

148

Age (years)

73.43 ± 71.98 ± 74.46 ±
6.29
7.42
8.39

Gender (%
Male)

51%

Education
(years)

16.63 ± 16.70 ± 15.61 ±
2.53
2.45
2.55

APOE ε4

carriers (%)
Ethnicity (%
Hispanic)

Asian)

(%
(%

54%

110

60%

27%

57%

69%

5.4%

1.4%

3.6%

95%

92%

7%

3%

4%

2%

1%

4%

Race (% White) 89%
Black)

147

7.207

0.0178

0.0272*

2.236

0.00554 0.3268

13.395

0.0332

0.0012*

53.653

0.133

<0.0001*

3.673

0.00909 0.1594

2.799

0.00693 0.2467

Cognitive data
MMSE

29.06 ± 27.61 ± 23.14 ±
1.14
1.82
2.03

246.414 0.61

<0.0001*

CDRSB

0.03 ±
0.13

1.71 ±
1.00

4.60 ±
1.61

351.755 0.871

<0.0001*

ADAS-cog 13

9.08 ±
4.58

18.57 ± 30.16
7.08
± 9.70

239.827 0.594

<0.0001*

ADNI_MEM

1.06 ±
0.63

-0.03 ±
0.66

-0.89 ±
0.54

266.260 0.63

<0.0001*

ADNI_EF

0.94 ±
0.81

0.16 ±
0.85

-0.83 ±
0.93

161.477 0.388

<0.0001*
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Values are displayed as the mean ± SD. The χ2-approx test statistic is calculated from a Kruskal-Wallis test
comparing the groups CU, LMCI, and AD. ε2 is the effect size calculated from a Kruskal-Wallis test.
Asterisk (*) next to P-value indicates statistical significance. DF=2 for all comparisons. CU = cognitively
unimpaired; LMCI = late mild cognitive impairment; AD = Alzheimer’s disease; MMSE = Mini-Mental
State Examination; CDRSB = Clinical Dementia Rating Sum of Boxes; ADAS-cog = Alzheimer’s Disease
Assessment Scale-Cognitive Subscale; ADNI_MEM = Composite memory score; ADNI_EF = Composite
executive functioning score.
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Table 6.2 Biomarkers used in the feature analysis
Data Source

Biomarker
Measure

Features

A/T/N
classification

1. Aβ-Frontal
Amyloid-beta
Positron
emission
tomography

(AV45;
18
Florbetapir)

2. Aβ-Cingulate
3. Aβ-Parietal
4. Aβ-Temporal

A

5. Aβ-Precuneus
6. Aβ-Hippocampus

(PET)
Glucose uptake
（18FDG）

7. FDG-Angular
8. FDG-Temporal
9. FDG-CingulumPost
10. Ventricle volume

Magnetic
resonance
imaging
(MRI)

11. Whole brain volume
(WBV)
Volumetric
measures

N

12. Entorhinal cortex volume
13. Hippocampal volume
14. Gray matter volume
(GMV)
15. White matter volume
(WMV)

Cerebrospinal
fluid (CSF)
18

phosphor-Tau
(181P)

16. Phosphorylated tau
(pTau)

T

FDG = Fluorodeoxyglucose

Amyloid-beta measures include Aβ from the frontal lobe (Aβ -Frontal), cingulate cortex (Aβ-Cingulate),
parietal lobe (Aβ-Parietal), temporal lobe (Aβ -Temporal), precuneus (Aβ -Precuneus), and hippocampus
(Aβ -Hippocampus).
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Glucose uptake measures include FDG from the angular gyrus (FDG-Angular), temporal lobe (FDGTemporal), and posterior cingulum (FDG CingulumPost).
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Table 6.3 Ranking of each biomarker feature importance to prediction of diagnosis
classification from the random forest analysis
CU vs LMCI

Top
half

Biomarker
Feature

1

Hippocampu
s Volume

12.69%

FDGTemporal

18.88%

FDG-Angular

23.78%

2

Aβ-Frontal

11.51%

FDG-Angular

17.36%

FDGCingulumPos
t

16.99%

3

Aβ-Temporal

8.57%

FDGCingulumPos
t

12.11%

Hippocampu
s Volume

12.93%

4

FDG-Angular

Hippocampu
s Volume

7.49%

FDGTemporal

10.00%

5

Entorhinal
Cortex
Volume

Aβ-Temporal

8.11%

6

AβPrecuneus

7.78%

Aβ-Temporal

4.97%

AβPrecuneus

6.20%

7

pTau

7.60%

pTau

4.82%

Entorhinal
Cortex
Volume

4.81%

8

Aβ-Cingulate

4.75%

Entorhinal
Cortex
Volume

pTau

3.92%

8.32%
7.88%

Biomarker
Feature

AβPrecuneus

Relative
Importanc
e

5.14%

4.76%

Biomarker
Feature

75.45%

69.1%

Relative
Importanc
e

86.74%

9

AβHippocampu
s

4.48%

Aβ-Parietal

4.71%

Aβ-Frontal

10

Ventricles

4.35%

Aβ-Frontal

3.98%

Aβ-Parietal

3.32%

11

FDGCingulumPos
t

4.29%

Ventricles

3.69%

AβHippocampu
s

3.17%

12

GMV

4.20%

AβHippocampu
s

3.14%

Aβ-Cingulate

0.99%

13

WMV

3.56%

Aβ-Cingulate

2.63%

Ventricles

0.65%

14

FDGTemporal

3.48%

GMV

2.59%

GMV

0.60%

15

WBV

3.45%

WBV

2.46%

WMV

0.38%

16

Aβ-Parietal

3.10%

WMV

1.29%

WBV

0.32%

Subtota
l
Sum

CU vs AD

Rank

Subtota
l

Botto
m
Half

LMCI vs AD
Relative
Importanc
e

24.55%

30.9%
100%

100%

3.81%

13.26%
100%

CU = cognitively unimpaired; LMCI = late mild cognitive impairment; AD = Alzheimer’s disease
FDG = fluorodeoxyglucose; GMV = gray matter volume; WMV = white matter volume; WBV = whole
brain volume
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Table 6.4 Accuracy of all 16 features and of the top 8 features in predicting diagnosis for
each participant group comparison
All 16 features
CU vs LMCI

LMCI vs AD

CU vs AD

Accuracy (%)

73.17

71.01

90.34

F1 Score (%)

73.09

70.84

90.32

Top 8 features
CU vs LMCI

LMCI vs AD

CU vs AD

Accuracy (%)

72.74

70.15

91.63

F1 Score (%)

72.59

70.02

91.59

124

Table 6.5 Average values of the top 8 biomarker features for each diagnosis group that
can be used to predict cognitive status
Features

CU

LMCI

AD

Aβ-Precuneus (SUV cm3
)

0.0715 ±
0.0154

0.0873 ± 0.0231

0.107 ± 0.0272

Aβ-Frontal (SUV cm-3)

0.00949 ±
0.00187

Aβ-Cingulate (SUV cm3
)

0.0692 ±
0.00111

Aβ-Temporal (SUV cm3
)

0.0259 ±
0.00523

pTau (pg ml-1)

21.50 ± 8.87

Z=5.79,
p<0.0001**
r=0.34
0.0114 ±
0.00260
Z=6.75,
p<0.0001**
r=0.39
0.0787 ±
0.00181
Z=4.87,
p<0.0001**
r=0.28
0.0302 ±
0.00678
Z=6.76,
p<0.0001**
r=0.39
29.70 ± 14.01

Z=9.89,
p<0.0001ǂǂ
r= 0.62
0.0129 ±
0.00286
Z=9.07,
p<0.0001ǂǂ
r=0.56
0.0892 ±
0.00192
Z=8.03,
p<0.0001ǂǂ
r=0.50
0.0331 ±
0.00672
Z=9.92,
p<0.0001ǂǂ
r=0.62
38.50 ± 16.52

FDG-Angular (SUV cm3
)

1.21 ± 0.104

Z=5.62,
p<0.0001**
r=0.33
1.13 ± 0.149

Z=9.56,
p<0.0001ǂǂ
r=0.60
0.956 ± 0.159

FDG-CingulumPost
(SUV cm-3)

3.03 ± 0.324

Z=5.31,
p<0.0001**
r=0.31
2.84 ± 0.391

Z=11.46,
p<0.0001ǂǂ
r=0.71
2.47 ± 0.343

FDG-Temporal (SUV
cm-3)

8.24 ± 0.706

Z=4.72,
p<0.0001**
r=0.27
7.78 ± 0.983

Z=10.69,
p<0.0001ǂǂ
r=0.67
6.73 ± 0.924

Hippocampus volume
(cm3)

7.49 ± 0.827

Z=4.54,
p<0.0001**
r=0.26
6.67 ± 1.11

Z=10.82,
p<0.0001ǂǂ
r=0.67
5.91 ± 0.923
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A/T/N
arm

A

T

N

Entorhinal cortex
volume (cm3)

3.85 ± 0.587

Z=6.62,
p<0.0001**
r=0.39
3.39 ± 0.710

Z=10.59,
p<0.0001ǂǂ
r=0.66
2.92 ± 0.622

Z=5.51,
p<0.0001**
r=0.32

Z=9.40,
p<0.0001ǂǂ
r=0.59

Values are displayed as the mean ± SD.
**P<0.0001 calculated with a Wilcoxon rank-sum test comparing CU vs LMCI
ǂǂ P<0.0001 calculated with a Wilcoxon rank-sum test comparing CU vs AD
SUV = standard uptake value; Z = Z-score test statistic for Wilcoxon rank-sum test; r = effect size for
Wilcoxon rank-sum test
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Figure 6.1 Receiver operating characteristic (ROC) curves depicting the accuracy of all 16 biomarker
features (top) vs. the top 8 biomarker features (bottom).
Comparison of receiver operating characteristic14 curves between all 16 biomarker features (top) and the
top 8 biomarker features (bottom) from the three diagnosis participant group comparisons: cognitively
unimpaired (CU) vs. late mild cognitive impairment (LMCI), LCMI vs. Alzheimer’s disease (AD), and CU
vs. AD. Groundline refers to a model that cannot predict better than random chance. The mean ROC is
calculated from the average of the five ROC curves produced from the k-fold cross validation.
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Figure 6.2 Correlation of top eight AD biomarkers with composite memory scores.

Scatter plots showing the correlations of the top eight features with performance on composite memory
tests in each pairwise analysis among the cognitive statuses. (a) CU vs. LMCI. (b) LMCI vs. AD. (c) CU
vs. AD. The order of the scatter plots in each panel is according to the rank of the r correlation value when
compared to composite memory score. The x-axis refers to the indicated biomarker score and the y-axis
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refers to the composite memory score. Each dot refers to the indicated biomarker score and composite
memory score of a single participant.
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Figure 6.3 Correlation of top eight AD biomarkers with executive functioning scores.

Scatter plots showing the correlations of the top eight features with performance on composite executive
functioning tests in each pairwise analysis among the cognitive statuses (a) CU vs. LMCI. (b) LMCI vs.
AD. (c) CU vs. AD. The order of the scatter plots in each panel is according to the rank of the r correlation
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value when compared to composite executive functioning score. The x-axis refers to the indicated
biomarker score and the y-axis refers to the composite memory score. Each dot refers to the indicated
biomarker score and composite executive functioning score of a single participant.
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Figure 6.4 Relative importance of biomarkers predicting AD clinical diagnosis.

Diagram depicting the relative importance of biomarkers in predicting AD clinical diagnosis
(predictability). In early AD, Aβ and pTau deposition in the brain have higher relative importance in
predicting AD clinical diagnosis. In late disease low glucose uptake in the brain has higher relative
importance in predicting AD clinical diagnosis.
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Figure 6.5 Flow chart of the random forest method used.

a Flow chart depicting the analysis used with the random forest method. The AD biomarkers from the
original dataset were randomly split into five equal-sized subsets. For evaluation, each complete data copy
was forwarded into a random forest (decision tree; see b) classifier model. Final predictions were
calculated and features were ranked based on the prediction of the majority of trees within that training
dataset. b Decision trees are classified in a binary fashion, where the split in the trees are from either true or
false responses to feature thresholds based on Gini Impurity. “Purity” is a measure homogeneity, with “0”
as maximal purity, and “1” as maximal impurity.
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CHAPTER 7. [SUPPLEMENT] HUMAN GRAY AND WHITE MATTER
METABOLOMICS TO DIFFERENTIATE APOE AND STAGE DEPENDENT
CHANGES IN ALZHEIMER’S DISEASE
7.1

Summary

Alzheimer’s disease (AD) is the most common form of dementia with hallmarks of βamyloid (Aβ) plaques, tau tangles and neurodegeneration. Studies have shown that
neurodegeneration components, especially brain metabolic deficits, are more predictable
for AD severity than Aβ and tau. However, a detailed knowledge of the biochemical
composition of AD brain tissue vs normal brain tissue remains unclear. In this study, we
performed a metabolomics analysis on the brain tissue of 158 community-based older
adults in the University of Kentucky AD Research Center brain bank to characterize the
biochemical profiles of brains with and without AD based on white/gray matter type,
apolipoprotein E genotype (ε3 vs ε4 variants), and disease stage (early vs late) as all these
factors influence metabolic processes. We also used machine learning to rank the top
metabolites that separates controls and AD in gray and white matter. Compared with
control samples, we found that glutamate and creatine metabolism were more important
for predicting AD in the gray matter, while glycine, fatty acid, pyrimidine, tricarboxylic
acid (TCA) cycle, and phosphatidylcholine metabolism were more important in the white
matter. In ε4 carriers, metabolites associated with the TCA cycle and oxidative
phosphorylation were prominent in advanced stages compared to the early stages. In ε3
carriers, metabolites associated with oxidative DNA damage, changes in inhibitory
neurotransmitters, and disruptions of neuronal membranes were prominent in advanced
stages compared to the early stages. In early disease, ε4 carriers had metabolites related to
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poor kidney function and altered neuronal sterol metabolism compared to ε3 carriers, but
there were few differences between genotypes in late disease. Our results indicate that
metabolism plays a pivotal role in differentiating APOE- and stage-dependent changes in
AD and may facilitate precision lifestyle and dietary interventions to mitigate AD risk in
the early stages, especially for ε4 carriers.
7.2

Introduction

Alzheimer’s disease (AD) is a leading cause of death and morbidity in the United
States371. The hallmarks of AD are β-amyloid (Aβ) and tau. However, studies have
indicated that metabolic dysfunction may play a more pivotal role in the progression of
AD372. Glucose hypometabolism and mitochondrial dysfunction are well-known features
of AD372. These irregularities are likely influenced by Apolipoprotein E (APOE) genotype,
the most common genetic risk factor for AD. APOE is a lipid transport carrier with direct
impact on metabolism whose function is dependent on the structure of the protein variant
(whether it is ε2, ε3, or ε4). Those who are carriers of the APOE ε4 allele have two to fourfold increased risk for developing AD373,374.
AD progresses differently in the white matter than the gray matter. While most
research has been focused on reporting changes in the gray matter of cortex, many studies
are now reporting changes in white matter tracts375. Metabolism is different in gray versus
white matter due to the unique composition of each type (more lipid metabolism in the
white matter376 and more glucose metabolism in the gray matter377). There is also evidence
to suggest that there is more glycolytic metabolism in the white matter and more oxidative
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metabolism in the gray matter378. Understanding the metabolic demands of the two
different brain environments could give important clues about the progression of AD.
A detailed knowledge of the biochemical composition of AD brain tissue vs normal
brain tissue will be key in understanding the metabolic processes underlying AD. To our
knowledge, only three reports have been published describing a brain metabolomics
signature of AD. These reports demonstrated that the top metabolites that classify AD in
brain tissue include glycerophospholipids, spermidine, sphingolipids, and changes in bile
acids379-381. These reports analyzed between 15 and 111 samples per group to develop brain
metabolomics signature based on targeted assays of lipids or bile acids. The analyses were
based on gray-enriched matter only. While these reports provide an introductory analysis
of brain metabolomics, a more complete understanding is needed that factors a larger
patient population, an untargeted assay, and samples that are enriched for both gray and
white matter. Furthermore, a better understanding of how AD progresses based on APOE
genotype is needed to eventually develop therapeutics for AD based on precision medicine.
Here we performed a metabolomics analysis on the brain tissue of a large cohort of
community-based participants in the University of Kentucky Alzheimer’s Disease
Research Center (UK-ADRC) brain bank. We used machine learning to identify the
differences between the biochemical profiles of white-enriched matter and gray-enriched
matter and identified the metabolites which were the top predictors in differentiating AD
from normal brain tissue. We proceeded to characterize the biochemical profiles of brains
with and without AD and other pathologies based on APOE genotype and disease stage.
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7.3
7.3.1

Methods

Participant Characteristics

Details of UK-ADC research volunteers’ recruitment, inclusion/exclusion criteria, and
clinical and pathological assessments have been described previously382. Briefly,
community-based older adult volunteers agreed to be followed annually for cognitive,
physical, and neurological examination and to donate their brain at the time of death.
Protocols were approved by the UK Institutional Review Board, and all participants
provided written informed consent. Included subjects were ≥70 years of age at death.
Research subjects with relatively rare dementia syndromes (e.g. prions, trinucleotide repeat
diseases, or Frontotemporal lobar degeneration (FTLD)), or any brain tumor were
excluded. Additionally, since our research questions focused on the association
between APOE and tau pathology, cases also had to have APOE genotyping available and
were dichotomized into APOE ε4 carriers and APOE ε3 homozygotes. Demographic
information included about our participants included age at death (years), sex, race
(nonwhite or white), and years of education. We describe diagnosed cognitive status
(normal cognition, impaired not mild cognitive impairment [MCI], MCI, dementia), and
primary clinical diagnosis (normal cognition, AD, LBD/Parkinson disease; vascular
disease, other) at the participant’s last visit before death. Using Braak NFT staging383, we
defined those as early stage with a Braak NFT score 0-III and those as late stage with a
braak score IV-VI. Participant characteristics are listed in Table 8.1.
Human brain tissue samples were collected and snap-frozen in liquid nitrogen at brain
autopsy. For the present study, samples were obtained from Brodmann’s area 9 (the
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dorsolateral prefrontal cortex) of the left hemisphere of 158 community-based older adult
volunteers. Brain tissue samples were further dissected into gray-enriched matter and
white-enriched matter samples, yielding a total of 316 brain samples. The education level
was the same across stage and genotype. Age differed between only late ε3 and late ε4
groups (87.97±6.96 vs 82.76±8.45). We profiled the brain tissue metabolomics using
Metabolon’s (Durham, NC) global screening platform. We separated our analyses by Braak
NFT stages (early 0-III vs late IV-VI) and APOE genotype (ε3 and ε4) (Table 8.2).
7.3.2

Metabolon Platform

We sent samples to Metabolon (Durham, NC) for a global metabolic profile for each
sample. All samples were maintained at -80oC until processed. Samples were prepared
using the automated MicroLab STAR® system from Hamilton Company. Proteins were
precipitated with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder
2000) followed by centrifugation. The resulting extract was divided into five fractions:
two for analysis by two separate reverse phase (RP)/UPLC-MS/MS methods with positive
ion mode electrospray ionization (ESI), one for analysis by RP/UPLC-MS/MS with
negative ion mode ESI, one for analysis by HILIC/UPLC-MS/MS with negative ion mode
ESI, and one sample was reserved for backup. Samples were placed briefly on a
TurboVap® (Zymark) to remove the organic solvent.
7.3.2.1 Ultra-high performance Liquid Chromatography-Tandem
Mass Spectroscopy
All methods utilized a Waters ACQUITY ultra-performance liquid chromatography
(UPLC) and a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer
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interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap mass
analyzer operated at 35,000 mass resolution.

The sample extract was dried then

reconstituted in solvents compatible to each of the four methods. Each reconstitution
solvent contained a series of standards at fixed concentrations to ensure injection and
chromatographic consistency.

One aliquot was analyzed using acidic positive ion

conditions, chromatographically optimized for more hydrophilic compounds. In this
method, the extract was gradient eluted from a C18 column (Waters UPLC BEH C182.1x100 mm, 1.7 µm) using water and methanol, containing 0.05% perfluoropentanoic acid
(PFPA) and 0.1% formic acid (FA). Another aliquot was also analyzed using acidic
positive ion conditions, however it was chromatographically optimized for more
hydrophobic compounds. In this method, the extract was gradient eluted from the same
afore mentioned C18 column using methanol, acetonitrile, water, 0.05% PFPA and 0.01%
FA and was operated at an overall higher organic content. Another aliquot was analyzed
using basic negative ion optimized conditions using a separate dedicated C18 column. The
basic extracts were gradient eluted from the column using methanol and water, however
with 6.5mM Ammonium Bicarbonate at pH 8. The fourth aliquot was analyzed via negative
ionization following elution from a HILIC column (Waters UPLC BEH Amide 2.1x150
mm, 1.7 µm) using a gradient consisting of water and acetonitrile with 10mM Ammonium
Formate, pH 10.8. The MS analysis alternated between MS and data-dependent MSn scans
using dynamic exclusion. The scan range varied slighted between methods but covered
70-1000 m/z.
7.3.2.2 Bioinformatics

139

The informatics system consisted of four major components, the Laboratory Information
Management System (LIMS), the data extraction and peak-identification software, data
processing tools for QC and compound identification, and a collection of information
interpretation and visualization tools for use by data analysts. The hardware and software
foundations for these informatics components were the LAN backbone, and a database
server running Oracle 10.2.0.1 Enterprise Edition.
7.3.2.3 LIMS
The purpose of the Metabolon LIMS system was to enable fully auditable laboratory
automation through a secure, easy to use, and highly specialized system. The scope of the
Metabolon LIMS system encompasses sample accessioning, sample preparation and
instrumental analysis and reporting and advanced data analysis. All of the subsequent
software systems are grounded in the LIMS data structures. It has been modified to
leverage and interface with the in-house information extraction and data visualization
systems, as well as third party instrumentation and data analysis software.
7.3.2.4 Data Extraction and Compound Identification
Raw data was extracted, peak-identified and QC processed using Metabolon’s hardware
and software. These systems are built on a web-service platform utilizing Microsoft’s
.NET technologies, which run on high-performance application servers and fiber-channel
storage arrays in clusters to provide active failover and load-balancing. Compounds were
identified by comparison to library entries of purified standards or recurrent unknown
entities. Metabolon maintains a library based on authenticated standards that contains the
retention time/index (RI), mass to charge ratio (m/z), and chromatographic data (including
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MS/MS spectral data) on all molecules present in the library. Furthermore, biochemical
identifications are based on three criteria: retention index within a narrow RI window of
the proposed identification, accurate mass match to the library +/- 10 ppm, and the MS/MS
forward and reverse scores between the experimental data and authentic standards. The
MS/MS scores are based on a comparison of the ions present in the experimental spectrum
to the ions present in the library spectrum. While there may be similarities between these
molecules based on one of these factors, the use of all three data points can be utilized to
distinguish and differentiate biochemicals.

More than 3300 commercially available

purified standard compounds have been acquired and registered into LIMS for analysis on
all platforms for determination of their analytical characteristics. Additional mass spectral
entries have been created for structurally unnamed biochemicals, which have been
identified by virtue of their recurrent nature (both chromatographic and mass spectral).
These compounds have the potential to be identified by future acquisition of a matching
purified standard or by classical structural analysis.
7.3.2.5 Metabolite Quantification and Data Normalization
Peaks were quantified using area-under-the-curve. For studies spanning multiple days, a
data normalization step was performed to correct variation resulting from instrument interday tuning differences. Essentially, each compound was corrected in run-day blocks by
registering the medians to equal one (1.00) and normalizing each data point proportionately
(termed the “block correction”; Figure 2). For studies that did not require more than one
day of analysis, no normalization is necessary, other than for purposes of data visualization.
In certain instances, biochemical data may have been normalized to an additional factor
(e.g., cell counts, total protein as determined by Bradford assay, osmolality, etc.) to account
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for differences in metabolite levels due to differences in the amount of material present in
each sample.
7.3.3

Statistical and Analytical Methods
7.3.3.1 Statistical Calculations

For many studies, two types of statistical analysis are usually performed: (1) significance
tests and (2) classification analysis.

Standard statistical analyses are performed in

ArrayStudio on log transformed data. For those analyses not standard in ArrayStudio, the
programs R or JMP are used. Below are examples of frequently employed significance
tests and classification methods followed by a discussion of p- and q-value significance
thresholds.
7.3.3.1 Machine Learning Classification
Random forest was used as a supervised classification technique to identify the relative
importance of the different biochemicals in predicting gray-enriched matter vs. whiteenriched matter, Alzheimer’s disease vs control, APOE ε4 vs APOE ε3 genotype in early
stage and late stage, early stage vs late stage in APOE E4 and APOE E3 genotype, and
Vascular dementia vs. control based on an ensemble of decision trees. For a given decision
tree, a random subset of the data with identifying true class information was selected to
build the tree, and the remaining data, the “out-of-bag” (OOB) variables, were passed down
the tree to obtain a class prediction for each sample. This process was repeated thousands
of times to produce the forest. The final classification of each sample was determined by
computing the class prediction frequency (“votes”) for the OOB variables over the whole
forest. This method is unbiased since the prediction for each sample is based on trees built
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from a subset of samples that do not include that sample. When the full forest is grown,
the class predictions are compared to the true classes, generating the “OOB error rate” as
a measure of prediction accuracy. Thus, the prediction accuracy is an unbiased estimate of
how well one can predict sample class in a new data set. Random forest has several
advantages – it makes no parametric assumptions, variable selection is not needed, it does
not overfit, it is invariant to transformation, and it is fairly easy to implement with R.
To determine which variables (biochemicals) make the largest contribution to the
classification, a “variable importance” measure is computed. We use the “Mean Decrease
Accuracy” (MDA) as this metric. The MDA is determined by randomly permuting a
variable, running the observed values through the trees, and then reassessing the prediction
accuracy. If a variable is not important, then this procedure will have little change in the
accuracy of the class prediction (permuting random noise will give random noise). By
contrast, if a variable is important to the classification, the prediction accuracy will drop
after such a permutation, which we record as the MDA. Thus, the random forest analysis
provides an “importance” rank ordering of biochemicals; we typically output the top 30
biochemicals in the list as potentially worthy of further investigation.
7.4
7.4.1

Results

Metabolomics differences in gray and white-enriched matters

In total, 540 of the 776 detected metabolites were either increased or decreased in the whiteenriched matter vs gray-enriched matter. White-enriched matter has more lipid metabolites
associated with myelin than gray-enriched matter.
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Using a random forest analysis, we found that the model was able to predict whether a
sample was gray-enriched matter or white-enriched matter based on the metabolomics
profile with 91.77% accuracy (Table 7.3A). Heat map of statistically significant
biochemicals profiled when comparing groups are labeled as follows: Red and green
shaded cells indicate p ≤ 0.05 (red specifies that the mean values are significantly higher
for that comparison; green values significantly lower). The top 10 predictors were all lipids,
which play a major role in the brain as structural components of membranes and signaling
molecules. Notably, there was an increase in prominent hexosylceramides, some
phosphatidylcholines, lysoplasmalogen, some plasmalogens, and phosphatidylserine,
whereas there was a decrease in other phosphatidylcholines, phosphatidylethanolamine,
and some plasmalogen metabolites. Most of the observed changes correlated with the
known differences in white and gray-enriched matter lipid populations due to the diverse
functions of neuron cell biology. All analyses were performed in both gray-enriched matter
and white-enriched matter to account for these differences.
7.4.2

Machine learning to classify AD from normal with metabolomics

Using random forest analysis, we found that the model predicted whether a sample
came from AD brain tissue or normal brain tissue based on the metabolomics profile with
80.0% accuracy in the gray-enriched matter (Table 7.3B) and an 81.54% accuracy in the
white-enriched matter (Table 7.3C). The top 9 predictors in gray-enriched matter mainly
consisted of increases in phospholipid and creatine metabolism, and decreases in amino
acid metabolism, and the monohydroxy fatty acid 13-HODE + 9-HODE. The top 12
predictors in white-enriched matter mainly consisted of increases in phospholipid
metabolism and decreases in amino acid metabolism, phosphatidylcholine, and some
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monohydroxy fatty acids. Glycerophosphocholine is formed in the breakdown of
phosphatidylcholine and is increased in both the gray-enriched matter and white-enriched
matter. N-acetylasparagine is a breakdown product of asparagine and is decreased in both
the gray-enriched matter and white-enriched matter. The human body produces
dimethylglycine when metabolizing choline into glycine, and it is decreased in the grayenriched matter. NAAG is a neuropeptide that is an agonist at mGluR3 receptors and an
antagonist at NMDA receptors and is decreased in the gray-enriched matter. Pipecolic acid
originates mainly from the catabolism of dietary lysine by intestinal bacteria rather than by
direct food intake, and it is decreased in both the gray-enriched matter and the whiteenriched matter. Ureidopropionic acid is a urea compound and is an intermediate in the
metabolism of uracil; it is decreased in the white-enriched matter.
Taken together, our findings indicate that glutamate and creatine metabolism are
more important for predicting disease in the gray matter, and glycine, fatty acid,
pyrimidine, TCA cycle, and phosphatidylcholine metabolism are more important for
predicting disease in the white matter.
7.4.3

Gray and white matter metabolomics between early and late in APOE ε4

We next investigated the differences between late stage and early stage disease in
the ε4 genotype (Table 7.4). We found that, compared with the early stage, late-stage
APOE4 carriers had significantly reduced metabolite levels in the gray matter. Notable
changes were found in pathways associated with mitochondrial function, glucose
metabolism, and neurotransmitters, including tricarboxylic acid (TCA) cycle, oxidative
phosphorylation, pentose metabolism, and acetyl-CoA and glutamate metabolism. We
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observed lower levels of serine and aspartate, whose declines are known to correlate with
the amount of Aβ plaques and neuronal pathology384, as well as tyrosine and leucine, which
are known to reduce atherosclerosis by improving the lipid profile and reducing systemic
inflammation385. Further, metabolites related to mitigating oxidative stress, such as
cysteine, arginine, gamma-glutamyl amino acid, pentose were also lower in gray matter in
the late stage. We also saw lipid decreases in seven lysophospholipid (LPL) species. LPL
receptor ligands are known to bind to and activate their cognate receptors located in the
cell membrane with a wide range of effects on the cell; these include the primary effects of
inhibition of adenylyl cyclase and the release of calcium from the endoplasmic reticulum,
as well as the secondary effects of preventing apoptosis and increasing cell proliferation386.
In white matter, reductions were found in biochemicals related to glutamate,
tyrosine, leucine and methionine/cysteine metabolism. Interestingly, diacylglycerol was
increased in the white matter in later disease similar to levels found in the e3 genotype.
Since diacylglycerol has been shown to reduce atherosclerosis in an APOE-deficient mouse
model387, the increase in diacylglycerol in the e4 genotype could be a compensatory
mechanism to combat rising levels of atherosclerosis.
The results show that with the disease progression, APOE4 carriers had alterations
in metabolites that are associated with increased Aβ retention, reducing atherosclerosis,
and the impaired TCA cycle and oxidative phosphorylation.
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7.4.4

Gray and white matter metabolomics between early and late in APOE ε3

We further investigated the differences between late stage and early stage in APOE
ε3 genotype (Table 7.5). Individuals with ε3 variants had similar changes in the gray and
white matters.
However, unlike ε4, which involves mitochondrial and glucose metabolism,
notable key reductions in ε3 carriers were found in glycolysis, glutamate, tryptophan, and
tyrosine metabolism. Glutamate is an excitatory neurotransmitter, which plays a critical
role in learning and memory388 and N-acetyl-aspartyl-glutamate (NAAG) has been shown
to have precognitive effects by binding to metabotropic glutamate receptors259. Tryptophan
metabolism is known to be altered in patients with AD389, and tryptophan-derived
metabolites can inhibit Aβ fibril formation in neurons and neuroblastoma cells390.
Tryptophan is an essential amino acid and is the precursor of serotonin. Indole-3-propionic
acid, a tryptophan-derived metabolite, can inhibit Aβ fibril formation in neurons and
neuroblastoma cells390. Metabolites that play a role in tyrosine metabolism including
phenol sulfate, phenol glucuronide, and p-cresol glucuronide are associated with
inflammation391.

We observed lower levels of dimethylglycine, which is linked to

increased oxidative DNA damage associated with Aβ deposition392, and homocarnosine,
which is part of the histidine pathway and generally declines with age393. Neuronal
histamine, phenylalanine, and tryptophan have a role on memory, reinforcement, and
emotions394-396. We also found lower levels of fatty acids, which are often found as
oxidized linoleic acid metabolites (OXLAMs) in the serum of AD patients397 and
phosphatidylcholine, which provides a reservoir of choline that can be used for
acetylcholine synthesis. Notable key increases were found in myo-inositol metabolism,
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urea cycle, lysine, nucleotide sugar, inositol, and phospholipid. Myo-inositol, a
neuroinflammatory marker, is negatively correlated with visuospatial working memory398.
Lysine can act as neurotransmitter modulating GABAergic transmission. Phospholipid is
known to be raised in AD by disrupting neural cell membranes and causing cell death399.
Taken together, our findings indicate that increases in metabolites linked to
oxidative DNA damage, changes in inhibitory neurotransmitters, and disruptions of
neuronal membranes and decreases in metabolites related to acetylcholine synthesis drive
the differences between early and late stage of AD among APOE ε3 carriers.
7.4.5

Gray and white metabolomics between APOE ε3 and ε4

We next compared the differences between APOE ε4 and ε3 carriers at early-stage
disease (Table 7.6). Notable changes were found in pathways associated with leucine,
glycine, arginine, gamma-glutamyl amino acid, pentose, and secondary bile acid
metabolism in APOE ε4 carriers compared to non-carriers. N,N,N-trimethyl-alanylproline
betaine (TMAP), part of arginine metabolism, was found to be lower in e4, and is
associated with poor kidney function400. We also found decreases in glutathione,
commonly decreased with age401, eicosanoid, and sterol - carriers of the APOE ε3/ε4 allele
are known to exhibit altered neuronal sterol metabolism.
Unique differences in gray-enriched matter include an amino acid increase of
histamine and 1-carboxyethylisoleucine (part of isoleucine metabolism), a peptide increase
of gamma-glutamylisoleucine, a lipid increase of arachidonate (a long chain
polyunsaturated fatty acid) and docosahexaenoyl ethanolamide (an endocannabinoid
implicated in the pathology of neurodegenerative diseases).
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Other differences were found only in the white-enriched matter. Unique differences
include amino acid decreases in formiminoglutamate (part of histidine metabolism) and
increases of 2-aminoadipate (part of lysine metabolism), lipid decreases in 1,2-dipalmitoylGPE

(a

phosphatidylethanolamine)

and

palmitoyl-docosahexaenoyl-glycerol

(a

diacylglycerol), and increases in 1,2-dioleoyl-GPG (a phosphatidylglycerol), 1-(1-enyloleoyl)-2-oleoyl-GPE (a lysoplasmalogen), glycosyl-N-stearoyl-sphingadienine and
glycosyl ceramide (both hexosylceramides), sphingomyelin, and sphingosine 1-phosphate.
Taken together, our findings indicate that increased metabolites in APOE ε4
carriers related to poor kidney function and altered neuronal sterol metabolism drive the
differences between the genotypes at early stage.
There were four detected metabolites that were detected to be increased between
APOE ε4 and ε3 carriers at late stages of AD. At an alpha=0.01, random chance would be
expected to generate ~8 significant observations. Since our results do not surpass this
threshold, our analyses did not identify metabolic differences between ε3 and ε4 carriers
at late stages of AD.
7.5

Discussion

We analyzed frontal cortical tissue from subjects across a spectrum of AD severity,
with different genotypes (APOE ε3/3 or APOE ε3/4) (summary of results are in Figure
7.2). We found distinct changes in the white versus gray-enriched matter of subjects as
demonstrated through peptide alterations and lipid changes that have been associated with
brain matter. There were increases in phospholipid metabolism and decreases in amino
acid metabolism in AD brains compared with normal brains. Taken together, our findings
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indicated that glutamate and creatine metabolism were more important for predicting
disease in the gray matter, and glycine, fatty acid, pyrimidine, TCA cycle, and
phosphatidylcholine metabolism are more important for predicting disease in the white
matter. As disease progressed in the APOE ε4 genotype, brains were characterized by
decreases in metabolites responsible for reducing atherosclerosis, and the TCA cycle and
oxidative phosphorylation. With disease progression in the APOE ε3 genotype, brains were
characterized by increases in metabolites related to oxidative DNA damage, changes in
inhibitory neurotransmitters, and disruptions of neuronal membranes and decreases in
metabolites related to acetylcholine synthesis. In early disease, the APOE ε4 genotype was
associated with increased metabolites related to poor kidney function and altered neuronal
sterol metabolism, but there were few metabolic differences between APOE ε3 and ε4
genotypes in more severe AD.
The major differences between the metabolite composition of white-enriched matter
and gray-enriched matter were characterized mainly by the metabolite components
inherent to the myelin sheath present in the white-enriched matter. The myelin sheath is
mainly comprised of lipids which insulate axons to speed action potentials, and it is not
surprising that our data show that the top predictors for distinguishing gray-enriched matter
from white-enriched matter were all lipids. Alpha-hydroxylated cerebrosides are the most
abundant lipids in the myelin sheath402 and the myelin sheath has a lower
phosphatidylcholine to phosphatidylethanolamine ratio compared with grey matter due to
its unique composition of myelin, which are all consistent with our data. It is important to
separate white-enriched matter from gray-enriched matter in brain metabolomics analyses
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so that differences found between samples aren’t confounded by the inherent differences
between tissue types (and sample-to-sample differences in ratios of white and gray matter).
Previous studies investigating metabolomics changes in AD reported changes in
phosphatidylcholine and acylcarnitine metabolism403, taurine transport, bile acid synthesis,
and cholesterol metabolism380,381,404, lipids, sphingolipids (notably GM3 gangliosides) and
lipid

classes

previously

associated

with

cardiometabolic

disease

(phosphatidylethanolamine and triglycerides)405,406. Results using Metabolon’s untargeted
assay showed changes in not only phospholipid, phosphatidylcholine, and fatty acid
metabolism, but also the TCA cycle, pyrimidine, and several amino acids including
aspartate, lysine, glycine, glutamate, creatine, histidine. In addition to the lipid changes
found by others, these important amino acid, energy, and nucleotide changes could give
important clues about the underlying disease mechanism of AD.
Separating our analysis by Braak NFT stages and APOE genotype allowed us to
better understand the nuances of metabolite changes unique to disease stage and genotype.
As disease progresses in the APOE ε4 carriers, metabolites associated with reducing
atherosclerosis and the TCA cycle and oxidative phosphorylation appeared to correlate
with (and perhaps to drive) the differences between early and late stage AD. Previous
studies have reported that age-related vascular changes accompany or even precede the
development of AD pathology407, and a plant based diet can reduce atherosclerosis408.
Further, it has been observed that the TCA cycle can regulate the pathogenesis of
neuroinflammation and neurodegeneration409. It is interesting that TCA cycle metabolite
decreases are statistically more significant in the gray matter than the white matter in the
ε4 genotype, but that the machine learning analysis revealed TCA cycle metabolites to be
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more important in predicting AD in the white matter. While TCA cycle decreases are more
commonly seen in late stage gray matter E4 as a whole, when TCA cycle decreases are
seen in white matter, they are more likely to be predictive of AD, whereas other metabolites
in the gray matter are more predictive of AD.
As AD progresses in the APOE ε3 genotype, metabolites linked to oxidative DNA
damage, changes in inhibitory neurotransmitters, disruptions of neuronal membranes, and
decreases in metabolites related to acetylcholine synthesis correlated best with the
differences between early and late stage AD. Oxidative stress may participate in the
development of AD by promoting Aβ deposition, tau hyperphosphorylation, and the
subsequent loss of synapses and neurons410. There is evidence that the Mediterranean diet
is protective against oxidative DNA damage411. There is growing evidence in support of
GABAergic remodeling in the AD brain, potentially beginning in early stages of disease
pathogenesis412. Alterations of fatty acids at the level of lipid rafts and cerebral lipid
peroxidation were found in the early stage of AD413. Cholinergic neurons located in the
basal forebrain, including the neurons comprising the nucleus basalis of Meynert, are
severely lost in AD414.
Separating by APOE genotype was an important part of our analysis as the APOE ε4
genotype is the most common genetic risk factor for developing AD. At the early stage of
disease, APOE ε4 carriers differed from APOE ε3/3 in metabolites related to poor kidney
function and altered neuronal sterol metabolism. Older patients on hemodialysis are at
substantial risk of diagnosis with dementia and Alzheimer's disease415. APOE ε4expressing cultured astrocytes and neurons have reduced cholesterol and phospholipid
secretion, decreased lipid-binding capacity, and increased intracellular degradation416. This
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is likely due to the changed domain interaction with cholesterol receptors and less stable
conformation of the APOE ε4 genotype that changes its involvement in lipid metabolism
and neurobiology, thereby impacting neuronal repair, remodeling, and degeneration417.
There were far fewer metabolic differences between APOE ε3 and ε4 genotype in later
disease stages. It is possible that genotype differences are pronounced during early disease,
but that the disease course causes both genotypes to exhibit a similar biochemical profile
as the disease progresses and neurons are lost. These genotype differences should be further
explored to determine whether precision interventions, like the consumption of inulin or
the administration of rapamycin, could be implemented for ε4 carriers418,419.
Taken together, our current findings and those of previous reports suggest that
maintaining normal brain glucose metabolism is critical for cognitive resilience; therefore,
therapeutic strategies for preventing or treating AD may need to shift focus from Aβ toward
the preservation and restoration of normal brain metabolism. Recently, aducanumab, an
Aβ directed antibody, was granted accelerated approval to verify its clinical benefit for use
in early AD after decades of failed drugs targeted at Aβ; it is possible that metabolic
interventions could be used across the disease course to provide clinical benefit to patients.
Interventions with a metabolic therapeutic strategy have been reported that use intranasal
insulin administration and a ketogenic diet. With regards to the potential benefits of a
ketogenic diet, ketone bodies can function as an alternative fuel substrate in the brain when
glucose is unavailable or when glucose metabolism is impaired due to insulin
resistance340,357-359. One study showed that a ketogenic diet can modulate deposition of Aβ
and Tau in the CSF of MCI patients in conjunction with its modulation of the gut
microbiome and the production of short-chain fatty acids360. This finding is consistent with
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an animal study showing that a ketogenic diet enhanced Aβ clearance across the bloodbrain barrier and improved the composition of the gut microbiome361.
The gut microbiome produces secondary bile acids, and, as mentioned above,
alterations of bile acid production have been observed in AD patients due to gut
microbiome imbalances, suggesting another mechanism by which AD patients may benefit
from therapeutic strategies aiming to restore normal brain metabolism like the ketogenic
diet344,345. Another animal study showed that by modulating the gut microbiome with a
prebiotic diet, mice with the human APOE ε4 gene had enhanced systemic metabolism and
reduced neuroinflammatory gene expression, another hallmark of AD pathology362,418.
Collectively, modulating metabolic function and the gut microbiome may have a profound
impact on reducing the risk of AD.
Implication of gut microbiome changes; we have shown that prebiotic diet inulin
can increase tryptophan and tyrosine level in the APOE3 mice. (our recent inulin study
shows to reduce DNA damage in the E3 mice).
Future studies that evaluate the serum of subjects may be helpful to evaluate
potential systemic metabolomic changes in subjects and if the changes observed here are
limited to brain tissue. Similarly, analyses of cell-sorted tissue could give additional
resolution into the results. Furthermore, minimizing drug usage in subjects (about 9% of
biochemicals in named dataset were pharmaceuticals which included AD therapies such as
donepezil and memantine and the anti-diabetic medication metformin) may provide some
additional clarity in the above observations.
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In conclusion, our study shows that metabolite differences are associated with
disease stage, genotype, and cognitive decline in AD. Further study in AD metabolomics
may elucidate new insights into disease mechanism and therapeutics.
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Table 7.1 Participant Characteristics
Number of Participants

158

Age

85.6 (84.4, 86.9)

APOE (% ε4 carriers)

36.7%

Braak Stage 0-3

51.3%

Braak Stage 4-6

48.7%

Gender (% Female)

58.9%

Race (% White)

94.9%

Race (% Black)

5.1%

MMSE

22.2 (20.8, 23.6)

Postmortem Interval

3.7 (3.36, 4.02)

Consensus Diagnosis (% AD)

10.8%

Consensus Diagnosis (% Mixed AD)

42.7%

Consensus
Dementia)

Diagnosis

(%

Other 17.2%

Consensus Diagnosis (% Normal)

29.3%

TDP-43 (% Positive)

27.9%
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Table 7.2 Number of samples belonging to APOE genotypes and Braak Stages
APOE ε3/ε3

APOE ε3/ε4

Total

Braak Stage 0-3

64

17

81

Braak Stage 4-6

36

41

77

Total

100

58

158

157

Table 7.3 Top ranked biochemicals in (A) predicting gray vs white matter all belong to
the lipid superclass, (B) in predicting AD vs Normal brain tissue in Gray and (C) White
Matter

A) Gray Matter vs White Matter

Rank
Order

Super
Pathway

Sub Pathway

Accuracy: 91.77%

Biochemical Name

Fold
Change

1

Lipid

Hexosylceramides (HCER)

glycosyl ceramide (d18:2/24:1, d18:1/24:2)*

2.35

2

Lipid

Phosphatidylcholine (PC)

1,2-dipalmitoyl-GPC (16:0/16:0)

0.38

3
4

Lipid
Lipid

Phosphatidylcholine (PC)
Lysoplasmalogen

1,2-dioleoyl-GPC (18:1/18:1)
1-(1-enyl-oleoyl)-2-oleoyl-GPE (P-18:1/18:1)*

2.61
3.01

5

Lipid

Plasmalogen

1-(1-enyl-palmitoyl)-2-oleoyl-GPE (P-16:0/18:1)*

2.37

6

Lipid

Hexosylceramides (HCER)

glycosyl ceramide (d18:2/25:1, d18:1/25:2)

2.01

7

Lipid

1-palmitoyl-2-docosahexaenoyl-GPE (16:0/22:6)*

0.41

8

Lipid

Phosphatidylethanolamine
(PE)
Phosphatidylserine (PS)

1-stearoyl-2-oleoyl-GPS (18:0/18:1)

2.11

9

Lipid

1-oleoyl-2-docosahexaenoyl-GPE (18:1/22:6)*

0.54

10

Lipid

Phosphatidylethanolamine
(PE)
Plasmalogen

1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0)*

0.58

B) Gray Matter AD vs Normal

Rank
Order
1
2
3
4
5
6
7
8
9

Super
Pathway
Lipid
Amino Acid
Lipid
Amino Acid
Lipid
Amino Acid
Amino Acid
Amino Acid
Amino Acid

Biochemical Name

Fold
Change

Phospholipid Metabolism
Alanine and Aspartate Metabolism
Fatty Acid, Monohydroxy
Lysine Metabolism
Phospholipid Metabolism
Glycine, Serine and Threonine Metabolism
Glutamate Metabolism
Creatine Metabolism
Histidine Metabolism

glycerophosphorylcholine (GPC)
N-acetylasparagine
13-HODE + 9-HODE
pipecolate
glycerophosphoethanolamine
dimethylglycine
N-acetyl-aspartyl-glutamate (NAAG)
Guanidinoacetate
N-acetylhistidine

1.51
0.67
0.50
0.47
1.26
0.58
0.75
1.49
0.57

Biochemical Name

Fold
Change

C) White Matter AD vs Normal
Rank
Order

Super
Pathway

Accuracy: 80.00%
Sub Pathway

Accuracy: 81.54%
Sub Pathway

1
2
3
4
5
6
7
8
9
10
11

Lipid
Lipid
Amino Acid
Amino Acid
Amino Acid
Lipid
Lipid
Nucleotide
Energy
Lipid
Amino Acid

Fatty Acid, Monohydroxy
Phospholipid Metabolism
Lysine Metabolism
Glycine, Serine and Threonine Metabolism
Histidine Metabolism
Fatty Acid, Monohydroxy
Phospholipid Metabolism
Pyrimidine Metabolism, Uracil containing
TCA Cycle
Phosphatidylcholine (PC)
Alanine and Aspartate Metabolism

13-HODE + 9-HODE
glycerophosphorylcholine (GPC)
pipecolate
betaine
N-acetylhistidine
2-hydroxyheptanoate*
glycerophosphoethanolamine
3-ureidopropionate
2-methylcitrate/homocitrate
1,2-dilinoleoyl-GPC (18:2/18:2)
N-acetylasparagine

0.56
1.47
0.48
0.74
0.62
0.81
1.25
0.56
0.80
0.74
0.69

12

Amino Acid

Glycine, Serine and Threonine Metabolism

dimethylglycine

0.59

Heat map of statistically significant biochemicals profiled when comparing groups are labeled as
follows: Red and green shaded cells indicate p ≤ 0.05 (red specifies that the mean values are
significantly higher for that comparison; green values significantly lower).
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Table 7.4 Gray and white matter metabolomics between early and late stage in APOE4

Super
Pathway
Amino Acid

Sub Pathway

Gray Matter

White Matter

Glycine, Serine and Threonine
Metabolism
Alanine and Aspartate Metabolism

N-acetylserine

0.84

0.91

N-acetylasparagine

0.74

0.80

Glutamate Metabolism

N-acetyl-aspartyl-glutamate
(NAAG)
4-hydroxyphenylpyruvate

0.72

0.70

0.81

0.67

Leucine, Isoleucine and Valine
Metabolism

methylsuccinate

0.65

0.70

methylsuccinoylcarnitine

0.73

0.72

Methionine, Cysteine, SAM and Taurine
Metabolism
Urea cycle; Arginine and Proline
Metabolism
Gamma-glutamyl Amino Acid

cystathionine

0.80

0.72

N-acetylarginine

0.80

0.93

gamma-glutamylisoleucine*

0.63

0.95

gamma-glutamylmethionine

0.68

0.73

Tyrosine Metabolism

Peptide

Biochemical Name

E4 Late Stage vs
Early Stage

gamma-glutamylthreonine

0.81

0.96

Carbohydrate

Pentose Metabolism

ribitol

0.73

0.77

galactose 1-phosphate

0.40

1.01

Energy

Fructose, Mannose and Galactose
Metabolism
TCA Cycle

fumarate

0.80

0.86

malate

0.81

0.89

Oxidative Phosphorylation

phosphate

0.94

0.92

Fatty Acid Metabolism

acetyl CoA

0.69

0.66

Phospholipid Metabolism

choline phosphate

0.83

0.79

Lysophospholipid (LPL)

1-palmitoleoyl-GPC (16:1)*

0.81

0.94

1-stearoyl-GPC (18:0)

0.88

0.92

1-oleoyl-GPC (18:1)

0.82

0.91

1-linoleoyl-GPC (18:2)

0.79

0.88

1-arachidonoyl-GPC (20:4n6)*

0.82

1.01

1-linoleoyl-GPE (18:2)*

0.77

0.94

1-arachidonoyl-GPE (20:4n6)*

0.80

0.98

palmitoyl-docosahexaenoylglycerol (16:0/22:6) [1]*

1.26

1.69

Lipid

Diacylglycerol
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Table 7.5 Gray and white matter metabolomics between early and late stage in APOE3

Super
Pathway
Amino Acid

Sub Pathway

N-acetylglycine

Gray
Matter
1.75

White
Matter
1.62

dimethylglycine

0.61

0.59

betaine

0.71

0.69

Alanine and Aspartate Metabolism

N-acetylasparagine

0.69

0.70

Glutamate Metabolism

N-acetyl-aspartyl-glutamate (NAAG)

0.80

0.88

beta-citrylglutamate

0.73

0.85

N-acetylhistidine

0.62

0.67

N-acetyl-3-methylhistidine*

1.48

1.48

homocarnosine

0.67

0.74

1-methylhistamine

0.65

0.67

1-methyl-4-imidazoleacetate

0.63

0.82

2-aminoadipate

1.21

1.24

pipecolate

0.51

0.56

N-acetyl-2-aminoadipate

1.05

1.15

Tyrosine Metabolism

3-methoxytyramine sulfate

0.26

0.33

Tryptophan Metabolism

tryptophan betaine

0.45

0.44

8-methoxykynurenate

0.64

0.67

5-hydroxyindoleacetate

0.62

0.72

argininate*

1.21

1.14

N-acetylputrescine

0.76

0.74

N1,N12-diacetylspermine

0.21

0.32

Glutathione Metabolism

S-lactoylglutathione

0.70

0.94

Glycolysis, Gluconeogenesis, and
Pyruvate Metabolism

fructose 1,6-diphosphate/glucose 1,6diphosphate/myo-inositol
diphosphates
dihydroxyacetone phosphate (DHAP)

0.51

0.92

0.57

0.79

Nucleotide Sugar

UDP-galactose

1.51

1.47

Long Chain Polyunsaturated Fatty
Acid (n3 and n6)
Fatty Acid, Dicarboxylate

tetradecadienoate (14:2)*

0.75

0.69

octadecenedioate (C18:1-DC)

0.55

0.59

Fatty Acid Metabolism (Acyl
Carnitine, Short Chain)
Fatty Acid Metabolism (Acyl
Carnitine, Polyunsaturated)

acetylcarnitine (C2)

0.86

0.70

arachidonoylcarnitine (C20:4)

0.65

0.84

docosahexaenoylcarnitine (C22:6)*

0.52

0.53

Fatty Acid, Monohydroxy

2-hydroxyheptanoate*

0.76

0.78

Glycine, Serine and Threonine
Metabolism

Histidine Metabolism

Lysine Metabolism

Urea cycle; Arginine and Proline
Metabolism
Polyamine Metabolism

Carbohydra
te

Lipid

Biochemical Name

E3 Late Stage vs
Early Stage

13-HODE + 9-HODE

0.62

0.54

Inositol Metabolism

myo-inositol

1.15

1.21

Phospholipid Metabolism

glycerophosphorylcholine (GPC)

1.34

1.34

glycerophosphoethanolamine

1.18

1.20

1-palmitoyl-2-linoleoyl-GPC
(16:0/18:2)
1,2-dilinoleoyl-GPC (18:2/18:2)

0.96

0.90

0.79

0.62

Phosphatidylcholine (PC)
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Table 7.6 Gray and white matter metabolomics between APOE3 and APOE4 at early and
late stages
Early Stage
Super Pathway
Amino Acid

Peptide

Sub Pathway

E4/E3 Fold Change
Gray Matter

White Matter

dimethylglycine

0.60

0.57

formiminoglutamate

0.03

0.02

histamine

1.28

1.15

1-methyl-4-imidazoleacetate

0.64

0.53

Lysine Metabolism

2-aminoadipate

1.27

1.28

Leucine, Isoleucine and
Valine Metabolism

1-carboxyethylisoleucine

1.40

1.22

methylsuccinate

1.38

1.41

methylsuccinoylcarnitine

1.36

1.42

Urea cycle; Arginine and
Proline Metabolism

N,N,N-trimethyl-alanylproline
betaine (TMAP)
argininate*

0.52

0.49

1.38

1.29

Glutathione Metabolism

4-hydroxy-nonenal-glutathione

0.55

0.49

Gamma-glutamyl Amino
Acid

gamma-glutamylisoleucine*

1.81

1.31

gamma-glutamylmethionine

1.31

1.24

gamma-glutamylthreonine

1.54

1.47

Glycine, Serine and
Threonine Metabolism
Histidine Metabolism

Biochemical Name

Carbohydrate

Pentose Metabolism

ribitol

1.30

1.23

Energy

Oxidative Phosphorylation

phosphate

1.06

1.09

Lipid

Long Chain
Polyunsaturated Fatty Acid
(n3 and n6)
Eicosanoid

arachidonate (20:4n6)

1.19

1.09

15-HETE

0.54

0.50

Endocannabinoid

docosahexaenoyl ethanolamide

1.32

0.99

Phosphatidylethanolamine
(PE)
Phosphatidylglycerol (PG)

1,2-dipalmitoyl-GPE (16:0/16:0)*

0.94

0.73

1,2-dioleoyl-GPG (18:1/18:1)

0.55

1.25

Lysophospholipid

1-oleoyl-GPC (18:1)

1.11

1.09

1-palmitoyl-GPS (16:0)*

1.36

0.96

Sterol

7-hydroxycholesterol (alpha or beta)

0.42

0.42

Secondary Bile Acid
Metabolism

glycodeoxycholate

0.46

0.59

Late Stage

Super Pathway

Sub Pathway

Biochemical Name

Amino Acid

Tryptophan Metabolism
Urea cycle; Arginine and
Proline Metabolism
Polyamine Metabolism
Primary Bile Acid
Metabolism

Lipid

E4/E3 Fold Change
Gray Matter

White Matter

indolelactate

2.58

1.76

homoarginine

1.66

1.53

N1,N12-diacetylspermine

6.95

10.26

glycochenodeoxycholate

2.67

3.68
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Figure 7.1 Schematic representation of study design.

We took brain tissue from Brodmann Area 9 of 158 participants in the University of
Kentucky Alzheimer’s Disease Center brain bank. We divided the samples into gray
matter and white matter and performed untargeted metabolomics. We compared 1) Gray
matter vs White matter, 2) AD vs control, 3) APOE 4 Early vs Late, 4) APOE 3 Early vs
Late, and 5) Early and Late APOE 3 vs 4
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Figure 7.2 Schematic representation of overall results.

Overall results from analysis of matter type, disease diagnosis, Braak stage, and APOE
genotype.
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CHAPTER 8. [SUPPLEMENT] GUT MICROBIAL DYSBIOSIS IS CORRELATED
WITH STROKE SEVERITY MARKERS IN AGED RATS FOLLOWING STROKE
8.1

Summary

An imbalanced gut microbial community, or dysbiosis, has been shown to occur
following stroke. It is possible that this dysbiosis negatively impacts stroke recovery and
rehabilitation. Species level resolution measurements of the gut microbiome following
stroke are needed to develop and test precision interventions such as probiotic or fecal
microbiota transplant therapies that target the gut microbiome following stroke. Previous
studies have used 16S rRNA amplicon sequencing in young male mice to obtain broad
profiling of the gut microbiome at the genus level following stroke, but further
investigations will be needed with whole genome shotgun sequencing in aged rats of both
sexes to obtain species level resolution in a model which will better translate to the
demographics of human stroke patients.
39 aged male and female rats underwent middle cerebral artery occlusion. Fecal samples
were collected before stroke and three days post stroke to measure gut microbiome.
Machine learning was used to identify the top ranked bacteria which were changed
following stroke. MRI imaging was used to obtain infarct and edema size and cerebral
blood flow (CBF). ELISA was used to obtain inflammatory markers.
Dysbiosis was demonstrated by an increase in pathogenic bacteria such as Butyricimonas
virosa (15.52 fold change, p<0.0001), Bacteroides vulgatus (7.36 fold change, p<0.0001),
and Escherichia coli (47.67 fold change, p<0.0001). These bacteria were positively
associated with infarct and edema size and with the inflammatory markers Ccl19, Ccl24,
IL17a, IL3, and complement C5; they were negatively correlated with CBF. Conversely,
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beneficial bacteria such as Ruminococcus flavefaciens (0.14 fold change, p<0.0001),
Akkermansia muciniphila (0.78 fold change, p<0.0001), and Lactobacillus murinus (0.40
fold change, p<0.0001) were decreased following stroke and associated with all the
previous parameters in the opposite direction of the pathogenic species. There were not
significant microbiome differences between the sexes.
The species level resolution measurements found here can be used as a foundation to
develop and test precision interventions targeting the gut microbiome following stroke.
Probiotics that include Ruminococcus flavefaciens, Akkermansia muciniphila, and
Lactobacillus murinus should be developed to target the deficit following stroke to measure
the impact on stroke severity.
8.2

Introduction

Over 795,000 people suffer a stroke every year in the United States alone1. Recent
advances in acute stroke therapies have lowered stroke mortality, but survivors are often
left severely impaired12. Rehabilitation therapies are beneficial at inducing neuroplasticity
to overcome these impairments, but over 40% of stroke survivors are left with moderate to
severe disabilities that markedly reduce quality of life21. Novel multimodal approaches are
needed to promote plasticity and sensorimotor function through a combination of current
rehabilitation therapies with other treatments designed to foster neuroplasticity.
Accumulating evidence suggests that gut microbes modulate brain plasticity via the
bidirectional gut-brain axis and may play a role in stroke rehabilitation67. A severely
imbalanced microbial community, or dysbiosis, has been shown to occur following stroke,
causing a systemic flood of neuro- and immunomodulatory substances due to increased gut
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permeability and decreased gut motility85. These substances can impact neuroinflammation
as commensal bacteria invade the bloodstream and as intestinal lymphocytes migrate from
gut-associated lymphoid tissue to the brain92. Fecal microbiota transplant has been shown
to normalize brain lesion-induced dysbiosis and to improve stroke outcome in mice92. The
microbiome is modifiable as it is influenced by environmental factors such as diet and
exercise and could potentially be a therapeutic target in stroke rehabilitation through
nutritional and pharmacological interventions and physical therapy89,145. To our
knowledge, no studies have measured the species level resolution necessary to develop
precision interventions such as probiotics or fecal microbiota transplants that target the gut
microbiota following stroke. Furthermore, no microbiome studies have been performed on
aged rats of both sexes, which are better matched to the demographics of human stroke
patient than the young male mice used in most studies. The microbiome changes found in
this study need to be examined and correlated with clinical imaging markers of stroke and
inflammatory markers to understand better whether the microbiome could be a therapeutic
target in stroke rehabilitation.
Here we identify the gut-brain axis changes that occur following stroke in aged rats using
high resolution whole genome shotgun sequencing and correlate them with clinical
imaging markers of stroke including MRI-based infarct size, edema size, and cerebral
blood flow (CBF) as well as inflammatory markers. We found that microbial communities
are disrupted in an aged rat population following stroke, showing significantly different
beta diversity, increased alpha diversity, and changes in the relative abundance of 5 of the
6 major phyla found in the gut. Changes in thirteen bacterial species as detected by machine
learning were highly associated with stroke and changes in these species were also
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associated with increased infarct and edema size and decreased CBF. Changes in the
microbiome due to stroke were also associated with increases in 49 inflammatory markers.
8.3

Results

We performed a middle cerebral artery occlusion on a sample of 39 aged rats of both
sexes (age 15-18 months). Half of the rats underwent a permanent occlusion and half
underwent a transient 5-hour occlusion. We analyzed male and female rats. We analyzed
all rats before and after middle cerebral artery occlusion and considered sex, surgery type,
and treatment with LIF or PBS in the analysis. We administered a leukemia inhibitory
factor (LIF) treatment on half of the rats based on previous work suggesting that LIF is an
anti-inflammatory that regulates the immune/inflammatory response to stroke 420. The rats
had an average of 96.50 mm3 infarct size, 131.0 mm3 edema size, and 1.31 ml/g/min CBF
from a permanent occlusion and 31.46 mm3 infarct size, 102.1 mm3 edema size, and 2.16
ml/g/min CBF from a transient occlusion. Infarct and edema volumes were not
significantly different between sex, treatment group, or occlusion type. No significant
difference in CBF was detected between sex or treatment, but, as expected, a significant
difference occurred between permanent and transient occlusion in CBF (Fig. 8.1). We used
four tests to determine motor function skills before and after stroke. 76% of the rats circled
following stroke (Fig. 8.2a), there was a swing bias of 8 (Fig. 8.2b), there was a step bias
of 9.3 (Fig. 8.2c), and only 26.5% of the rats extended their paw (Fig 8.2d).
8.3.1

The aged rat gut microbiome is disrupted following stroke

We performed an analysis on the gut microbial communities of the rats by running
whole genome shotgun sequencing using DNA quantification services provided by
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CosmosID. We collected fecal samples 24 hours before stroke and within 72 hours
following stroke. Comparing the alpha diversity before and after stroke, we found that
richness and evenness increased from 3.818 on the Shannon diversity index

421

to 4.178

(Fig. 8.3A). There were no differences in the change of alpha diversity between sex,
treatment, or occlusion type. Comparing the beta diversity before and after stroke, we
found that the microbial communities were significantly different between baseline and
stroke (p=0.0001), but no significant microbial community differences were detected based
on sex, treatment, or occlusion type. (Fig. 8.3B).
We investigated specific differences in the relative abundance of the major bacterial phyla
in the gut (Fig. 8.4). We found increases in proteobacteria and Bacteroidetes and decreases
in firmicutes, verrucomicrobia, and actinobacteria following stroke. This translates to a
sharp decrease in the firmicutes to bacteroidetes ratio. Using linear regression, the major
bacterial phyla predict infarct size with an R2=0.3866 and edema size with an R2=0.6022.
8.3.2

The top 13 disrupted bacterial species following stroke

We investigated specific differences in the relative abundance of the major bacterial
species in the gut. There was a total of 29 species increased and 23 species decreased
following stroke (Table 8.1). Using random forest machine learning classification, we
found the most important bacterial species that predict stroke verse baseline with an
85.14% accuracy. They include an increase in Butyricimonas virosa, Bacteroides vulgatus,
Escherichia coli, Bacteroides uniformis, Bacteroides dorei, Parabacteroides distasonis,
and Alistipes indistinctus and a decrease in Ruminococcus flavefaciens, Akkermansia
muciniphila, Ruminococcus_u_s, [Clostridium] clostridioforme, Lactobacillus murinus,
and Lachnospiraceae bacterium 3-1. Using linear regression with backwards elimination
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(Table 8.2), we found that increases in Ruminococcus_u_s and Alistipes indistinctus and
decreases in Lachnospiraceae bacterium 3-1 predict infarct volume with an R2=0.4433.
Increases in Butyricinomas virosa, Bacteroides uniformis, and Ruminococcus_u_s and
decreases in Ruminococcus flavefaciens predict edema with an R2=0.6230. Finally,
decreases in Alistipes indistinctus predict CBF with an R2=0.1825.
We investigated potential interactions between bacterial species in predicting infarct
size, edema size, and CBF. Using a feasible solution algorithm (FSA) for finding
interactions, we found that decreases in Lachnospiraceae bacterium A2 and Lactobacillus
murinus predict infarct size, but a combination of the two predicts a dramatic increase in
the prediction value with an R2=0.6206. Decreases in Lachnospiraceae bacterium A4 and
Lactobacillus murinus predict edema size, but a combination of the two have stronger
predictive ability with an R2=0.6454. Decreases in Adlercreutzia equolifaciens and
Desulfovibrio desulfuricans predict CBF, but again, a combination of the two has a stronger
prediction with an R2=0.8093.
8.3.3

Bacterial disruptions following stroke are correlated with stroke severity

We investigated the correlation of all the bacterial species with infarct size and edema
size (Table 8.3). Using the MaAsLin 2 R package422, which automatically normalizes and
transforms all variables in preparation for linear regression, we correlated metagenomic
sequencing with imaging variables of stroke severity. Twenty-seven bacterial species were
positively correlated and 19 negatively correlated with infarct volume. Thirty species were
positively correlated, and 31 species were negatively correlated with edema volume. No
species were correlated with CBF.
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8.3.4

Bacterial disruptions following stroke are correlated with inflammation

We investigated the correlation of all the bacterial species with infarct size and edema
size (Table 8.3). Using the MaAsLin 2 R package422, which automatically normalizes and
transforms all variables in preparation for linear regression, we correlated metagenomic
sequencing with imaging variables of stroke severity. Twenty-seven bacterial species were
positively correlated and 19 negatively correlated with infarct volume. Thirty species were
positively correlated, and 31 species were negatively correlated with edema volume. No
species were correlated with CBF.
8.4

Discussion

To our knowledge, we are the first to report on the gut microbial changes with
species level resolution in aged male and female rats and to correlate these changes with
clinical MRI imaging markers of stroke and inflammatory markers. Following stroke, we
found that alpha diversity significantly increased, beta diversity significantly changed, and
5 of the 6 major bacterial phyla were altered. Using machine learning, the top 13 bacterial
species that predict whether a sample came from the baseline or post-stroke time point.
These bacterial species had independent significant correlations with infarct size, edema
size, and CBF. We also identified several species whose interactions with one another were
significant in correlating with stroke imaging outcomes. Finally, we found 49 inflammatory
markers that correlated with the changes in microbiome from stroke. These changes are
representative of a shift from beneficial to pathogenic bacterial species following stroke
which results in an increased inflammatory response.
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Figure 8.5 summarizes the changes in gut microbial communities in response to
stroke. Following stroke there is a significant shift in the gut microbiome, with alterations
to 52 major bacterial species. These bacterial fluctuations shift the environment to a more
inflammatory state that adversely affect injury. The microbial community dysbiosis is
likely due to the increased gut permeability and decreased gut motility in addition to the
immunodepression caused by the amplified stress response (increased sympathetic nervous
system response and hypothalamic-pituitary-adrenal (HPA) axis response) following
stroke 423. Previous groups have reported a decrease in alpha diversity following stroke in
a mouse model92 and an increase in a human model

107

. Our findings are consistent with

others who have seen that microbial communities differ before and after stroke based on
measures of beta diversity

424

. We did not find any significant differences in the

microbiome between males and females. Some groups have found sex differences in the
microbiome that are largely attributed to hormone differences 425. It is possible that we did
not see these differences because the female rats we used are aged and reproductively
senescent.
We saw increases in proteobacteria following stroke. In previous studies,
proteobacteria have been associated with increased cognitive impairment following stroke
198

. Dysbiosis related to metabolic disorders, inflammation, and cancer is often related to

an increase in proteobacteria 426,427. This is possibly due to increased oxygen content in the
gut following increases in inflammation, providing an optimal environment for these
facultative anaerobes

428

. We also saw decreases in firmicutes and increases in

bacteroidetes species. Decreased firmicutes have also been associated with Alzheimer’s
disease

429

. Obesity is often characterized by a significantly increased firmicutes to
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bacteroidetes (F/B) ratio

430

; interestingly, our study found that stroke has the opposite

effect on F/B ratio. Actinobacteria was significantly decreased following stroke.
Actinobacteria downregulates inflammation by production of IL-4 and IL-13

431

and is

known to have anti-biofilm properties against pathogenic bacteria 432. It is possible that a
decrease in actinobacteria allows other pathogenic bacteria to flourish.
Of the bacteria we found that are increased following stroke, many were of the
bacteroides species. Bacteroides species have the ability to reduce oxygen levels and
breakdown food products to liberate fucose and sialic acid residues from glycoproteins that
can be consumed by other microorganisms, including pathogens. Higher bacteroides
species are associated with type I diabetes 433. Bacteroides vulgatus and Bacteroides dorei
reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis 219, but they
are also associated with insulin resistance, altered bile acid metabolism, and reduced
interleukin-22 secretion 434. Butyricimonas virosa, Escherichia coli, and Parabacteroides
distasonis were also elevated following stroke. An increase of Butyricimonas virosa has
also been seen in divers with high occupational exposure to a hyperoxic environment 435,
which is very different from the hypoxic environment of stroke. Escherichia coli is a very
common commensal bacteria that has the potential to cause extraintestinal infections based
on its genome content and phenotypic traits

220

and is famous for causing post-stroke

infections, especially pneumonia. Parabacteroides distasonis has been shown to alleviate
obesity and metabolic dysfunctions via production of succinate and secondary bile acids
436

, which is interesting since stroke is often associated with obesity and metabolic

dysfunctions.
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Many bacteria which are generally considered beneficial were decreased following
stroke including akkermansia, lactobacillus, and ruminococcus species. Akkermansia
muciniphila is a mucin-degrading bacterium 437 that can be increased with fasting 438 that
is known to improve host metabolic functions and immune responses
murinus can combat inflammaging

440

439

. Lactobacillus

, and a reduction of L. murinus due to high salt

consumption has been associated with an increase in proinflammatory TH17 cells

441

,

which have been correlated with post stroke dysbiosis and secondary injury

442

.

Lactobacillus reuteri was also significantly reduced following stroke. A randomized
control trial in children showed administration of L. reuteri as a probiotic to be useful in
treating constipation in children

443

. Constipation is a common morbidity in stroke, and

administration of this species could help to alleviate symptoms. Ruminococcus flavefaciens
has also been shown to decrease the therapeutic effects of antidepressants, having
implications for the treatment of post-stroke depression.
Many of the bacterial changes were associated with increases in inflammatory
markers. The major markers that were increased were CCL19, CCL24, IL-17A, IL-3, and
complement factor C5. CCL19 is a chemokine that is commonly upregulated as a result of
viral infections444, and attracts dendritic cells and T lymphocytes 445; it promotes thymocyte
development, secondary lymphoid organogenesis, high affinity antibody responses,
regulatory and memory T cell function, and lymphocyte egress from tissues organs
446,447

. CCL19 suppresses angiogenesis and can inhibit proliferation, migration, and

sprouting responses of tumors

448

. CCL19 has previously been found to be upregulated

following stroke after damage to the intestinal epithelium

449

and has been shown to

facilitate T-cell migration to the insult site and microglial activation following stroke 450.
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CCL24 plays an important role in pathological processes of skin and lung inflammation
and fibrosis
CCR3

452

451

and regulates inflammatory and fibrotic activities through its receptor,

. CCR3 is a mediator of neural cell death

453

. In host defense, IL-17A has been

shown to be mostly beneficial against infection caused by extracellular bacteria and fungi
454

and IL-17A has been shown to be increased following stroke, especially in males

455

.

IL3 is strongly associated with brain volume variation and plays pivotal roles in the
expansion and maintenance of the neural progenitor pool and the number of surviving
neurons 456; our work has previously identified IL3 increased in the spleen with our aged
rat model of stroke 420. Activation of complement C5 generates the potent anaphylatoxin
C5a and leads to pathogen lysis, inflammation, and cell damage

457

. Activated C5

complement components are a part of the cerebral tissue inflammation following ischemia
458

.
This study lays an important foundation upon which precision interventions can be

developed to target the gut microbiome in stroke rehabilitation. Future studies should
attempt to manipulate the microbiome to change stroke outcomes. This could be achieved
through diet interventions, antibiotic therapy, probiotics, or fecal microbiota transplant. For
example, a future probiotics study should include the use of Ruminococcus flavefaciens,
Akkermansia muciniphila, and Lactobacillus murinus as these were deficient in our
population. Stroke severity measures from imaging and inflammatory markers could be
used as outcomes to compare to the current study. While the present study identified
associations of various inflammatory markers with changes in gut microbial composition,
it would also be useful to perform mechanistic studies to determine how the microbiota
change the expression of these markers and what their downstream effects are. Finally,
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human studies will be needed to determine whether the microbial changes seen in animals
following stroke are similar to the changes seen in animals. Such results can then be used
to alter the gut microbiome to favor positive clinical outcomes after stroke.
8.5
8.5.1

Methods

Ethics approval and animals

Details of ethics approval and animals have been reported previously459. Briefly, aged
male and female rats (18‐month‐old Sprague‐Dawley rats (ENVIGO, Indianapolis, IN)
were used for all procedures. The aged female rats on average weighed between 245g and
425g, and aged male rats approximately weighed between 505g and 705g. The study was
conducted in accordance with the National Institutes of Health Guide for the Care and Use
of Laboratory Animals and study protocols were approved by University of Kentucky’s
(UK) Institutional Animal Care and Use Committee. Reporting in this manuscript follows
the recommendations in the ARRIVE guidelines. Animals were housed in a climatecontrolled room on a 12‐hr light and dark cycle (0700–1900) with access to food and water.
Per Division of Laboratory Animal Resources (DLAR) cage requirements at UK’s
vivarium facility, the animals can be paired in one cage if the animal weight is under 650
grams. We typically house two animals (males or females) per cage upon arrival to DLAR.
Once the rats are over 650 grams, they are then split into a separate cage by themselves.
Fecal samples were collected for all animals at 24 hours before surgery and 72 hours postsurgery and for 4 animals at 30 days post-surgery. The rats underwent MRI at 72 hours to
measure infarct and edema volumes and CBF then euthanized.

175

8.5.2

Middle cerebral artery occlusion

Details of the middle cerebral artery occlusion have been reported previously459.
Briefly, 22 of the rats received a permanent Middle Cerebral Artery Occlusion (p-MCAO)
and 17 of the rats received a 5-hour transient Middle Cerebral Artery Occlusion (5tMCAO). All animals were induced with oxygen containing 5% isoflurane, then shaved,
prepped with Hibiclens (chlorohexidine scrub) prior to 70% EtOH and then a betadine
solution. Maintenance isoflurane was maintained at 2.5% in O2 was delivered via a
nosecone placed in line with the binner tubeQ (gas delivery tube) of the anesthesia circuit.
Under bnear sterileQ conditions and with the use of a Zeiss operating microscope (Carl
Zeiss AG, Gottingen, Germany) at 4 to 25 magnification, the procedure was performed.
First, the skin was opened with a midline vertical incision, and the underlying
submandibular gland bluntly dissected in the midline to produce left and right lobes, which
were retracted laterally. Division of the omohyoid muscle, then dissection medial to the
right sternocleidomastoid (SCM) muscle was used to expose the common carotid artery
(CCA), which was separated from the vagus nerve. Elastic hooks (Lone Star Medical
Products, Houston, TX, USA) tethered to metal stays on the customized surgery table were
used to retract the skin and the SCM muscle. In the p-MCAO, a hand-held electrocautery
(Aaron Medical, St. Petersburg, FL, USA) is used to cauterize the superior thyroid artery
(STA), a collateral off the ECA, and the occipital artery (OA), a collateral off the ICA.
Two 5-0 silk sutures (Surgical Specialties, Reading, PA, USA) were used to ligate the
external carotid artery (ECA) as distal as possible to the ECA/ICA bifurcation, and a
second tie that was applied just proximal to the first, leaving enough space in between the
two ties to cut the artery with micro scissors. At this point, blunt dissection was used to
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isolate the internal carotid artery (ICA) and its collateral, the pterygopalatine artery. Next,
microvascular aneurysm clips (Mizuho, Beverly, MA, USA) were applied to the CCA and
the ICA. A 5-0 PDS II monofilament embolus (Ethicon, Cornelia, GA, USA), was
introduced into an arteriotomy hole–produced with a 26-gauge hypodermic needle–in the
reflected ECA stump and fed distally into the ICA. At this time, a collar suture at the base
of the ECA stump was tightened around the embolus, and the ICA clamp was removed.
The embolus was advanced 20 mm from the carotid bifurcation, with care taken to avoid
entrance into the pterygopalatine artery.
For the transient occlusion, the same steps were done as stated with the pMCAO, with
the exception that Doccol Corporation silicone rubber-coated monofilaments were used for
the occlusion of the middle cerebral artery (MCA). Multiple sized Doccol monofilaments
are used in the MCAO surgery depending on the sex and weight of the rat. Two 18-inch
length of 5-0 silk suture were used for the ligation of the external carotid artery (ECA) to
secure the ECA stump, and the entry point of the monofilament into the ECA/ICA
bifurcation. The third 5-0 silk suture was used to secure the monofilament within the ECA.
A micro-serrefines arterial clamp (FST, Fine Science Tools, #18055-01) was used to
occlude the internal carotid artery (ICA) and common carotid artery (CCA) prior to
advancement of the monofilament into the MCA. After 5 hours, the embolus was gently
removed and the collar suture at the base of the ECA stump tightened. The skin was closed
with 3-0 nylon suture (Ethicon, Cornelia, GA, USA), anesthesia discontinued, and the
animal allowed to recover. Animals used for control underwent a neck dissection and
coagulation of the external carotid artery, but no manipulation or occlusion of the common
or internal carotid arteries.
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8.5.3

Post-surgical fluid management and pain control

Details of the post-surgical fluid management and pain control have been reported
previously459. Briefly, immediately post‐operatively the animals received 2 ml of sterile
saline (0.9%) subcutaneous. An additional 1 ml of saline was given if extra blood loss
occurred during surgery. The animals were injected with sterile filtered PBS pH 7.4 at 6
(for the p-MCAO), 24, 48, and 72 hours post‐MCAO. The animals were weighed every
morning post‐MCAO to determine dehydration. Hydration status was checked by pinching
up or “tenting” the skin over the nape of the neck. The skin should immediately relax into
its normal position. If the skin remains tented longer than normal, the rat was deemed
dehydrated, and saline was given. Per DLAR guidelines, rats can receive up to 10 ml at a
time and no more than 2 ml at any one location per 6 hr. If warranted, additional saline (1–
2 ml) will be given in addition to 6, 24, 48, and 72 hr. Also, we added an additional water
bottle in each cage to allow more avail‐ ability to free water for the rats to consume and
moistened food was provided on the bottom of the cage to encourage feeding and additional
water intake. Post‐surgical pain control was managed with carprofen, which is based on
weight of the animal. Animal weights are taken prior to surgery (pMCAO) and daily until
animals are euthanized at 72 hr. (post MRI). The animals received a dosage of carprofen
5mg/kg prior to surgery and every 24 hr. for three days post‐pMCAO until 72 hr. when
they were euthanized (post MRI). Termination of survival criteria include that all animals
were weighed and monitored, especially for dehydration and pain, each morning post
surgery. This includes specific attention to the animal as a whole, as well as incision sights.
If symptoms such as pain, fatigue, loss of energy, excess energy, ruffled hair coat,
reluctance to move, failure to groom or feed, hypoactivity, hyperactivity, restlessness, self‐
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trauma, aggressiveness, ataxia, pale mucous membranes, cyanosis, rapid, shallow and/or
labored breathing, cachexia, porphyria, soiled anogenital area, inactivity, failure to respond
to stimuli, lack of inquisitiveness, vocalization, and/or hunched posture were observed, the
research team obtained advice from the vivarium veterinary staff on how best to intervene
to alleviate discomfort; if that was not possible the animal was euthanatized. Additional
checks were made in the afternoon if there was any rat of concern. The animals were
removed from the study if adverse signs persisted despite carprofen and treatment past 24
hr. If the signs fail to resolve, the vivarium veterinarian was consulted and decided the time
course when such animals were euthanized. Additionally, weight loss greater than 20%
(emaciated appearance, rapid weight loss over two days) was considered an endpoint.
Rapid weight loss was considered greater than 10% a day for two days.
8.5.4

Microbiome Sequencing

Fecal samples were collected for all animals at 24 hours before surgery and 72 hours
post-surgery and for 4 animals at 30 days post-surgery. Genomic DNA were extracted from
0.25 grams of stool using ZymoBIOMICS™ DNA Mini Kit and shipped to CosmosID for
DNA quantification using fluorometer Qubit 3.0. Libraries were constructed and the PCR
products were purified using 1.0X speed beads and eluted in 15 µL of nuclease-free water
and quantified by PicoGreen fluorometric assay (100X final dilution). The libraries were
pooled and loaded onto a high sensitivity chip run on the Caliper LabChipGX (Perkin
Elmer, Waltham, MA) for size estimation and sequenced using Illumina NextSeq/HiSeq
platform. Unassembled sequencing reads were analyzed by CosmosID bioinformatics
platform (CosmosID Inc., Rockville, MD)

460-463

for microbiome analysis. Heatmaps,

stacked bar graphs, and Principal Component Analysis (PCA) plots were generated to
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visualize the diversity and abundance of each microbial taxa. Alpha- and beta-diversity
were calculated to determine the number of species present in a cohort and diversity
similarities between groups.
8.5.5

Magnetic resonance imaging

MRI images were acquired on a 7T Bruker Clinscan horizontal bore system (7.0T, 30
cm, 300 Hz) equipped with a triple‐axis gradient system (630 mT/m and 6,300 T m‐1 s ‐1)
with a closed cycle. PCASL (pseudo conintous arterial spin labelling) images were
acquired coronally to determine CBF with a fat saturated, double refocused echo planar
sequence: TR 4000 ms, TE 26 ms, Matrix 74 x 56, FOV 26 mm x 19.7 mm, Slice 1.2 mm,
Slices 6, 120 Tagged-Untagged Pairs, 10 M0 Images, Tagging Plane Offset 12mm, Bolus
duration 1.86sec, Post Labeling Delay 0sec, and Acquisition Time of 10 min. T2 weighted
images were acquired coronally with a RARE sequence: TR 6000 ms, TE 29 ms, Turbo
Factor 5, Matrix 190 x 190, FOV 240 mm x 240 mm, Slice 0.4 mm, Slices 44, and
Acquisition Time of 9 min. Male rats were anesthetized with an average of 2.25%
isoflurane in oxygen, while female rats were anesthetized with an average of 1.75%
isoflurane in oxygen using an MRI compatible CWE Inc. equipment (Ardmore, PA). They
were held in place on a Bruker scanning bed with a tooth bar, ear bars, and tape. Body
temperature, heart rate, and respiratory rate were continuously monitored throughout the
MRI scans (SA Instruments, Inc., Stony Brook, NY). The animal's body temperatures were
maintained at 37°C with a water heating system built into the scanning bed. The scanning
procedure took approximately 40-60 mins. per animal.
The MR images were analyzed by a blinded neuroradiologist who visually identified
infarct volume and edema volume. These volumes were counted, and this number was
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normalized to the number of images counted to provide a per section count. The volume
of brain parenchyma demonstrating infarct volume visibly affected was calculated by
manual segmentation using ITK‐SNAP software464. The volume of brain parenchyma
visibly affected by T2 hyperintensity (edema volume) was calculated in a similar fashion.
The data are given as absolute volume in cubic millimeters. The calculation was based on
all slices from each MR sequence. Cerebral perfusion values of the area of lesion within
the ipsilateral hemisphere, and the equivalent region within the contralateral hemisphere
were generated using the quantification as previously described.358,419
8.5.6

Biochemical analysis

In following STAIR guidelines, clinically relevant biomarkers were determined in our
aged male and female rats465. Blood was taken from the jugular vein at three different time
points: immediately prior to MCAO surgery and 5 mins after reperfusion of the MCA in
the pMCAO, and 5 hours post MCAO procedure in the 5t-MCAO. Blood was immediately
placed on ice and centrifuged at 2000 g for 15 minutes. Plasma was extracted and stored
separately, both pellet and plasma were frozen at -80˚C for later analysis. RNA extraction
and Amplification followed the methods of Martha et.al 2020466. Briefly, total RNA was
extracted from the pellet portion via a Nucleospin Blood Kit (Macherey-Nagel, Düren,
Germany), RNA quantity was estimated using a Qubit 4 Fluorometer (Thermo-Fisher;
Waltham, MA), cDNA was synthesized using a RT² PreAMP cDNA synthesis Kit from
Qiagen and expression of 84 genes were measured using an ABI StepOne Plus
(Germantown, MD) and a RT² Profiler Rat Chemokine and Receptor Array from Qiagen.
Delta Delta CT was calculated using the fold change of the gene expression measurement
from pre to 3-day.
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8.5.7

Statistical analysis

Descriptive microbiome analyses were performed with CosmosID bioinformatics
software to generate alpha diversity, beta diversity, and relative abundance data. Alpha
diversities amongst groups were compared using Wilcoxon Rank Sum test. Beta diversities
amongst groups were compared using PermANOVA. Relative abundance data was
compared to measures of stroke severity as determined by imaging (infarct size, edema
size, CBF) using general linear models within the MaAsLin 2 R package422. Random forest
was used to determine top bacterial species that were changed following stroke using the
randomForest R package467. All imaging variables in the study were transformed to meet
assumptions of normality. The transformation procedures began with Shapiro‐Wilks and
for measures with p < 0.05, the variables were square root transformed. A p‐value of 0.05
was set a priori to determine statistical significance.
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Table 8.1 Top 13 bacterial species changes following stroke as detected by random forest
Bacterial Species

Change in Relative Abundance

Gram Stain

Phylum

Butyricimonas virosa

15.52

(-)

Bacteroides

Ruminococcus flavefaciens

0.14

(+)

Firmicutes

Akkermansia muciniphila

0.78

(-)

Verrucomicrobia

Bacteroides vulgatus

7.36

(-)

Bacteroidetes

Escherichia coli

47.67

(-)

Proteobacteria
Bacteroidetes

Bacteroides uniformis

5.15

(-)

Bacteroides dorei

5.29

(-)

Bacteroidetes

Ruminococcus_u_s

0.25

(+)

Firmicutes

Parabacteroides distasonis

10.84

(-)

Bacteroidetes

[Clostridium] clostridioforme

0.42

(+)

Firmicutes

Alistipes indistinctus

335.73

(-)

Bacteroidetes

Lactobacillus murinus

0.36

(+)

Firmicutes

Lachnospiraceae bacterium 3-1

0.40

(+)

Firmicutes

Predictive Accuracy of Random Forest Model: 85.14%
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Table 8.2 Linear Regression models predicting infarct, edema, and CBF by top 13 species
Parameter

Estimate

DF

SS

F-Ratio

P-value
1

Predicting Infarct
Intercept

10.41

1

0

0

Ruminococcus_u_s

5.34

1

201.66

11.85

0.0015

Alistipes indistinctus

3.05

1

122.20

7.18

0.0112

Lachnospiraceae bacterium 3-1

-24.97

1

141.01

8.28

0.0068

Intercept

3.05

1

0

0

1

Butyricimonas virosa

35.48

1

73.77

5.68

0.0229

Ruminococcus flavefaciens

-6.50

1

276.79

21.30

<0.0001

Bacteroides uniformis

12.93

1

59.99

4.62

0.0394

Ruminococcus_u_s

4.92

1

152.28

11.72

0.0016

Predicting Edema

Predicting Cerebral Blood Flow
Intercept

1.48

1

0

0

1

Alistipes indistinctus

-0.46

1

3.53

7.82

0.008

Model parameters selected using backward elimination from top 13 list in Table 1
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Table 8.3 Correlation of bacterial species with infarct and edema
Bacteria
Coefficient
Species Increase associated with infarct
Alistipes finegoldii
0.32
Alistipes indistinctus
0.29
Alistipe sp HGB5
0.33
Alistipes timonensis
0.16
Bacteroides caccae
0.29
Bacteroides dorei
0.38
Bacteroides eggerthii
0.30
Bacteroides fragilis
0.09
Bacteroides intestinalis
0.17
Bacteroides massiliensis
0.25
Bacteroides ovatus
0.10
Bacteroides sartorii
0.19
Bacteroides sp 3.1.40A
0.24
Bacteroides uniformis
0.35
Bacteroides vulgatus
0.47
Butyricimonas virosa
0.41
Desulfovibrio_u_s
0.23
Enterococcus_u_s
0.15
Enterococcus faecalis
0.22
Escherichia coli
0.52
Parabacteroides_u_s
0.33
Parabacteroides distasonis
0.49
Parabacteroides goldsteinii
0.18
Parabacteroides merdae
0.13
Parabacteroides sp D13
0.21
Porphyromonas sp 31.2
0.15
Species decrease associated with infarct
Bifidobacterium animalis
-0.21
Bifidobacterium bifidum
-0.13
Bifidobacterium pseudolongum
-0.14
Eubacterium plexicaudatum
-0.15
Lachnospiraceae bacterium 10-1
-0.21
Lachnospiraceae bacterium 28-4
-0.19
Lachnospiraceae bacterium 3-1
-0.38
Lachnospiraceae bacterium A2
-0.23
Lachnospiraceae bacterium A4
-0.31
Lachnospiraceae bacterium COE1
-0.23
Lactobacillus murinus
-0.37
Oscillibacter sp 1-3
-0.13
Ruminococcus flavefaciens
-0.45
Clostridium clostridioforme
-0.20
P<0.01 for all bacteria

Bacteria
Coefficient
Species Increase associated with edema
Alistipes finegoldii
0.35
Alistipes indistinctus
0.34
Alistipes sp HGB5
0.38
Alistipes timonensis
0.17
Bacteroides caccae
0.32
Bacteroides dorei
0.43
Bacteroides eggerthii
0.34
Bacteroides fragilis
0.11
Bacteroides intestinalis
0.25
Bacteroides massiliensis
0.26
Bacteroides ovatus
0.12
Bacteroides rodentium
0.15
Bacteroides sartorii
0.22
Bacteroides sp 3.1.40A
0.26
Bacteroides uniformis
0.41
Bacteroides vulgatus
0.53
Butyricimonas virosa
0.48
Desulfovibrio_u_s
0.26
Enterococcus faecalis
0.26
Escherichia coli
0.60
Parabacteroides_u_s
0.34
Parabacteroides distasonis
0.55
Parabacteroides goldsteinii
0.21
Parabacteroides merdae
0.17
Parabacteroides sp D13
0.24
Porphyromonas sp 31.2
0.19
Proteus mirabilis
0.13
Species decrease associated with edema
Bifidobacterium animalis
-0.24
Bifidobacterium bifidum
-0.12
Bifidobacterium pseudolongum
-0.16
Clostridium saudiense
-0.08
Eubacterium plexicaudatum
-0.16
Imtechella halotolerans
-0.12
Lachnospiraceae bacterium A4
-0.35
Lachnospiraceae bacterium COE1
-0.26
Lactobacillus animalis
-0.16
Lactobacillus johnsonii
-0.23
Lactobacillus murinus
-0.42
Lactobacillus reuteri
-0.20
Oscillibacter sp 1-3
-0.11
Ruminococcus bromii
-0.09
Ruminococcus flavefaciens
-0.56
Clostridium clostridioforme
-0.20
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Table 8.4 Association of Inflammatory Markers and Bacterial Species
Feature

Coef

Q value

Aerococcus.urinaeequi

-0.272821

0.008123

Aerococcus.viridans

-0.2502272

0.00710756

Alistipes.indistinctus
Bacteroides.caccae

0.49548605
0.55294244

0.00010758
2.70E-05

Bacteroides.intestinalis

0.39545256

0.00090266

Imtechella.halotolerans

-0.2698021

0.00513494

Parabacteroides.goldsteinii

0.36960675

0.00061701

Parabacteroides.sp..D13
Porphyromonas.sp..31_2

0.37087382
0.36233409

0.00010987
0.00022155

Inflammatory Marker
Ccl11
Ccl24
Ccl4
Ccl5
Ccl6
Cxcl9
Cxcr1
Cxcr5
Il10ra
IL11
Il13
Il16
Il3
Il4
RGD1561905
Ccl11
Ccl12
Ccl2
Ccl22
Ccl24
Ccl4
Ccl5
Ccl6
Cxcl9
Cxcr1
Cxcr5
Il10ra
IL11
Il13
Il16
Il3
Il4
RGD1561905
Il17a
Lfng
Ccl19
Cxcl1
Tnfrsf11b
Il2rb
Il3
Il6st
Tnfsf4
Ccl24
Ccl24

Coef
-0.20556
-0.20162
-0.19439
-0.19492
-0.19490
-0.18666
-0.19420
-0.19052
-0.19083
-0.19497
-0.19468
-0.19442
-0.21801
-0.19464
-0.20264
-0.29201
-0.27568
-0.27670
-0.27693
-0.28641
-0.27615
-0.27689
-0.27687
-0.26517
-0.27587
-0.27065
-0.27109
-0.27697
-0.27655
-0.27619
-0.30971
-0.27650
-0.28786
0.190118
0.592807
0.21675248
0.23004667
-0.3915736
0.51806
0.55259618
0.52789004
0.51998756
0.36028464
0.35003715

Q Value
1.94E-10
0.004625
1.15E-06
2.35E-09
1.57E-09
0.005476
0.002162
0.000588
0.000597
2.08E-10
9.21E-08
1.19E-06
8.19E-07
4.19E-07
0.003346
1.94E-10
1.57E-05
1.43E-06
2.58E-09
0.004625
1.15E-06
2.35E-09
1.57E-09
0.005476
0.002162
0.000588
0.000597
2.08E-10
9.21E-08
1.19E-06
8.19E-07
4.19E-07
0.003346
3.32E-05
0.008044
0.0014087
0.00219959
7.93E-16
0.00364866
2.34E-20
0.00072493
0.00362087
0.00462557
0.00462557

Q-Value<0.01 for all bacteria and inflammatory markers
Negative coefficients for bacteria with negative coefficients for inflammatory markers indicate increase in inflammatory marker
Positive coefficients for bacteria with positive coefficients for inflammatory markers indicate increase in inflammatory marker
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Figure 8.1 Imaging features following stroke
A) Infarct volume, B) Edema volume, and C) Cerebral Blood Flow (CBF) Mean
following stroke in overall rats and separated by male, female, LIF, PBS, Permanent, and
Transient.
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Figure 8.2 Motor function skills before and after stroke
Four test were used to measure motor function before and after stroke: A) circling, B)
elevated body swing test, C) step test, D) paw extension test.
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Figure 8.3 Diversity changes following stroke.
A) Alpha diversity as measured by the Shannon diversity index detecting species richness
and evenness is increased following stroke. There is no difference in change across sex,
treatment, or stroke type. B) Beta Diversity as measured by Bray-Curtis method comparing
how different samples are
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Figure 8.4 Phyla changes as a result of stroke.
Relative Abundance shows phyla composition before and after stroke.
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Figure 8.5 Summary figure depicting changes in gut microbial communities in response
to stroke
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